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1. Summary 
The dramatic and progressive increase in worldwide obesity during the past years puts an enormous 
financial strain on national healthcare systems. Despite the continuous and tremendous effort to find 
pharmacological treatment options for morbid obesity, bariatric surgery remains the most effective 
long-term treatment. Roux-en-Y gastric bypass (RYGB) is considered the gold standard of bariatric 
procedures, although the mechanisms by which the anatomical rearrangement of the intestinal tract 
leads to sustained weight loss and a rapid decrease in comorbidities are still mostly unknown. 
Contrary to the traditional classification of RYGB as a restrictive and malabsorptive procedure, these 
factors seem to play a minor role. Increasing evidence suggests that changes in gut hormone levels, 
such as glucagon-like peptide-1 (GLP-1), and potentially in neuroendocrine signaling may account 
for the majority of the effects.  
 
Increasing evidence suggests that one major side effect of RYGB surgery is a decrease in bone 
density. Vitamin D and calcium malabsorption with consequential secondary hyperparathyroidism 
have been suggested as potential causes, but the exact mechanisms are still unclear. In a 
longitudinal study in rats, we showed that bone mineral density decreased early after RYGB surgery 
and coincieded with intestinal calcium malabsorption. However, this seemed to be independent of 
vitamin D malabsorption, since increased vitamin D activation compensated for lower total vitamin D 
levels, and PTH levels were not elevated in RYGB rats. Although intestinal calcium absorption 
normalized between two and seven weeks after surgery, there was no restoration of bone mass. We 
identified chronic metabolic acidosis, which was associated with increased lactate levels and 
increased urinary calcium loss, as a potential mechanism underlying inhibited bone mass 
restoration. The RYGB-induced changes in bone metabolism occurred independent of weight loss, 
since they were not found in a sham-operated control group that was body weight-matched to the 
RYGB rats by food restriction. 
 
Previous studies have shown that the compensatory decrease in energy expenditure in response to 
body weight loss is attenuated in RYGB rats. Since increased GLP-1 levels contribute to the 
reduced caloric intake after RYGB surgery, we hypothesized that they may also be involved in the 
reported alterations in energy expenditure. We therefore investigated the effects of acute peripheral 
GLP-1 agonism and antagonism on energy expenditure in RYGB and sham-operated control rats; 
however, we did not find any effect of either treatment on energy expenditure. In contrast, GLP-1 
agonism decreased food intake more in RYGB than in sham rats, and GLP-1 antagonism 
significantly increased food intake in RYGB, but not in sham rats. This indicates that RYGB rats are 
more sensitive to the satiating effect of both endogenous GLP-1 and an exogenous GLP-1 agonist.  
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One important factor that has to be considered when measuring energy expenditure is body 
composition. Since fat is metabolically less active than lean tissue, differences in the fat to lean 
mass proportion between groups could lead to differences in energy expenditure. By computed 
tomography analysis, we were able to show that body composition did not differ between RYGB rats 
and sham operated rats that were food restricted to match the body weight of RYGB rats. We 
thereby confirmed that weight loss after RYGB surgery and by caloric restriction led to the same 
changes in body composition, which suggests that the reported alterations in energy expenditure In 
RYGB rats are not caused by differences in body composition.  
 
The thermoneutral zone, i.e. the ambient temperature at which energy expenditure is lowest 
because there is no need for thermogenesis, is higher in rodents than in humans. This means that if 
energy expenditure in rodents is measured at room temperature, the animals may be under 
moderate cold stress leading to increased energy expenditure due to adaptive thermogenesis. We 
speculated that the reported alterations in energy expenditure of RYGB rats could be caused by an 
upward shift in the thermoneutral zone and therefore a higher requirement for thermogenesis at 
lower temperatures. However, we found no difference in the thermoneutral zone of RYGB compared 
to ad libitum fed sham operated rats and showed that the RYGB-induced changes in energy 
expenditure persisted at thermoneutrality.  
 
In conclusion, we confirmed in our rat model that RYGB surgery leads to bone loss, potentially 
caused by intestinal calcium malabsorption. However, this seemed to be independent of vitamin D 
malabsorption or secondary hyperparathyroidism; but metabolic acidosis may play a role in the 
inhibition of bone mass restoration after normalization of calcium absorption. 
We also confirmed that the compensatory decrease in energy expenditure after weight loss is 
attenuated by RYGB surgery and showed that this effect is not caused by differences in body 
composition or the thermoneutral zone of RYGB rats. Acute modulation of GLP-1 signaling did not 
influence the RYGB-induced alterations in energy expenditure, suggesting that other factors than 
increased GLP-1 levels underlie these findings. 
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2. Zusammenfassung 
Die weltweit ansteigende Prävalenz von Obesitas und ihren Folgeerkrankungen führt zu einer 
massiven finanziellen Belastung der Gesundheitssysteme. Die zur Zeit einzig wirksame Therapie 
krankhafter Fettleibigkeit stellt die bariatrische Chirurgie dar, da die verfügbaren pharmakologischen 
Optionen entweder keinen ausreichenden und dauerhaften Gewichtsverlust erzielen oder zu 
schwerwiegenden Nebeneffekten führen. Der Roux-en-Y-Magenbypass (RYMB) ist der 
Goldstandard der bariatrischen Eingriffe, obwohl die genauen Mechanismen, welche zum 
Gewichtsverlust und zu einer schnellen Besserung der Begleiterkrankungen führen, noch nicht 
genau bekannt sind. Im Gegensatz zur ursprünglichen Idee, dass die Einschränkung der 
Magenkapazität zu einer verminderten Nahrungsaufnahme führt und dass gleichzeitig die 
Nährstoffabsorption im Darm durch die veränderte Anatomie reduziert  wird, haben neuere Studien 
gezeigt dass diese Faktoren nur eine untergeordnete Rolle spielen. Hingegen scheinen eine erhöhte 
Sekretion gastrointestinaler Sättigungshormone wie zum Beispiel Glucagon-like Peptide-1 (GLP-1) 
sowie möglicherweise Veränderungen der neuroendokrinen Signalübertragung zu den positiven 
Effekten des RYMB beizutragen. 
 
Immer mehr Studien deuten darauf hin, dass eine reduzierte Knochendichte als negative 
Begleiterscheinung des RYMB auftreten kann. Als mögliche Ursachen wurden Vitamin D- und 
Kalziummalabsorption mit daraus folgendem sekundärem Hyperparathyroidismus vorgeschlagen, 
die genauen Mechanismen sind jedoch ungeklärt. In einer Longitudinalstudie in Ratten konnten wir 
zeigen, dass die Knochen-Mineraldichte bereits kurz nach der RYMB-Operation abnahm. Dies fiel 
zeitlich zusammen mit intestinaler Kalziummalabsorption, schien jedoch unabhängig von einer 
Vitamin D-Malabsorption zu sein. Obwohl die Gesamtwerte von Vitamin D in RYMB-Ratten reduziert 
waren, war das aktive Vtamin D erhöht; die Parathormonwerte waren unverändert. Die intestinale 
Kalziumabsorption normalisierte sich zwar zwischen zwei und sieben Wochen nach der Operation, 
die Knochenmasse blieb jedoch reduziert. Wir konnten chronische metabolische Azidose im 
Zusammenhang mit erhöhten Laktatwerten und erhöhter renaler Kalziumausscheidung als mögliche 
Ursache für den fehlenden Knochenwiederaufbau identifizieren. Die Veränderungen im 
Knochenmetabolismus nach RYMB-Operation waren unabhängig vom Gewichtsverlust, da sie in 
einer restrikitv gefütterten Kontrollgruppe mit gleichem Gewichtsverlust nicht auftraten. 
 
Frühere Studien haben gezeigt, dass die kompensatorische Herunterregulierung des 
Energieumsatzes als Folge von Gewichtsverlust in RYMB-Ratten abgeschwächt ist. Da die erhöhte 
GLP-1 Sekretion nach RYMB-Operation zur reduzierten Energiaufnahme beiträgt, könnte sie auch 
einen Einfluss auf den Energieumsatz haben. Wir untersuchten deshalb die Auswirkungen von 
akuten peripheren Injektionen eines GLP-1 Agonisten und eines GLP-1 Antagonisten auf den 
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Energieumsatz und die Energieaufnahme von RYMB und Sham-operierten Ratten. Beide 
Substanzen hatten keinen Effekt auf den Energieumsatz; der Effekt auf die Energieaufnahme war 
jedoch stärker in den RYMB-Ratten als in den Sham-operierten Ratten. Dies deutet darauf hin, dass 
das Sättigungspotential sowohl von endogenem GLP-1 als auch eines exogen verabreichten GLP-1 
Agonisten in RYMB-Ratten erhöht ist. 
 
Ein wichtiger Faktor bei der Bestimmung des Energieumsatzes ist die Körperzusammensetzung, 
beziehungsweise das Verhältnis zwischen Fett- und Magermasse. Da Fett eine wesentlich 
geringere metabolische Aktivität als andere Gewebe hat, können Unterschiede im Körperfettanteil 
bei gleichem Körpergewicht zu einem unterschiedlichen Energieumsatz führen.  Wir konnten jedoch 
mittels computertomographischer Analyse zeigen, dass keine Unterschiede im Körperfettanteil von 
RYMB-Ratten und einer restriktiv gefütterten Kontrollgruppe mit gleichem Gewichtsverlust 
bestanden. Dies bestätigt, dass die beschriebenen Veränderungen im Energieumsatz von RYMB-
Ratten nicht durch ein unterschiedliches Verhältnis zwischen Fett- und  Magermasse verursacht 
wurden. 
 
Die Umgebungstemperatur, bei welcher keine zusätzliche Wärmeerzeugung zur Erhaltung der 
Körpertemperatur notwendig ist, wird als thermoneutrale Zone bezeichnet. Diese ist für Nagetiere 
höher als für Menschen, weshalb Ratten und Mäuse bei Raumtemperatur unter einem gewissen 
Kältestress stehen und aktiv Thermogenese betreiben, was den Energieumsatz erhöht. Wir 
spekulierten, dass die beschriebenen Veränderungen im Energieumsatz von RYMB-Ratten durch 
eine Erhöhung der thermoneutralen Zone und dadurch erhöhte Thermogenese bei Raumtemperatur 
verursacht wurden; fanden jedoch keinen Unterschied in der thermoneutralen Zone im Vergleich zu 
Sham-operierten und ad libitum gefütterten Ratten. Zusätzlich konnten wir zeigen, dass die 
Veränderungen auch bei Thermoneutralität bestehen blieben. 
 
Zusammenfassend konnten wir in unserem Rattenmodell  bestätigen, dass die RYMB-Operation zu 
Knochenverlust führt, möglicherweise durch Kalziummalabsorption im Darm. Dies scheint 
unabhängig von Vitamin D-Malabsorption oder sekundärem Hyperparathyroidismus zu sein, jedoch 
könnte eine chronische metabolische Azidose den Knochenwiederaufbau nach Normalisierung der 
Kalziumabsorption hemmen. 
Wir haben zusätzlich bestätigt, dass die kompensatorische Herunterregulierung des 
Energieumsatzes als Folge von Gewichtsverlust in RYMB-Ratten abgeschwächt ist und konnten 
zeigen, dass dies nicht durch einen reduzierten Körperfettanteil oder eine Erhöhung der 
thermoneutralen Zone verursacht wird. Ebenfalls scheinen die erhöhten GLP-1 Werte nach RYMB-
Operation keine direkte Rolle bei den beschriebenen Veränderungen zu spielen. 
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3. Introduction 
3.1. Energy homeostasis 
Maintenance of energy homeostasis, i.e. the balance between energy intake and energy 
expenditure, is crucial to keep body weight stable. The modern world is confronted with a wide 
increase in the prevalence of obesity and of related disorders such as diabetes mellitus, 
atherosclerosis and hypertension; together, they express the dramatic consequences of imbalances 
in energy homeostasis.  
3.1.1. Energy intake 
The hormonal system controlling energy intake consists of two main categories, satiation signals 
and adiposity signals, which are sensed and integrated by the central nervous system (CNS).  
Satiation signals consist of peptides released from the gastrointestinal tract in response to food 
intake. The variable distribution of different cell types secreting specific peptides within the 
gastrointestinal tract, combined with specific secretion stimuli for each peptide, provide the body with 
accurate information about the amount and composition of ingested nutrients and thus facilitate 
appropriate digestion and processing of nutrients. In addition, these hormones exert acute effects on 
food intake and thereby contribute to meal termination. If administered shortly before a meal, they 
dose-dependently reduce meal size; while blocking endogenous signaling with specific receptor 
antagonists before a meal increases meal size. Such effects have been shown, among others, for 
cholecystokinin (CCK),1-3 amylin,4-6 GLP-1,7,8 glucagon9 and peptide YY (PYY)8,10,11; although it often 
proves difficult to block actions of endogenous peptides.7,12 Since the magnitude of the postprandial 
gut hormone response depends on the amount of calories ingested,13,14 satiation signals play a 
crucial role in the short-term control of energy intake. 
Adiposity signals on the other hand are hormones secreted in proportion to body fat and therefore 
provide long-term information about the energetic status of the body. The best-characterized 
adiposity signals are leptin, secreted directly from white adipocytes,15-17 and insulin, which is 
secreted from pancreatic beta cells.18,19 It has recently become clear that, in contrast to the 
traditional view, adipose tissue is not just a metabolically inactive organ for fat storage, but also an 
endocrine organ secreting diverse hormones and cytokines that are involved in the control of 
metabolic function. However, none of these newly discovered adipose-derived signals have been 
identified as classical adiposity signals yet.20 
After their release, satiation signals either reach their central site of action via the bloodstream or act 
in a paracrine manner on local nerve endings. The β-cell derived hormone amylin for example is co-
secreted with insulin into the blood and acts directly on the area postrema in the hindbrain,21 which 
is accessible to blood-borne signals due to the lack of a functional blood brain barrier.22 Other 
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gastrointestinal hormones, including CCK,23 GLP-124 and PYY10,24 mediate their effects at least 
partly via receptors on local afferent fibers of the vagus nerve. Although there may also be a non-
vagal component to the signaling of these peptides, the integrity of the vagus seems to be crucial for 
their effects. The plasma half-life of satiation signals is generally very short, reflecting their role in 
the short-term control of food intake. However, the half-life of peptides acting on vagal afferents 
generally seems to be even shorter compared to the ones acting via the bloodstream, which is 
consistent with them exerting paracrine rather than endocrine effects.25-28 The signals from satiating 
peptides acting on the area postrema and on the vagus nerve are both received by the nucleus of 
the solitary tract (NTS) in the hindbrain, where they are integrated with other signals from the 
gastrointestinal tract, such as gastric distension.29 
Ascending projections from the NTS go to numerous other brain regions, including the 
hypothalamus in the forebrain, which is an important control center of the autonomic nervous 
system.30 One hypothalamic nucleus involved in energy homeostasis is the arcuate nucleus (ARC). 
In addition to receiving inputs from the NTS, the ARC is also the central site of action for the 
adiposity signals insulin and leptin. They exert their direct effects on food intake by stimulating pro-
opiomelanocortin (POMC) neurons, which release the anorexigenic α-melanocyte stimulating 
hormone (αMSH), and by inhibiting neurons releasing the orexigenic transmitters agouti-related 
protein and neuropeptide Y (AgRP/NPY).31 Other regions of the hypothalamus have also been 
shown to mediate various effects of leptin on energy homeostasis and glucose metabolism. The 
ventromedial nucleus of the hypothalamus seems to be involved in leptin-mediated regulation of 
blood glucose levels,32 while the dorsomedial hypothalamus is necessary for the leptin-induced 
increase in sympathetic tone, which is thought to cause activation of brown adipose tissue 
thermogenesis.33 The ventromedial hypothalamus34 and the lateral hypothalamic area35 are also 
critical for the control of body weight by leptin, which shows that a complex connectivity of different 
hypothalamic nuclei is required for leptin to exert its regulatory functions on energy homeostasis. 
Furthermore, insulin and leptin also interact with gut peptide signaling in the hindbrain. By altering 
the sensitivity to short-term satiation signals, this provides an additional way to regulate long-term 
energy homeostasis.36 
3.1.2. Energy expenditure 
Although the hormonal regulation of food intake is quite well understood by now, that knowledge has 
so far not resulted in a successful weight loss drug that acts by decreasing long-term energy intake. 
This has recently led to an increasing interest in the other side of the energy balance equation, 
namely energy expenditure (EE). However, the determination of EE is technically much more 
challenging than the measurement of food intake and there are still many open questions to the 
analysis of EE data. 
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Total daily energy expenditure (TEE) of an animal consists of three main components. The major 
determinant is the basal metabolic rate (BMR), which contributes to about 60-75% of TEE.37 BMR is 
the minimal energy that is required to maintain vital body functions and increases with increasing 
body mass; however, this correlation is not linear due to a higher influence of lean tissue mass 
compared to fat tissue mass.38 Furthermore, lean tissue is metabolically not homogenous but 
comprises different organs, some of which are metabolically much more active (e.g. brain, kidneys, 
heart) than others (e.g. bone, skeletal muscle).39,40 
The second component of TEE is diet-induced thermogenesis (DIT), also referred to as the thermic 
effect of food. It is defined as the increase in EE after a meal, which is associated with the digestion, 
absorption and storage of nutrients, and accounts for about 10-15% of TEE.41 DIT does not only 
depend on the size of the ingested meal, i.e. its caloric content, but also on its nutrient composition. 
A protein-rich meal leads to a higher DIT compared to an isocaloric carbohydrate-rich meal, and a 
high fat content further decreases DIT.37 
The third major contribution to TEE comes from activity related energy expenditure (AEE), which 
can be further divided into exercise and non-exercise activity thermogenesis. Non-exercise activity 
thermogenesis includes all muscle activity that not part of planned exercising, e.g. the energy 
expended for ambulation, posture or daily occupation.42 
3.1.2.1. Control of energy expenditure 
In contrast to the broad knowledge about food intake control, the processes and pathways 
regulating EE are still very poorly understood. This is to a large part due to the technical difficulties 
of EE measurement and the challenging data analysis (see below). In addition, the different 
components of EE seem to be controlled at least partly independent of each other, and their 
individual contribution to TEE is strongly influenced by environmental conditions. As mentioned 
previously, BMR is mainly determined by body mass and composition. However, it is strongly 
influenced by ambient temperature, since the maintenance of a constant body core temperature 
requires either active heat production at low ambient temperatures or physiological and behavioral 
responses to increase heat loss at high ambient temperatures, which both leads to an increase in 
BMR.43 Assessment of BMR is relatively easy in rodents; it is usually done during the light phase 
when physical activity is low and after an overnight fast to exclude the effects of DIT. 
AEE and DIT are more complex to evaluate since they are closely linked to each other under ad 
libitum fed conditions; i.e. an increase in EE caused by meal consumption is always associated with 
increased physical activity. Both can be calculated based on regression analyses by first evaluating 
the correlation between TEE and physical activity. If a good correlation is found, AEE can be 
estimated and subtracted from TEE; after this correction, measured changes in EE can theoretically 
be purely attributed to DIT. However, such analyses require a high sampling resolution and either a 
very high number of subjects or a long sampling interval.44 
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Interestingly, AEE is not only determined by the amount of physical activity but also by the energy 
cost of activity, which can vary widely between subjects and potentially provides one means of 
decreasing TEE in response to caloric restriction.45 Even et al.41 recently suggested that the energy 
cost of activity correlates with the efficiency of the coupling of O2 consumption and ATP synthesis in 
muscles. This hypothesis is supported by studies showing a decreased expression of uncoupling-
protein-3 in skeletal muscle in response to food restriction.46,47 
Finally, DIT strongly depends on caloric content and composition of a meal. However, numerous 
other factors have been suggested to influence DIT, such as meal patterns,48,49 exercise,50,51 and 
insulin resistance associated with obesity.52-54 Both exercise and obesity have been suggested to 
influence DIT by altering the activity of the sympathetic nervous system (SNS). SNS signaling to 
brown adipose tissue (BAT) is thought to be the main mechanism mediating DIT. How exactly this 
effect is mediated is not known, but there is evidence of a potential involvement of adiposity and 
satiation signals. Insulin and leptin act in the ARC to increase SNS activity.55,56 Morbid obesity 
eventually leads to a reduction in insulin and leptin sensitivity, while exercise increases insulin and 
leptin sensitivity. Furthermore, some satiation signals have been shown to activate the SNS;57,58 
since insulin and leptin alter the sensitivity to satiation signals, insulin and leptin resistance could 
thereby further decrease SNS signaling indirectly. 
3.1.2.2. Methods of energy expenditure measurement 
As previously mentioned, the measurement of EE is technically challenging. The two options are 
direct calorimetry, which allows the accurate measurement of heat production in an animal, and 
indirect calorimetry, which estimates heat production based on an animal’s oxygen consumption 
(VO2) and carbon dioxide production (VCO2). Direct calorimetry used to be the gold standard for EE 
measurement with the major advantage that the results do not depend on calculations based on 
generalized assumptions about metabolic functions.59 However, the equipment is very expensive 
and complex. 
Indirect calorimetry has become a popular and widely used alternative due to its commercial 
availability and comparably easy use. In contrast to direct calorimetry, the measurement of gas 
exchange also gives information about the substrates that are utilized for energy production. Due to 
the different C to O ratio in carbohydrate, lipid and protein, the amount of oxygen that is required for 
complete substrate oxidation is different among substrates, which leads to a specific VCO2/VO2 ratio 
(respiratory quotient, RQ) for each substrate. The RQ expected for pure carbohydrate oxidation is 
1.0, for pure fat oxidation 0.7. Protein oxidation or mixed substrates lead to RQ values between 0.7 
and 1.0.41 An RQ higher than 1 suggests a positive energy balance, i.e. the deposition of fat in 
response to carbohydrate ingestion, for example after long periods of fasting. One potential 
disadvantage of indirect calorimetry is that the calculation of EE from O2 consumption and CO2 
production assumes a normally functioning metabolism. For example, it is assumed that there is 
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only negligible substrate interconversion, which is not the case during rapid changes in body weight, 
or that anaerobic metabolism only plays a negligible role.59 It is therefore crucial that scientists using 
indirect calorimetry are aware of these limitations, especially since this method is often used to 
investigate genetically modified animals or effects of pharmacological and dietary interventions 
associated with various metabolic dysfunctions.  
An additional problem regarding EE data analysis is the normalization of EE, more specifically the 
need to consider differences in body weight and body composition when comparing groups. The 
importance of this issue has become evident in the past few years with the increasing interest in 
genetically modified animals that display extreme abnormalities in both body weight and body 
composition. As mentioned before, BMR and therefore also TEE increase with increasing body 
mass, which led to the approach of normalizing EE for body weight. However, the correlation 
between BMR and body weight is not linear since weight gain in adults is usually associated with 
alterations in body composition, i.e. a higher percentage of fat mass. Normalizing EE for body 
weight therefore underestimates EE in obese animals, which has led to many controversial 
conclusions about the cause and effect of obesity-associated changes in EE. A frequently used 
alternative is the normalization for lean body mass, but this approach induces a very similar bias by 
overestimating EE in obese animals, because the additional energy produced by increased fat mass 
is attributed to the lean body mass. One option that has been proposed is the normalization for lean 
body mass + 0.2* fat mass.41 The factor 0.2 is an estimation of the metabolic activity of adipose 
tissue compared to lean body mass; this formula should therefore provide a better approximation 
than the traditionally used ones. However, increased body mass not only affects BMR, but also AEE 
due to increased energetic cost of movement and probably DIT due to higher food intake and 
protein turnover.60 The quantitative consideration of these components when analyzing differences 
in EE between animal groups with different body weights is extremely difficult, which is reflected in 
the number of recent publications on this issue in highly ranked journals.41,44,61-64 It is recommended 
that, whenever possible, EE recordings should be performed before significant differences in body 
weight or composition between groups. This ensures that the causative differences, rather than 
consequences of the observed phenotypes, are measured. 
3.1.2.3. Thermoneutrality 
In addition to the question of how to compare EE between animals with differences in body weight 
and composition, the influence of the ambient temperature when performing metabolic studies is 
currently widely discussed. This issue first attracted broad attention due to mice lacking uncoupling 
protein-1 (UCP-1), which were expected to become spontaneously obese due to the incapability of 
DIT. Several studies performed at 20-23°C failed to detect such an effect65-67 until Feldmann et al.68 
reported that UCP-1 ablation indeed induced obesity if the experiments were performed at 
thermoneutrality, i.e at 29°C. It was concluded that at lower temperatures, the large increase in EE 
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to maintain body core temperature masked potential differences due to the inability of BAT 
thermogenesis. Even though cold-induced thermogenesis is also mediated by UCP-1, there are 
other mechanisms that can compensate for a lack in cold-induced BAT thermogenesis, such as 
increased activity or shivering. However, at thermoneutrality the effects of UCP-1 ablation become 
evident since the UCP-1 dependent DIT accounts for an important fraction of TEE. 
These findings clearly revealed the importance of considering housing temperatures when 
performing metabolic studies in rodents and have led to a rapidly growing body of literature on this 
issue. In order to maximize the utility of rodent models for the investigation of human diseases, 
particularly of those associated with metabolic abnormalities, it is now strongly recommended to 
perform experiments at thermoneutral temperatures.69-71 The thermoneutral zone (TNZ) of an animal 
is defined by the temperature range within which metabolic rate is minimal and stable. The 
metabolic rate increases due to active heat production if ambient temperature falls below the lower 
critical temperature (LCT). If ambient temperature is elevated above the upper critical temperature 
(UCT), physiological and behavioral responses such as escape behavior, thermoregulatory 
grooming and increased breathing rate lead to a higher metabolic rate.43 The LCT is relatively easy 
to determine by gradually lowering ambient temperature since the activation of heat-producing 
mechanisms directly correlates with an increase in metabolic rate. Reported values for the LCT of 
mice and rats vary, but seems to be around 30°C and 28°C for mice and rats, respectively.72-76 
Determination of the UCT is more difficult because of different behavioral thermoregulatory 
responses that influence metabolic rate not as directly as adaptive thermogenesis. Changes in 
activity, water intake, evaporative water loss and skin temperature or skin blood flow should be 
included when defining the UCT. However, except for the distinct study of heat exposure effects, the 
UCT is of less practical interest than the LCT. It has been shown that some thermoregulatory 
responses, such as evaporative water loss and increased thermal conductance, are already 
activated when the LCT is reached and increase when ambient temperature is further elevated.73 
Therefore, experiments should ideally be performed at ambient temperatures only slightly above the 
LCT to minimize the influence of any thermoregulatory effects. 
3.2. Dysregulation of energy homeostasis: The obesity epidemic 
As discussed before, the hormonal control of food intake has been studied extensively. However, 
the results of experiments investigating the control of eating behavior are often very inconsistent 
even when performed under similar conditions.77 This suggests that although energy homeostasis is 
a tightly controlled system, it is highly susceptible to external influences. The progressive rise in 
worldwide obesity prevalence supports the existence of such dysregulating factors, which currently 
attract huge interest in obesity research. Some of them have already been well characterized, 
including psychosocial stress,78,79 addiction susceptibility or alterations in the reward system80-82 and 
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prenatal influences,83-85 the latter potentially leading to epigenetic changes and thereby also 
affecting future generations.83 However, this increasing awareness of environmental factors leading 
to obesity has so far not resulted in any successful treatment or prevention options. 
3.2.1. Current situation 
Overweight and obesity with their resulting comorbidities have become a major topic in global 
healthcare and disease prevention. Overweight and obesity are defined by the World Health 
Organization as a Body Mass Index (BMI) of 25 or higher and 30 or higher, respectively. The BMI is 
a widely accepted index for obesity classification in adults, defined as a person's weight in kilograms 
divided by the square of the height in meters (kg/m2).86 
According to the World Health Organization, worldwide obesity has more than doubled since 1980; 
over 10% of the total adult population was considered obese in 2008. In recent years, obesity 
prevalence has also increased in low- to middle-income countries. In 2010, nearly 80% of the 
approximately 43 million overweight children under five lived in developing countries, indicating that 
rising problems are to be expected in particular in countries that might not have the financial 
possibilities to combat obesity and its consequences.87 
3.2.2. Treatment options 
The continuing increase in the worldwide obesity prevalence indicates that effective treatment 
options have not yet been identified or are at least not widely and easily accessible. The available 
options can be classified as conservative weight loss strategies, consisting of lifestyle and dietary 
modifications, as pharmacological treatment or surgical intervention.   
3.2.2.1. Conservative weight loss strategies 
Classical weight loss programs aim at reducing energy intake by dietary manipulation while 
increasing EE by enhancing physical activity. This leads to an energy deficit and thereby to a 
reduction in body weight by up to 10%;88 however, the majority of patients regain a considerable 
amount of the lost weight after completing a closely supervised treatment.89 This is not only the 
consequence of poor adherence to long-term therapies including profound lifestyle changes, but 
very likely also due to compensatory metabolic responses to the reduced body weight, such as a 
decrease in resting EE.90 Overall, the metabolic changes after weight loss seem to favor weight 
regain. 
3.2.2.2. Pharmacological treatment 
Pharmacological treatment is considered in patients who fail to lose the intended amount of body 
weight by lifestyle changes alone, but there are many limitations to the use of pharmacotherapy in 
obesity treatment. The weight loss achieved with long-term drug therapy is generally smaller than 
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with strict adherence to diet modifications and activity increase,91 and weight regain occurs as soon 
as the drug is discontinued.92 In addition, safety concerns have repeatedly led to the withdrawal of 
popular weight loss drugs from the US and European market.93,94 Although some new 
pharmacotherapies have recently been approved and many others are in the phase of clinical trials, 
their long-term effectiveness in morbidly obese patients have yet to be proven.95,96 
3.2.2.3. Bariatric surgery 
Surgical intervention is the treatment option for obese patients who have not responded to weight 
loss strategies or pharmacotherapy. It is by far the most effective option today and weight loss 
maintenance is achieved in many cases; further, it is the only treatment that leads to an 
improvement of the co-morbidities of obesity such as type 2 diabetes and cardiovascular disease. 
However, due to the associated risks of bariatric surgery, including micronutrient deficiency and 
mortality,97 there are strict guidelines for the patients who qualify for surgery. In Switzerland, patients 
with a BMI of ≥35 (equates e.g. to a body weight of 113.5 kg for a person 1.80 m tall) are considered 
eligible for surgical intervention.98 
Bariatric surgeries have traditionally been classified as malabsorptive, restrictive or combined 
procedures by the component that was thought to be mainly responsible for weight loss. 
Accordingly, gastric banding was considered to be a restrictive, jejunoileal bypass a malabsorptive 
and RYGB a mixed procedure.99,100 However, the exact mechanisms behind most bariatric 
procedures are still poorly understood, and recent data indicate that endocrine mechanisms may not 
only underlie reduced eating after RYGB, but also after gastric banding.101 Further, the rapid 
improvement of certain comorbidities that is observed after surgery seems to be independent of 
weight loss, pointing to more complex events.102,103 Until recently, RYGB and adjustable gastric 
banding were the bariatric procedures that were most performed worldwide.104 However, a relatively 
new procedure, vertical sleeve gastrectomy, has become very popular among bariatric surgeons in 
the past few years. It consists of resection of the greater curvature and fundus of the stomach, 
thereby strongly reducing gastric volume; it does however not involve any rearrangement of the 
intestinal anatomy. Although more invasive than the adjustable gastric band, it has now widely 
replaced this procedure because of its higher effectiveness.105 The first short-term evaluations 
suggest that sleeve gastrectomy leads to similar weight loss as RYGB and there is also evidence 
that it may have beneficial effects on type 2 diabetes and cardiovascular disease.100,106-108 However, 
in contrast to RYGB and adjustable gastric banding,109 there is a lack of data regarding long-term 
sustainability of weight loss and diabetes remission after vertical sleeve gastrectomy. 
3.3. Roux-en-Y gastric bypass 
In spite of evolving less invasive new techniques with good short-term effects on weight loss, the 
RYGB is still considered the gold standard of bariatric procedures. It involves the creation of a small 
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gastric pouch, which is separated from the rest of the 
stomach and represents the restrictive element of 
the surgery. The duodenum and proximal jejunum 
remain attached to the stomach but are divided from 
the distal small intestine, thereby creating the 
“biliopancreatic limb”. The gastric pouch is then 
anastomosed to the distal remnant of the jejunum, 
creating the “alimentary limb”, and the biliopancreatic 
limb is reanastomosed distal to the 
gastrojejunostomy. This leads to the typical “Y” 
shape, in which food bypasses the major part of the 
stomach and the proximal small intestine. Food is mixed with bile and pancreatic enzymes only 
where the alimentary and the biliopancreatic limb are connected and form the “common channel”, 
the length of which was thought to determine the magnitude of malabsorption (Figure 1). 
Intensive research on the weight loss mechanisms after RYGB surgery during the past years has 
led to many unexpected findings. Due to fast adaptations of the gastrointestinal tract to the 
anatomical rearrangement, the malabsorption observed immediately after surgery resolves 
quickly.110,111 Therefore, nutrient malabsorption only plays a minor role for the resulting body weight 
loss, while alterations in caloric intake account for the larger portion of weight loss.112 These 
changes in eating behavior are probably at least partly caused by differences in the postprandial 
release of satiating gut hormones, such as GLP-1, PYY and amylin.113-115 It has been shown in rats 
that the effects of RYGB on food intake and body weight are partially abolished if the vagal nerve is 
not preserved during the surgery,116 which supports an important role of gastrointestinal peptides in 
RYGB-induced weight loss, many of which act via the vagus nerve (see 3.1.1). 
There are several other factors that might contribute to weight loss after RYGB. Studies in rat 
models of RYGB have shown a reduced preference for high fat diet117,118 and alterations in sweet 
taste function,119-121 and patients have repeatedly reported a shift in food preferences away from 
very sweet or fatty foods.117 Miras et al. recently confirmed that the reward values of sweet and fat 
tastants were decreased in patients after RYGB compared to their preoperative values and to 
control subjects.122 Further, changes in meal patterns towards smaller, but more frequent meals 
have been described and are associated with a reduced total food intake.118 Recently, it has also 
been suggested that alterations in gut microbiota due to the anatomical changes of the digestive 
tract play a crucial role in RYGB-induced weight loss.123 Finally, the effects of weight loss on EE are 
different after RYGB compared to caloric restriction, which could explain the better body weight 
maintenance after bariatric surgery.124,125 
Figure 1 Illustration of the Roux-en-Y gastric 
bypass procedure. (A) Normal anatomy of the 
gastrointestinal tract, (B) gastrointestinal tract 
after gastric bypass surgery. 
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3.3.1. Effects of RYGB on energy expenditure 
We and others reported that body weight loss in rats after RYGB is not associated with the same 
decrease in EE that is observed with traditional weight loss strategies.118,124,125 Compensatory 
metabolic responses, such as decreased resting metabolic rate, are the main reason why 
maintenance of a lower body weight only by caloric restriction fails in the majority of obese 
patients90. The attenuation of this compensatory decrease in EE and in RYGB compared to control 
rats is therefore a very interesting and promising finding that requires further investigation in order to 
detect the underlying mechanisms. 
There are several potential causes for the observed alterations in 24-hours EE. As mentioned 
above, the RYGB procedure leads to increased basal and postprandial release of GLP-1 from the 
distal small intestine. GLP-1 is the hormone that has most consistently been reported to be elevated 
after RYGB in humans and rats and is thought to be at least partly responsible for the reduction in 
food intake and the early improvement of glucose tolerance after surgery. Its effects on food intake 
have been characterized in numerous studies,7,24,126,127 but GLP-1’s role in the control of EE is less 
well investigated. 
There are, however, a few studies that point to an involvement of GLP-1 in EE. Osaka et al.57 
showed a dose-dependent increase in oxygen consumption after intravenous GLP-1 administration, 
which was mediated by the lower brainstem and required the integrity of the sympathoadrenal 
system. Since GLP-1 levels rise rapidly in response to a meal and then return to baseline levels 
within one to two hours,128 these data suggest that GLP-1 may be involved in mediating DIT. Even 
though other studies suggest a decrease of DIT by GLP-1 due to delayed gastric emptying,129,130 
Osaka’s findings are interesting particularly in the context of the RYGB procedure. Due to the 
rearrangement of the gastrointestinal tract and the exclusion of the stomach as a temporary food 
storage organ, the confounding effects of GLP-1 on gastric emptying are less relevant after surgery; 
this then could explain differences in the role of GLP-1 in DIT between RYGB rats and rats with an 
intact stomach. Further evidence for a role of GLP-1 in EE control comes from mice lacking the 
GLP-1 degrading enzyme, dipeptidyl peptidase IV (DPP IV). These mice have more bioactive GLP-1 
and are resistant to high fat diet-induced obesity because of reduced food intake and increased 
EE.131 However, the results have to be interpreted with caution regarding their significance for GLP-
1, since DPP IV not only degrades GLP-1, but processes many other peptides including PYY, 
oxyntomodulin (OXM) and GLP-2. Like GLP-1, postprandial levels of these hormones are increased 
after RYGB surgery,113-115,132-134 and there are at least some studies showing an involvement of 
PYY11 and OXM135,136 in the control of EE.  
GLP-2 has well-characterized, positive effects on epithelial proliferation particularly in the small 
intestine.137 The resorptive surface is increased by enhanced crypt cell proliferation and reduced 
apoptosis of enterocytes.138,139 It was therefore hypothesized that increased GLP-2 levels after 
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RYGB lead to mucosa hypertrophy and thereby limit malabsorptive consequences of the RYGB 
surgery, which in fact has been shown by Le Roux et al.124,134 The gastrointestinal tract is a 
metabolically very active organ140 and its hypertrophy is likely to contribute to the increase in EE 
after RYGB especially in response to a meal. 
Therefore, it has to be considered that, similar to changes in food intake, the changes in EE in 
RYGB rats might be caused by the combined effects of several different factors rather than by just 
one specific gut hormone. 
3.3.1.1. Brown adipose tissue and diet-induced thermogenesis 
The elevation of the postprandial gut hormone response after RYGB has been reported repeatedly 
in rats and humans,141-146 whereas the results on basal hormone levels are less consistent.113,134,147-
149 Therefore, if the alterations in EE that we observed in RYGB rats were at least partly caused by 
increased gut hormones, alterations in DIT might be expected. 
As previously mentioned (see 3.1.2.1), DIT is mediated in part by the BAT.150,151 In contrast to white 
adipose tissue (WAT), which is the primary organ for energy storage, the main function of BAT is the 
production of heat. Brown adipocytes are characterized by a large number of mitochondria that 
contain UCP-1. UCP-1 can uncouple mitochondrial respiration from ATP synthesis and thereby 
accounts for the thermogenic potential of BAT.152,153 In addition, it is an excellent marker for BAT 
since its presence is unique to brown adipocytes. 
The recent finding that BAT presence in adult humans correlated negatively with BMI, fasting 
glucose levels154 and non-alcoholic fatty liver disease155 led to increasing interest in the mechanisms 
behind BAT presence and activity.154,156-159 This was further encouraged by the finding of emerging 
brown adipocytes in WAT depots. These adipocytes seem to transdifferentiate from mature white 
adipocytes or to differentiate from white preadipocytes,160,161 distinguishing them from the ones 
found in classical BAT depots derived from myoblastic stem cells.162,163 Differentiation of WAT into 
BAT has been shown in response to cold-exposure,164 stimulation of β3-adrenergic stimulation,165,166 
and peroxisome proliferator-activated gamma (PPARγ) activation.167 WAT to BAT differentiation also 
occurred spontaneously in a diet-induced obesity resistant rat model, possibly due to increased 
sympathetic innervation of WAT depots.168,169 Together with the evidence suggesting an involvement 
of GLP-1 in the regulation of the sympathoadrenal system,57 these findings may provide a 
connection between RYGB surgery, elevated GLP-1 levels and DIT. 
3.3.2. Effects of RYGB on bone metabolism 
3.3.2.1. Obesity-related changes in bone metabolism 
Due to a positive correlation between BMI and bone mineral density (BMD),170-173 the higher 
mechanical loading by increased fat mass is usually thought to be protective of bone mass. 
However, the interaction between fat and bone mass is far more complex than the traditional purely 
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weight-centered concept suggests and is influenced by diverse factors. Thus, even if the BMI/BMD 
correlation might be true in many cases, amounting evidence suggests that in individual subjects, 
this protective effect might be overridden by other obesity-associated mechanisms.174-178  
It is well established that vitamin D deficiency occurs in obese people179-181 and is mainly caused by 
increased vitamin D scavenging in fat compartments180 and insufficient UV light exposure.181 In 
accordance with this, presurgical evaluations of patients undergoing RYGB revealed low vitamin D 
levels in many cases, which was often accompanied by secondary hyperparathyroidism.182,183 This 
compensatory response activates different mechanisms to prevent hypocalcemia, including 
increased calcium resorption from the bone reservoir.184 Obesity can therefore affect bone 
metabolism by indirectly increasing parathyroid hormone (PTH) levels. 
However, there are several additional factors that link adipose tissue and bone mass control. First, 
obesity leads to a chronic low-grade inflammatory state that is strongly involved in the development 
of obesity-associated comorbidities.185 Proinflammatory cytokines, such as tumor necrosis factor-α 
(TNF-α), interleukin-6 (IL-6) and C-reactive protein, are elevated in the adipose tissue and plasma of 
obese individuals.186-189 Some of these cytokines, including TNF-α and IL-6, have been shown to 
stimulate osteoclast activity and bone resorption; a mechanism that also plays a role in 
postmenopausal osteoporosis.190-192 Thus, obesity leads to changes in bone mass and quality by 
causing a chronic inflammatory response. 
Second, plasma levels of the WAT-derived hormone leptin increase proportionally to total body fat 
mass.193 Leptin potentially affects bone mass by contributing to the increase in proinflammatory 
markers.194,195 Further, leptin has also been associated with bone mass control by affecting 
hypothalamic serotonin signaling leading to increased sympathetic activity.56,196,197 However, while 
some studies suggest an inhibition of bone formation by leptin,198,199 these findings are controversial 
and reports about the effects of leptin on bone mass diverge widely. Some studies show positive 
effects in different animal models, including leptin-deficient ob/ob mice,200-203 others suggest 
differences between peripheral and central leptin signaling,204 and human studies find neither an 
influence of leptin administration on bone metabolism,205 nor a body weight-independent correlation 
between leptin levels and bone mass.206 Therefore, even if leptin interacted with different factors that 
are involved in bone mass regulation, its overall role is unclear and leptin may in fact be of minor 
importance. 
Third, dietary calcium and fat content influence the absorption of each other. Several studies in the 
past years have linked high dietary calcium intake with lower body weight gain and higher body 
weight loss compared to diets with normal calcium content.207-210 This effect may in part be caused 
by the formation of insoluble calcium fatty acid soaps that lead to decreased fat absorption.208,211,212 
Conversely, maintenance on high fat diet has been shown to decrease calcium absorption and 
affect bone morphology.213-215 The suggested mechanism behind these findings is a high fat diet-
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induced redox imbalance particularly in the duodenum that leads to oxidative damage and down-
regulation of genes involved in calcium absorption.215 Since obesity is in many cases associated 
with the intake of foods containing high amounts of fat, reduced calcium absorption might be a 
widespread problem in the obese population. 
Finally, adipocytes and osteoblasts originate from the same mesenchymal stem cells; an increase in 
bone marrow adipogenesis, as seen in aging, is accompanied by a decrease in osteogenesis.216-218 
However, this interaction is independent of whole body adiposity; bone marrow fat seems to be 
regulated differently and is, in contrast to other fat depots, not immediately affected by caloric 
restriction.219 Recent studies suggest that the fat infiltration of bone marrow is not simply a 
consequence of reduced bone density as traditionally assumed. Instead, altered expression of local 
growth and transcription factors leads to predominant differentiation of mesenchymal stem cells into 
adipocytes.220,221 PPARγ has been identified as the main transcription factor directing stem cell 
differentiation into adipocytes and thereby decreasing osteoblast differentiation.217,222 Additionally to 
its suppressive effect on bone formation, PPARγ might also stimulate bone resorption by activating 
osteoclasts.223,224 This is a very important finding, because thiazolidinediones, widely used in the 
therapy of type 2 diabetes, which is a primary co-morbidity of obesity, activate PPARγ, and 
increasing evidence suggests that these substances may lead to severe side effects on bone 
quality.225,226 
Together, these data show that the influence of increased body adiposity on bone metabolism is 
complex and involves diverse factors. The consequences of obesity on bone quality can therefore 
vary between individuals. 
3.3.2.2. Changes in bone metabolism after RYGB surgery 
In accordance with the generally impaired vitamin D status in the obese population, vitamin D levels 
have repeatedly been shown to be low in patients before undergoing gastric bypass surgery. As 
RYGB decreases fat depots and usually also leads to a less sedentary lifestyle with more sunlight 
exposure, it would be expected to normalize calcium and vitamin D metabolism. Other factors 
associated with obesity that impair bone quality also improve after RYGB. Oxidative stress and 
inflammatory markers decrease soon after surgery,227-229 and food preferences are reported to shift 
towards diets with a smaller fat content,117,118,230 which should contribute to better calcium 
availability. 
In contrast to this, the studies that evaluated bone metabolism after RYGB in humans mostly 
showed reduced BMD231,232 or bone mineral content233 that was accompanied by increased markers 
of bone resorption.233-236 Even more frequently, an exacerbation of vitamin D deficiency and 
secondary hyperparathyroidism, in postsurgical follow-ups have been reported.237-239 Most authors 
explain these findings by impaired absorption of fat and fat-soluble vitamins, such as vitamin D, due 
to the delayed mixing with bile and pancreatic enzymes.240-242 Some state that calcium 
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malabsorption is the direct consequence of the insufficient vitamin D supply,243 while others show 
evidence of a selective calcium malabsorption independent of vitamin D status.240,244 Some studies 
also report secondary hyperparathyroidism after RYGB that is independent of the vitamin D 
status.235,245,246 
The inconsistency of these results suggests that there may be unknown factors influencing bone 
metabolism after gastric bypass surgery. Especially the correlation between vitamin D levels and 
bone density has to be interpreted with caution, since there is a considerable seasonal variation in 
vitamin D levels.238,247 
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4. Aims of the project 
 
Aim 1: To characterize longitudinal changes in bone metabolism after RYGB surgery in rats. 
Increasing evidence from human studies suggests that RYGB surgery may cause bone loss. This 
has been attributed to vitamin D and calcium malabsorption, potentially leading to secondary 
hyperparathyroidism and increased bone resorption. However, the exact mechanisms are still 
unknown, and some studies have also shown bone loss in RYGB patients independent of vitamin D 
status. We therefore assessed bone mineral density, calcium and phosphorus balance, vitamin D 
levels, acid-base status and markers of bone turnover at different time points for 14 weeks after 
surgery in RYGB and sham-operated rats. In order to distinguish between effects of the surgery and 
weight loss per se, a control group was included that was body weight-matched to RYGB rats by 
food restriction. 
 
Aim 2: To determine the effects of acute peripheral GLP-1 agonism and antagonism on 
energy expenditure and food intake in RYGB and sham-operated rats. 
The compensatory decrease in EE after weight loss is attenuated in RYGB rats. GLP-1 may be 
involved in EE control, and basal and postprandial GLP-1 levels are increased after RYGB surgery. 
We hypothesized that increased GLP-1 levels are involved in RYGB-induced alterations in EE. We 
investigated the effects of acute peripheral administration of the GLP-1 agonist exendin-4 and the 
GLP-1 antagonist exendin-9 on EE in RYGB, sham-operated ad libitum fed and sham operated 
body weight-matched rats. The effects of exendin-4 and exendin-9 on food intake were evaluated to 
confirm successful drug administration and to test if RYGB surgery increases the satiating potential 
of both an exogenous GLP-1 agonist and endogenous GLP-1.  
 
Aim 3: To assess changes in body composition after RYGB surgery 
It has repeatedly been speculated that the reported alterations in EE could be caused by differences 
in body composition, i.e. a decreased fat mass proportion in RYGB rats. We therefore evaluated 
whole body composition of RYGB, sham operated ad libitum fed and sham operated body weight-
matched rats with a validated rodent computer tomography scanner. 
 
Aim 4: To identify the thermoneutral zone of RYGB and sham operated rats 
Since the impact of ambient temperature when performing EE recordings in rodents has become 
obvious in the past few years, we hypothesized that a shift in the TNZ  of RYGB rats towards higher 
temperatures may be responsible for their changes in EE when measured at ambient temperatures 
below thermoneutrality. We wanted to identify the TNZ of RYGB, sham operated ad libitum fed and 
 	   23 
sham operated body weight-matched rats by gradually decreasing ambient temperature from 32 to 
22°C and determine the temperature at which EE was lowest for each group. 
  
I was also involved in other projects, which, although not directly related to the main focus of my 
thesis, provided additional insights into mechanism underlying weight loss and other metabolic 
effects of RYGB surgery. These included the investigation of (1) the influence of estrogen 
replacement in ovariectomized rats on body weight loss and the satiating potential of gut hormones 
after RYGB surgery, and (2) changes in gut microbiota composition in RYGB rats. 
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5. Original Research Article: “Roux-en-Y gastric bypass surgery 
reduces bone mineral density and induces metabolic 
acidosis in rats” 
 
 
This section contains an original research article that was first submitted for publication to the 
American Journal of Physiology – Regulatory, Integrative and Comparative Physiology in January 
2013 and accepted for publication in revised form in September 2013. 
 
My contribution to this manuscript includes the study design, data acquisition, data analysis, data 
interpretation and drafting and revising the manuscript. 
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Abegg K, Gehring N, Wagner CA, Liesegang A, Schiesser M,
Bueter M, Lutz TA. Roux-en-Y gastric bypass surgery reduces bone
mineral density and induces metabolic acidosis in rats. Am J Physiol
Regul Integr Comp Physiol 305: R999–R1009, 2013. First published
September 11, 2013; doi:10.1152/ajpregu.00038.2013.—Roux-en-Y
gastric bypass (RYGB) surgery leads to bone loss in humans, which
may be caused by vitamin D and calcium malabsorption and subse-
quent secondary hyperparathyroidism. However, because these con-
ditions occur frequently in obese people, it is unclear whether they are
the primary causes of bone loss after RYGB. To determine the
contribution of calcium and vitamin D malabsorption to bone loss in
a rat RYGB model, adult male Wistar rats were randomized for
RYGB surgery, sham-operation–ad libitum fed, or sham-operation–
body weight-matched. Bone mineral density, calcium and phosphorus
balance, acid-base status, and markers of bone turnover were assessed
at different time points for 14 wk after surgery. Bone mineral density
decreased for several weeks after RYGB. Intestinal calcium absorp-
tion was reduced early after surgery, but plasma calcium and para-
thyroid hormone levels were normal. 25-hydroxyvitamin D levels
decreased, while levels of active 1,25-dihydroxyvitamin D increased
after surgery. RYGB rats displayed metabolic acidosis due to in-
creased plasma lactate levels and increased urinary calcium loss
throughout the study. These results suggest that initial calcium mal-
absorption may play a key role in bone loss early after RYGB in rats,
but other factors, including chronic metabolic acidosis, contribute to
insufficient bone restoration after normalization of intestinal calcium
absorption. Secondary hyperparathyroidism is not involved in post-
operative bone loss. Upregulated vitamin D activation may compen-
sate for any vitamin D malabsorption.
Roux-en-Y gastric bypass; vitamin D; metabolic acidosis; secondary
hyperparathyroidism
BARIATRIC SURGERY IS CURRENTLY the only effective long-term
treatment for morbid obesity and its comorbidities. Roux-en-Y
gastric bypass (RYGB) is the most commonly performed
procedure and can be considered the gold standard for weight
loss surgery. Recently, however, there has been an increasing
focus on potential negative side effects of weight loss surgery,
in particular, its effects on changes in bone metabolism (46,
49). Several prospective studies have reported significant de-
creases in bone mineral density (BMD) of the lumbar spine,
hip, and femoral neck in men and women during the first year
after RYGB surgery (13, 19, 39). The scarce data on long-term
effects of RYGB surgery on bone mass suggest that reduced
BMD may persist beyond the first postsurgical year (26, 50).
The anatomical rearrangement of the gastrointestinal tract
after RYGB surgery leads to malabsorption of several micro-
nutrients, including vitamin D (1, 19), and vitamin D defi-
ciency is a common finding in patients after RYGB surgery (6).
This may reduce intestinal calcium absorption (41), cause
secondary hyperparathyroidism (2° HPT), and ultimately cause
bone loss (19). Therefore, it has been proposed that postsurgi-
cal vitamin D levels should be regularly monitored and sup-
plemented when necessary (43). However, several studies have
reported a decrease in BMD after RYGB surgery despite
vitamin D supplementation, indicating that vitamin D defi-
ciency may not be the only cause of RYGB-associated changes
in bone metabolism (12, 13, 39, 44). In addition, obesity per se
is generally associated with low vitamin D levels due to
vitamin D sequestration in adipose tissue and insufficient
sunlight exposure (16). Therefore, presurgical evaluation of
vitamin D and parathyroid hormone (PTH) status in patients
undergoing RYGB often reveal substantial vitamin D defi-
ciency and 2° HPT (21, 44). This complicates the assessment
of postsurgical RYGB-induced changes and the interpretation
of their specific contribution to bone loss. Finally, most studies
report only values for 25-hydroxyvitamin D [25(OH)D] and
not for the biologically active form 1,25-dihydroxyvitamin D
[1,25(OH)2D]. To investigate the functional consequences of
vitamin D malabsorption after RYGB surgery, measurement of
1,25(OH)2D is indispensable. Interestingly, while presurgical
levels of 1,25(OH)2D have been reported to be decreased in
RYGB patients (21), some studies report unaltered (1, 2) or
even increased (44) postsurgical 1,25(OH)2D levels. Overall,
these conflicting results suggest that the role of vitamin D
malabsorption as a single cause for postsurgical bone loss after
RYGB seems unlikely and that more in-depth studies are
required.
The aim of this longitudinal study was to characterize the
time course of dynamic changes in bone metabolism after
RYGB surgery in rats under standardized conditions without
dietary calcium or vitamin D supplementation. We hypothe-
sized that factors other than vitamin D deficiency may contrib-
ute to increased bone resorption and dysregulation of calcium
homeostasis after RYGB.
MATERIALS AND METHODS
Animals and housing. Thirty-two adult male Wistar rats weighing
450–500 g were allocated to either RYGB surgery (n ! 15), sham
Address for reprint requests and other correspondence: K. Abegg, Institute
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operation with no dietary manipulation [n ! 9, ad libitum fed sham
rats (AL)], or sham operation with food restriction to match the
postoperative body weight of RYGB rats [n ! 8, body weight-
matched shams (BWm)]. RYGB and AL rats were housed in groups
of four and three animals per cage, respectively; BWm rats were
housed individually to allow food restriction. Animals were main-
tained under an artificial 12:12-h light-dark cycle at room temperature
(24°C) and had ad libitum access to normal chow (Provimi Kliba,
Kaiseraugst, Switzerland) and tap water unless otherwise stated. All
experiments were approved by the Veterinary Office of the Canton
Zurich, Switzerland.
Surgery. RYGB surgery was performed as previously described
(10). Briefly, the small bowel was transected "20 cm distal to the
pylorus of the stomach, creating a proximal and distal end of small
bowel. The proximal end constituted the biliopancreatic limb and was
anastomosed to the ileum "40 cm from the cecum, creating the
common channel. The stomach was transected "5 mm below the
gastroesophageal junction, creating a gastric pouch of a size of no
more than 2–3% of original stomach size. The Roux-en-Y reconstruc-
tion was completed by connecting the distal end of the small bowel to
the gastric pouch leading to the formation of the alimentary limb. For
sham operations, an anterior gastrotomy and a jejunotomy with
subsequent closures were performed.
Microcomputed tomography scans. Two, seven, and fourteen
weeks after surgery, BMD of lumbar vertebrae 1 to 6 was measured
by quantitative microcomputed tomography (CT) with a LaTheta
LCT-100A scanner (Hitachi-Aloka Medical, Tokyo, Japan). Rats
were anesthetized with 2–3% isoflurane in oxygen (0.5 liter per min)
during the measurement. Continuous 2-mm slice images with a pixel
size of 250 # 250 $m were utilized for calculation of BMD using
LaTheta software (version 2.10).
Sample collection. Rats were allowed to recover from anesthesia and
CT scans for 1 day before being single-housed in metabolic cages
(Tecniplast, Buguggiate, Italy) for urine and feces collection. Food
consumption, water consumption, and body weight were recorded daily.
After a 3-day adaptation period, urine and feces were collected for 24 h.
Urine samples were collected under mineral oil to prevent evaporative
losses. Rats were then anesthetized by inhalation of isoflurane/air, and
venous blood was collected from the sublingual vein. Heparinized blood
was immediately analyzed for pH, blood gases, and electrolytes on an
ABL 800 Flex blood gas analyzer (Radiometer, Copenhagen, Denmark).
Serum was stored at %20°C until further analysis. Sixteen weeks after
surgery, rats were killed by decapitation after overnight fasting. To ensure
comparability of the intestinal gene expression between animals, samples
of the duodenum, jejunum, and ileum were taken 10 cm distal to the
pylorus, 20 cm proximal to the cecum, and 60 cm proximal to the cecum,
respectively.
Kidney and intestinal tissue was immediately frozen with liquid
nitrogen and stored at %80°C for analysis by quantitative PCR and
Western blotting.
Blood, urine, and feces analysis. Serum total calcium and phos-
phorus were measured using the chemistry analyzer Cobas Integra
800 (Roche Diagnostic System, Basel, Switzerland). Serum-intact
parathyroid hormone and osteocalcin levels and urine total deoxypyr-
idinoline crosslinks were measured by two-site enzyme-linked immu-
nosorbent assays (iPTH: Immutopics, San Clemente, CA; MicroVue
osteocalcin and MicroVue total DPD: Quidel, San Diego, CA),
according to the manufacturer’s protocols. Serum 25(OH)D and
1,25(OH)2D levels were measured by radioimmunoassays (Immuno-
diagnostic Systems, Baldon, UK).
Ammonium in urine was measured by the method of Berthelot (7).
For pH measurements of feces, 1 g of fresh feces was extracted with
5 ml of distilled water and centrifuged (10600 g, 20 min). pH of the
feces extracts and urine pH were determined with a Metrohm 744 pH
meter. Calcium and phosphorus in urine and feces were measured
with the chemistry analyzer Cobas Integra 800. Duplicates of feces
samples were dried at 105°C for 3 h to constant weight and then
reduced to ashes in a muffle oven for 16 h at 550°C. The ash was
dissolved in 10 ml 8% HCl, and the supernatant was used for analysis
after centrifugation (3000 g, 10 min). Urine was acidified to pH &2.0
with HCl before analysis. Relative intestinal calcium and phosphorus
absorption were calculated as relative absorption ! [intake (mg) %
fecal loss (mg)]/intake (mg).
RNA isolation and cDNA synthesis. Total RNA from kidney and
intestine was extracted using the Qiagen RNeasy Mini Kit (Qiagen,
Hilden, Germany). Snap-frozen tissue was homogenized in a pestle
homogenizer with 1 ml of precooled RLT buffer (Qiagen) supple-
mented with '-mercaptoethanol at a final concentration of 1%. Sub-
sequently, 200 $l of the homogenate were used for RNA preparation,
which was carried out according to the manufacturer’s protocol.
DNase digestion was performed using the RNase-free DNAase set
(Qiagen). Total RNA extractions were analyzed for quality, purity,
and concentration using the NanoDrop ND-1000 spectrophotometer.
RNA samples were diluted to a final concentration of 100 ng/$l, and
cDNA was prepared using the TaqMan reverse transcriptase reagent
kit (Applied Biosystems/Roche, Foster City, CA).
In brief, in a reaction volume of 40 $l, 300 ng of RNA was used
as a template and mixed with the following final concentrations of RT
buffer (1#), MgCl2 (5.5 mM), random hexamers (2.5 $M), dNTP mix
(500 $M each), RNase inhibitor (0.4 U/$l), multiscribe reverse
transcriptase (1.25 U/$l), and RNase-free water. Reverse transcription
was performed with thermocycling conditions set at 25°C for 10 min,
48°C for 30 min, and 95°C for 5 min on a thermocycler (Biometra,
Göttingen, Germany).
Real-time RT-PCR analysis. Semiquantitative real-time qRT-PCR
was performed on the ABI PRISM 7700 Sequence Detection System
(Applied Biosystems). Primers for all genes of interest were designed
using Primer Express Software (v.2.0.; Applied Biosystems), and
primers were tested by PCR with cDNA and always resulted in a
single product of the expected size. Primers were chosen to result in
amplicons no longer than 150 bp spanning intron-exon boundaries to
exclude genomic DNA contamination (Table 1). Probes were labeled
with the reporter dye FAM at the 5= end and the quencher dye
TAMRA at the 3= end (Microsynth, Balgach, Switzerland). Real-time
PCR reactions were performed using the TaqMan Universal PCR
Master Mix (Applied Biosystems). Briefly, 3.5 $l cDNA, 1 $l of each
Table 1. Primers used for semi-quantitative real-time PCR
Gene1 Accession No.2
Forward Primer (5= - 3=) Reverse Primer
(3= - 5=)
TRPV5 NM_053787 AGA GCA GCC AAG GAA AAT GA
TAG CAG CAT CCA GGT GGT CA
TPRV6 NM_053686 GCT GCA GCA GAA GAG GAT CT
AGG GCA GCT ATG TGA AGT GC
Calb1 NM_031984 CCA CCT GCA GTC ATC TCT GA
GCT CCT GGA TCA AGT TCT GC
Cyp24a1 NM_201635 TTG AAA GCA TCT GCC TTG TG
GGG GTC ACC ATC ATC TTC C
Cyp27b1 Applied Biosystems Rn00678310_g1
Slc9a3 (NHE3) NM_012654 CAC CCA CCA CAC GTT GCA
GTG AGC TCG TGC CGA CTG T
Slc4a4 (NBCE1) NM_053424 GGT GTG GAT ACT CCG AAG CTA
ATT
CAA AGG GTG GGA CAA ACC AA
HPRT NM_012583 GCT GAA GAT TTG GAA AAG GTG
TTT A
ACA CAG AGG GCC ACA ATG TGA
1TRPV5/6, transient receptor potential vanilloid 5/6; Calb1, calbindin D28k;
Cyp24a1, 1,25-dihydroxyvitamin D 24-hydroxylase; Cyp27b1, 25-hydroxyvi-
tamin D 1-alpha-hydroxylase; Slc9a3, solute carrier family 9 (sodium/hydro-
gen exchanger) member 3; Slc4a4, solute carrier family 4 (sodium/bicarbonate
cotransporter) member 4; HPRT, hypoxanthine guanine phosphoribosyl trans-
ferase. 2NCBI Entrez Nucleotide Database (https://www.ncbi.nlm.nih.gov/
nucleotide).
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primer (25 !M), 0.5 !l labeled probe (5 !M), 6.5 !l RNase free
water, and 12.5 !l TaqMan Universal PCR Master Mix reached 25 !l
of final reaction volume. Reaction conditions were the following:
denaturation at 95°C for 10 min followed by 40 cycles of denaturation
at 95°C for 15 s and annealing/elongation at 60°C for 60 s with auto
ramp time. All reactions were run in duplicate. For analyzing the
data, the threshold was set to 0.06, as this value had been deter-
mined to be in the linear range of the amplification curves for all
mRNAs in all experimental runs. The expression of the gene of
interest was calculated in relation to hypoxanthine guanine phos-
phoribosyl transferase (HPRT). Relative expression ratios were
calculated as R " 2(Ct(HPRT)#Ct(test gene), where Ct represents the
cycle number at the threshold 0.06 (35).
Western blot analysis. Snap-frozen kidneys were homogenized in
ice-cold RIPA buffer containing 1 mM PMSF, 2 !g/ml aprotinin, 10
!g/ml leupeptin, and 5 mM EDTA. After measurement of the protein
concentration using the method of Pierce (45), 50 !g of proteins were
solubilized in loading buffer containing $-mercaptoethanol and sep-
arated on 10% polyacrylamide gels. For immunoblotting, proteins
were transferred electrophoretically to nitrocellulose membranes. Af-
ter blocking with 5% BSA in PBS/0.1% Tween-20 for 60 min, blots
were incubated with the primary antibodies: mouse monoclonal anti-
VDR D6 (51 kDa; Santa Cruz Biotechnology, Santa Cruz, CA; 1:100)
(51) and mouse monoclonal horseradish peroxidase (HRP)-conju-
gated anti-GAPDH (40 kDa; Abcam, Cambridge, UK; 1:10,000)
overnight at 4°C. Membranes were then incubated for 1 h at room
temperature with secondary goat anti-mouse antibodies 1:5,000 linked
to HRP (Santa Cruz Biotechnology). The protein signal was detected
with the appropriate substrates from Bio-Rad using the LAS-3000
chemiluminescence detection system (FujiFilm, Tokyo, Japan). All
images were analyzed using the software ImageJ (20) to calculate the
VDR/GAPDH ratio.
Bone histology. Bone specimens were fixed in 40% ethanol at 4°C for
3 days and further dehydrated in an ascending series of ethanol (50%,
70%, 80%, 90% 96%, and 100% at 4°C, 2 days per concentration) before
being defatted in xylene under vacuum for 4 days. Embedding of
specimens in methylmetacrylate was performed in customized Teflon
forms. Tibiae and L3 vertebral bodies were embedded in a position that
allowed midsagittal and coronal sectioning, respectively. After polymer-
ization, the blocks were mounted on plastic frames and cut with a
precision saw (Leica SP 1600, Leica Biosystems, Nussloch, Germany).
Ground sections were mounted on acrylic glass slides (Perspex GS
Acrylglas Opal 1013; Wachendorf AG, Basel, Switzerland), polished to
200-!m sections, and surface stained with toluidine blue. Sections were
digitally recorded (Axiovision, Carl Zeiss AG, Oberkochen, Germany;
magnification 10 % 4); bone volume fraction and trabecular thickness
were quantified with the software ImageJ and the plug-in BoneJ (15,
17) in vertebral bodies and proximal tibiae. To exclude the primary
spongiosa from the analysis, cancellous bone within 0.5 mm from
the growth plate and within 0.25 mm from the endocortical bone
surface was excluded (18).
For the measurement of growth plate width, images of the total
growth plate were obtained at a magnification of 10 % 10. Seven
vertical (perpendicular to chondro-osseous junction) lines were drawn
throughout the growth plate and measured; growth plate width was
calculated as an average of these seven measurements (23).
Statistical analysis. Data were analyzed with one-way ANOVA
and are expressed as means & SE. Following a significant F ratio,
Bonferroni-Hochberg post hoc tests were used to determine differ-
ences between groups. Significance was established at P ' 0.05.
RESULTS
RYGB surgery leads to body weight loss and maintenance of
a lower body weight. RYGB rats lost (15% of their original
body weight within the first 2 wk after surgery and maintained
a significantly lower body weight compared with AL rats from
postoperative day 4 (P ' 0.05). From week 2 after surgery,
body weight was significantly lower in BWm rats compared
with AL rats (P ' 0.001), but there was no difference between
RYGB and BWm rats (Fig. 1). We have previously shown that
BWm rats require significantly less food than RYGB rats to
maintain a similar body weight and that the lower food effi-
ciency in our RYGB model is not caused by nutrient malab-
sorption, but it is associated with an increase in energy expen-
diture (11).
BMD decreases after RYGB surgery. BMD was significantly
reduced in RYGB rats already 2 wk after surgery and de-
creased further between weeks 2 and 7; thereafter, the differ-
ence in BMD between RYGB and AL rats remained un-
changed until week 14. There was no difference in BMD
between AL and BWm rats at any time point, which suggests
that the decrease of BMD in RYGB rats was not directly
caused by body weight loss (Fig. 2A). The results obtained by
CT were confirmed by bone histomorphometry, which showed
reduced bone volume and trabecular thickness in vertebrae and
reduced bone volume in tibiae of RYGB, but not BWm rats
(Fig. 2, B–F).
RYGB leads to transient calcium malabsorption and in-
creased urinary calcium excretion. To determine the potential
role of malabsorption in the observed bone changes, calcium
and phosphorus absorption was calculated from 24-h intake
and fecal losses. Two weeks after surgery, both the absorption
relative to intake and the absolute absorption of calcium
were lower in RYGB rats compared with sham controls.
However, there was no evidence of calcium malabsorption
in RYGB rats 7 and 14 wk after surgery (Fig. 3A). The
absorption of phosphorus was not impaired at any time point
in RYGB rats (Fig. 3B). Fourteen weeks after surgery, there
was a decrease in calcium and phosphorus absorption com-
pared with the earlier time points in all rats. We speculate that
this was because rats had reached the age when linear growth
stopped (Fig. 1), since it is known that mineral absorption is
markedly decreased in older rats (3).
We expected RYGB rats to compensate for the initial cal-
cium malabsorption by decreasing urinary calcium excretion.
Paradoxically, urinary calcium and phosphorus concentrations,
as well as the absolute 24-h excretions, were increased in
RYGB rats throughout the entire study (Fig. 3, C and D).
RYGB causes chronic metabolic acidosis. Because overall
bone metabolism and renal calcium excretion are strongly
affected by acid-base imbalances, we investigated systemic
acid-base status after RYGB surgery. Throughout the study,
Fig. 1. Body weight changes of sham-operated, ad libitum-fed (AL), sham-
operated, body weight-matched (BWm), and Roux-en-Y gastric bypass
(RYGB) rats. Data are expressed as mean values & SE (***P ' 0.001 AL vs.
RYGB; )))P ' 0.001 AL vs. BWm).
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venous blood pH was significantly decreased in RYGB com-
pared with sham rats, and the anion gap and lactate levels were
increased (Fig. 4A). There was a significant negative correla-
tion between lactate levels and blood pH in RYGB rats (R !
"0.667), but not in AL or BWm rats, suggesting that increased
lactate levels at least partly accounted for the metabolic aci-
dosis of RYGB rats.
Chronic metabolic acidosis (CMA) leads to an activation of
compensatory mechanisms in the kidney and intestine, in-
cluding increased renal ammonium excretion and upregula-
tion of the intestinal ion transporters sodium-hydrogen ex-
changer 3 (NHE3) and sodium-bicarbonate cotransporter 1
(NBCe1) (31). Accordingly, urinary and fecal pH were
decreased (Fig. 4B) in RYGB rats, while urinary ammonium
excretion was increased (Fig. 4C). mRNA expression of NHE3
was increased in the jejunum and of NBCe1 in the jejunum and
ileum of RYGB rats, respectively (Fig. 4D). Together, these
results indicate an adaptive response to the CMA in RYGB
rats; however, this response seemed to be insufficient to fully
compensate for the increased lactate levels and systemic aci-
dosis.
Changes in parameters of mineral homeostasis and bone
metabolism after RYGB surgery. Total and ionized serum
calcium levels were unchanged in RYGB rats except for a
small decrease after 14 wk compared with AL rats. Serum
phosphorus levels were increased compared with BWm, but
not AL rats 2 wk after surgery. There was no difference 7 or 14
wk after surgery (Fig. 5A). Surprisingly, there was no signifi-
cant difference between PTH levels of RYGB and sham-
operated rats at any time point (Fig. 5B).
Serum osteocalcin levels and urinary deoxypyridinoline
(DPD) excretion were measured as markers of bone formation
and resorption, respectively. While osteocalcin was unchanged
throughout the study, DPD excretion was increased compared
with BWm rats at 2 and 7 wk after surgery, suggesting
increased bone resorption at these time points, at least com-
pared with weight-matched animals (Fig. 5C).
Renal activation of vitamin D is increased, but vitamin
D-induced gene upregulation in the kidney is lower after
RYGB. Consistent with human studies reporting 25(OH)D
deficiency in patients after RYGB surgery, RYGB rats had
significantly lower levels of 25(OH)D than both AL and
Fig. 2. Decreased bone mass in RYGB rats. A: bone mineral density (BMD) of lumbar vertebrae measured by computed tomography (CT) and change in BMD
compared with AL rats 2, 7, and 14 wk after surgery. B and C: bone volume/trabecular volume fraction (BV/TV) and trabecular thickness (Tb. Thk.) of lumbar
vertebrae (B) and tibiae (C) evaluated by histomorphometric analysis 16 wk after surgery. D and E: representative images of toluidine blue stained L3 vertebral
bodies (D) and tibiae (E) of AL, BWm, and RYGB rats. F: higher magnification illustrating reduced trabecular thickness in L3 vertebral bodies of RYGB,
compared with AL and BWm rats. Data represent mean values # SE (*P $ 0.05; **P $ 0.01; ***P $ 0.001). Bar ! 1 mm (D and E); 200 %m (F).
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BWm control rats. However, active 1,25(OH)2D was in-
creased more than twofold (Fig. 6A). Consistent with the
circulating blood levels, RYGB rats displayed both in-
creased renal expression of the vitamin D-activating enzyme
1-!-hydroxylase (CYP27B1) mRNA and decreased renal
expression of the vitamin D-inactivating enzyme 24-hydrox-
ylase (CYP24A1) mRNA (Fig. 6B), suggesting that both
increased activation and decreased inactivation contributed
to elevated circulating 1,25(OH)2D levels.
The vitamin D receptor (VDR) is a nuclear transcription
factor that is expressed in various tissues (51). Binding of
1,25(OH)2D to the VDR leads to upregulation of genes in-
volved in calcium homeostasis, including the VDR itself, to
increase intestinal calcium absorption and decrease renal cal-
cium excretion. In the kidney, the membrane calcium channel
transient receptor potential vanilloid 5 (TRPV5) and the cyto-
solic calcium buffer calbindin D28k (CALB1) are upregulated
by 1,25(OH)2D (53); VDR binding in the intestine leads to
upregulation of TRPV6 under normal conditions (28). Never-
theless, mRNA expression of TRPV5 and CALB1 in RYGB
rats was unchanged (Fig. 6C), and VDR protein levels were
lower in the kidney of RYGB rats (Fig. 6D). In contrast,
1,25(OH)2D signaling in the intestine seemed to be intact
because TRPV6 mRNA expression was increased in the duo-
Fig. 3. Relative and absolute 24-h intestinal absorption of calcium (A) and phosphorus (B), 24-h urinary concentration and absolute urinary loss of calcium (C)
and phosphorus (D) in AL, BWm, and RYGB rats 2, 7, and 14 wk after surgery. Data are expressed as means " SE (*P # 0.05; **P # 0.01; ***P # 0.001).
Fig. 4. Venous blood pH, anion gap, and lactate levels (A), pH of urine and feces extracts (B), and 24-h urinary ammonium (NH4$) excretion (C) in AL, BWm,
and RYGB rats 2, 7, and 14 wk after surgery. D: mRNA expression of the apical sodium-hydrogen exchanger NHE3 and the basolateral sodium-bicarbonate
cotransporter NBCe1 in duodenum (biliopancreatic limb in RYGB), jejunum (alimentary limb in RYGB), and ileum (common channel in RYGB) of AL, BWm,
and RYGB rats 16 wk after surgery. Data are expressed as means " SE (*P # 0.05; **P # 0.01; ***P # 0.001).
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denum and jejunum of RYGB rats, as expected. TRPV6
expression was also upregulated in the duodenum of BWm
rats, which may potentially be considered an adaptive response
to reduced dietary calcium intake (Fig. 6E).
Increased 1,25(OH)2D levels in RYGB rats potentially affect
growth plate maturation. Vitamin D deficiency or lack of the
VDR lead to characteristic changes in the epiphyseal growth
plates, i.e., growth plate widening with disorganized structure
and accumulation of immature, unmineralized bone mass (8).
1,25(OH)2D on the other hand reduces growth plate width in
young rats (23). In our study, the histological evaluation of the
epiphyseal growth plate in the proximal tibia revealed a trend
toward narrowing of the growth plates in adult RYGB rats
(P ! 0.1; Fig. 7).
DISCUSSION
We performed the first comprehensive longitudinal investi-
gation of changes in bone metabolism after RYGB surgery in
a rat model. Postoperative bone loss has repeatedly been
described in RYGB patients and is often associated with low
25(OH)D levels and 2° HPT (6, 14, 25). To our knowledge,
however, no causal relationship among vitamin D status, PTH
levels, and bone loss after RYGB surgery has been demon-
Fig. 5. Serum levels of total calcium, ionized
calcium, and phosphorus (A) and of parathyroid
hormone (PTH) (B). C: serum levels of osteo-
calcin and urinary 24-h deoxypyridinoline
(DPD) excretion in AL, BWm, and RYGB rats
2, 7, and 14 wk after surgery. Data represent
mean values " SE (*P ! 0.05; **P ! 0.01;
***P ! 0.001).
Fig. 6. Altered vitamin D metabolism and signaling after RYGB surgery. A: serum levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D
[1,25(OH)2D] in AL, BWm, and RYGB rats 2, 7, and 14 wk after surgery. B–D: renal mRNA expression of CYP24A1 and CYP27B1, the genes encoding the
24-hydroxylase and the 1-#-hydroxylase, respectively (B), renal transient receptor potential vanilloid 5 (TRPV5), and calbindin D28k (CALB1) mRNA
expression (C) and renal vitamin D receptor (VDR) protein expression (D) in AL, BWm, and RYGB rats 16 wk after surgery. E: TRPV6 mRNA expression in
duodenum, jejunum, and ileum of AL, BWm, and RYGB rats 16 wk after surgery. Data represent mean values " SE (*P ! 0.05; **P ! 0.01; ***P ! 0.001).
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strated. Since vitamin D deficiency and 2° HPT often occur in
obese patients even before any weight loss intervention, it is
difficult to dissect the specific contribution of RYGB surgery to
these conditions. Using a well-established RYGB rat model
with standardized light exposure and access to standard labo-
ratory chow without calcium or vitamin D supplementation, we
showed that BMD decreased progressively for several weeks
after surgery. Bone loss was initially associated with calcium
malabsorption; however, no restoration of bone mass was
detectable in RYGB rats even after normalization of intestinal
calcium absorption. No signs of 2° HPT were detected, but
elevated active vitamin D levels and metabolic acidosis caused
by increased lactate levels occurred throughout, which may
have adversely affected bone metabolism. These data suggest
that initially, reduced calcium absorption after RYGB may lead
to calcium mobilization from bone; however, this seems to be
independent of vitamin D malabsorption. In contrast, RYGB-
induced metabolic acidosis may interfere with the hormonal
control of calcium homeostasis and bone mass. Importantly,
these changes were independent of body weight loss, since
they did not occur in the food-restricted, body weight-matched
control group.
Our data show that after an initial decrease in BMD, the
difference between AL and RYGB rats remained unchanged
between postoperative weeks 7 and 14. Together with the
normalization of intestinal calcium absorption at these time
points, this suggests that impaired intestinal calcium absorption
contributed to bone loss, at least initially. Under physiological
conditions, most of dietary calcium is absorbed in the duode-
num (42) by active transcellular transport, which requires the
TRPV6 calcium channel (29). TRPV6 is almost exclusively
expressed in the duodenum and is upregulated in response to
increased 1,25(OH)2D levels. In the distal small intestine,
passive calcium absorption is predominant (38). The passive
absorption strongly depends on the luminal calcium concen-
trations and is, therefore, lower at low dietary calcium intake.
After RYGB surgery, the proximal small intestine is excluded
from nutrient flow, most likely leading to impaired transcellu-
lar calcium absorption. However, the direct delivery of nutri-
ents to more distal parts of the small intestine and the increased
luminal calcium concentrations could lead to increased passive
calcium absorption in the jejunum and ileum. A recent study by
Pan et al. (37) suggests that the sodium bicarbonate exchanger
NHE3 is involved in passive calcium absorption. Interestingly,
NHE3 mRNA expression was increased in the jejunum of
RYGB rats, which may enhance passive calcium absorption in
the distal small intestine. Thus, the initial calcium malabsorp-
tion observed in RYGB rats is most likely caused by the
absence of active transport in the excluded proximal small
intestine. The upregulation of TRPV6 expression in the duo-
denum and jejunum of RYGB rats indicates a compensatory
response to the sudden decrease in calcium availability. This
response, however, is futile since the proximal small intestine
is excluded from nutrient flow; nonetheless, the data show that
the duodenum of RYGB rats remains responsive to elevated
1,25(OH)2D levels, even in the absence of direct nutrient
contact. The compensation by increased passive absorption in
the distal small intestine seems to be insufficient shortly after
surgery, potentially due to a lack of adaptation time of the gut
to the altered anatomy. Duodenal TRPV6 expression was also
increased in BWm rats; however, their 1,25(OH)2D levels were
comparable to AL rats. It has been described in animals on a
calcium-deficient diet that reduced dietary calcium intake leads
to increased 1,25(OH)2D-mediated TRPV6 expression (48,
52); it is, therefore, surprising that the food-restricted BWm
rats did not display increased 1,25(OH)2D levels. It must be noted,
however, that in contrast to animals fed a calcium-deficient diet ad
libitum, our animals were fed a restricted amount of a diet with
normal calcium content. This might physiologically represent a
completely different situation since, unlike a calcium-deficient
diet, our approach presumably does not influence the luminal
calcium concentration in the intestine. To our knowledge, the
effects of chronic food restriction on 1,25(OH)2D levels and on
intestinal calcium transporter gene expression have never been
investigated. Therefore, we speculate that in this situation,
either a vitamin D-independent mechanism or a change in
vitamin D receptor sensitivity led to duodenal TRPV6 upregu-
lation.
The finding of increased PTH levels in many patients after
RYGB surgery has led to the assumption that PTH-induced bone
resorption is the main cause of reduced BMD. However, the high
prevalence of 2° HPT in obese people already before RYGB
surgery complicates the assessment of a potential causal link
between PTH and postsurgical bone loss. Interestingly, we did not
find a significant increase in PTH levels in RYGB rats, which
suggests that PTH-independent mechanisms causing bone loss
seem to prevail in the first weeks after surgery.
Consistent with previous studies reporting 25(OH)D defi-
ciency in patients after RYGB surgery, our RYGB rats had
decreased 25(OH)D levels. Importantly, however, we found
that levels of the hormonally active metabolite 1,25(OH)2D
were markedly increased. Even though 1,25(OH)2D increases
Fig. 7. Representative images showing growth plates of toluidine blue-stained tibiae of sham-operated, ad libitum fed (AL; A), sham-operated, body
weight-matched (BWm; B) and Roux-en-Y gastric bypass-operated (RYGB; C) rats and quantification of growth plate width (D) 16 wk postsurgery. Data are
expressed as mean values ! SE. Scale bar: 100 "m.
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active calcium absorption under physiological conditions, we
cannot exclude that in combination with intestinal calcium
malabsorption, 1,25(OH)2D may, in fact, have negative effects
on bone mass. A recent study by Lieben et al. (30) showed that
specific disruption of intestinal vitamin D signaling in intes-
tine-specific VDR knockout mice increased 1,25(OH)2D lev-
els, which contributed to maintaining normocalcemia by mo-
bilization of skeletal calcium and inhibition of bone mineral-
ization. Because the main physiological effect of intestinal
vitamin D signaling is to increase active calcium absorption in
the proximal intestine, intestine-specific VDR knockout mice
may, to some extent, be comparable to the situation after
RYGB surgery, where duodenal vitamin D signaling, although
intact, remains ineffective, due to the altered gut anatomy. We,
therefore, speculate that increased 1,25(OH)2D levels contrib-
ute to bone loss in the initial phase of intestinal calcium
malabsorption and to the insufficient restoration of bone mass
after normalization of calcium absorption (22).
The exact mechanism behind increased 1,25(OH)2D levels
in our RYGB rats is not clear. The fact that 1,25(OH)2D levels
remained elevated after normalization of calcium absorption
suggest that the increased vitamin D activation may not only be
related to serum calcium levels. Our data show that RYGB
surgery led to severe systemic CMA that was at least partly due
to increased plasma lactate levels. We did not determine the
source of increased lactate levels; however, we speculate that
alterations in the bacterial flora of the intestine (54) led to
increased lactate production after carbohydrate digestion, a
phenomenon frequently observed in patients with short-bowel
syndrome or jejuno-ileal bypass surgery (40). CMA leads to a
PTH-independent increase in 1,25(OH)2D production (27)
and could, therefore, play a role in vitamin D metabolism
after RYGB surgery. In addition, it has previously been
speculated that enterocytes may have the capacity to sense
changes in dietary calcium intake and to increase renal 1-!
hydroxylase activity via an unknown signal in response to
decreased intestinal calcium concentrations (32). The sud-
den absence of luminal calcium in the proximal small
intestine after the RYGB procedure could, thereby, directly
induce an increase in 1,25(OH)2D levels.
An unexpected finding of our study was that renal calcium
excretion was increased in RYGB rats; this was already seen in
the initial phase of the study with intestinal calcium malab-
sorption and massive bone loss, but also later in the study. A
decrease in intestinal calcium availability normally leads
to 1,25(OH)2D-mediated upregulation of renal CALB1 and
TRPV5 expression (53) to minimize urinary calcium loss.
Despite higher 1,25(OH)2D levels, urinary calcium concentra-
tion and absolute calcium excretion were increased in RYGB
rats throughout the study, and there was no change in renal
CALB1 and TRPV5 expression when examined at study end.
This suggests that additional factors may have counteracted the
control of renal calcium metabolism by 1,25(OH)2D. CMA has
been shown to enhance calciuresis by decreasing the expres-
sion of CALB1 and TRPV5 in the kidney (34); therefore, the
CMA detected in RYGB rats is one possible explanation for
increased urinary calcium loss. CMA has additional direct
effects on bone metabolism, including a stimulatory effect of
H" on osteoclast activation (4) and an inhibition of bone
formation and mineralization (9). CMA may, therefore, play an
important facilitator role in bone resorption after RYGB sur-
gery and in the prevention of bone mass restoration after
normalization of calcium absorption.
Since the original submission of our paper, Stemmer et al.
(47) published data on the effect of RYGB surgery on bone
mass in rats. Our data are largely consistent with their findings.
Similar to our results, Stemmer et al. (47) found that bone mass
was reduced by RYGB 8 wk after surgery, which was associ-
ated with decreased 25(OH)D levels. A calcium and vitamin
D-enriched diet attenuated the effects of RYGB surgery on
bone mass; however, it did not fully prevent bone loss, which
further suggests that additional factors to calcium and vita-
min D malabsorption may be involved in RYGB-induced
bone loss. In addition to their findings, we now report that
lower 25(OH)D may not be a pathophysiologically relevant
factor because increased conversion to the active metabolite
may compensate for lower absorption. Hence, our data nicely
complement the findings by Stemmer et al. (47) and suggest
further mechanisms that may contribute to the significant bone
loss that occurs after RYGB in rats.
Relevance to human disease. The current study provides
valuable new insights into the effects of RYGB surgery on
bone metabolism that may be of high clinical interest (Fig. 8).
The increased levels of active 1,25(OH)2D in our RYGB rats
indicate that vitamin D deficiency may not be the sole cause of
RYGB-induced bone loss (44) because insufficient 25(OH)D
absorption may be compensated by a higher proportion of
transformation to the active 1,25(OH)2D form of vitamin D.
This finding suggests that the need of vitamin D supplemen-
tation after surgery should be evaluated on the basis of mea-
sured 25(OH)D and 1,25(OH)2D levels. Further, we believe
that calcium supplementation may have beneficial effects on
bone mass, especially in the first months after the procedure,
because calcium malabsorption was transient and because there
was no further bone loss in our RYGB rats after normalization
of calcium absorption. It has to be mentioned in this context
that the jejunojejunostomy in our rat model is performed more
distally than in most human RYGB procedures. This could
potentially contribute to the reported calcium malabsorption;
however, it has previously been shown that the true fractional
calcium absorption also decreases after RYGB surgery in
humans (41), suggesting that this observation is not specific to
our model but of general relevance. Finally, metabolic acidosis
should be monitored and treated with alkaline supplementa-
tions, if necessary. Alkaline treatment has been shown to
increase bone mass, even in nonacidotic postmenopausal
women (24).
Even though the clinical relevance of bone loss after RYGB
surgery in humans is still unclear, there are at least two patient
subpopulations that are of particular interest for potential future
studies. First, a majority of patients undergoing RYGB surgery
are women, and many of them are perimenopausal or post-
menopausal. We have recently established an RYGB model in
female rats and have shown that the reproductive axis function
may influence the outcome of RYGB surgery in women (5).
Given the strong connection between menopause and osteopo-
rosis, it will be of high interest to determine whether the
menopausal state directly influences bone loss after RYGB
surgery and whether there are potential interactions between
the mechanisms of postsurgical and postmenopausal bone loss
in women.
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Second, bariatric surgery has become an important treatment
option for morbid obesity in adolescents in recent years (36).
Besides the loss of bone mass that has been described in adult
patients, there may be additional negative effects of RYGB
surgery on skeleton development during growth. 1,25(OH)2D
treatment causes altered maturation and narrowing of the epiph-
yseal growth plate in rats (23). The chronically elevated
1,25(OH)2D levels detected in RYGB rats and also previously
reported in adults after RYGB surgery could, therefore, have
effects on the growing skeleton that may not be detected in adults.
Finally, we want to mention that there are some limitations
of our study. Although our RYGB rat model has repeatedly
been shown to mimic changes in physiology after RYGB
surgery in humans, we sometimes find exaggerated responses
to the surgery in animal models. Hence, the extent of postsur-
gical bone loss in humans and the question of whether there are
relevant functional consequences may still be disputed, al-
though recent evidence suggests a connection between RYGB
surgery and fracture incidence (33). However, as already men-
tioned, the evaluation of changes in bone and calcium metab-
olism after RYGB surgery in humans is very challenging
because of preexisting conditions, such as 25(OH)D deficiency
and 2° HPT. In addition, most patients are supplemented with
vitamin D and calcium after the surgery, but there is often no
information about vitamin D and calcium levels prior to sup-
plementation, there is no standardized replacement protocol,
and information about compliance is difficult to obtain.
Another potential limitation of our study is that there are
currently no data showing that RYGB surgery leads to meta-
bolic acidosis in humans, even though cases of D-lactic acido-
sis have been described (7a). However, the most common
calcium supplements, calcium citrate and calcium carbonate,
also confer alkali load that could unintentionally prevent the
development of an acidotic state; long-term assessment of
acid-base imbalances in RYGB patients is, therefore, similarly
challenging to the investigation of bone metabolism.
Lastly, we want to point out that the major advantages of using
animal models such as ours are the close controllability of envi-
ronmental factors, the standardization among groups, and the
inclusion of different control groups, in particular, a group
matched for body weight loss. We can, therefore, use the new
evidence provided by experiments in animal models to improve
and refine the design of studies involving human RYGB patients.
Perspectives and Significance
Our data point to a complex disruption of bone homeostasis
after RYGB that is not a simple consequence of alterations in
vitamin D and calcium levels. By the use of a body weight-
matched control group, we demonstrated that chronic food
restriction in sham-operated rats did not have comparable
effects on bone metabolism. We showed that increased activa-
tion of vitamin D may compensate for intestinal vitamin D
malabsorption in RYGB rats. Together with the absence of 2°
HPT, this questions the role of vitamin D deficiency and 2°
HPT in RYGB-induced bone loss. Interestingly, RYGB sur-
gery led to increased lactate levels and chronic metabolic
acidosis, which may have contributed to both the initial bone
loss and the insufficient subsequent restoration of bone mass.
Even though cases of D-lactic acidosis have been described in
humans after RYGB surgery, there are no studies on postsur-
gical changes in acid-base status. Our data suggest that future
studies should include consideration of metabolic acidosis.
Fig. 8. Proposed mechanisms for bone loss and changes in calcium and vitamin D metabolism early after RYGB surgery (A) and after compensation of initial
calcium malabsorption (B). A: active intestinal calcium absorption decreases early after Roux-en-Y gastric bypass surgery due to the exclusion of the duodenum
from nutrient flow. Subsequently, increased conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D [1,25(OH)2D] may be further supported by
metabolic acidosis and direct signaling from calcium-sensing enterocytes in the duodenum. Compensatory upregulation of the intestinal calcium channel TRPV6
by 1,25(OH)2D is futile since TRPV6 is mainly expressed in the duodenum. Calcium mobilization from bones ensures stable blood calcium levels, which may
be partly mediated by elevated 1,25(OH)2D. In addition, metabolic acidosis potentially contributes to bone resorption and leads to decreased renal calcium
reabsorption. B: after adaptation to the altered anatomy of the gastrointestinal tract, direct delivery of nutrients to the distal small intestine facilitates passive
calcium absorption, which compensates for the decreased active absorption in the duodenum. The normalization of intestinal calcium malabsorption does not
lead to a restoration of bone mass due to inhibitory effects of metabolic acidosis and potentially 1,25(OH)2D on bone formation. Vitamin D activation and renal
calcium loss remain increased. Thick arrows represent the proposed predominant mechanisms.
R1007GASTRIC BYPASS CAUSES BONE LOSS IN RATS
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00038.2013 • www.ajpregu.org
 	   34   
ACKNOWLEDGMENTS
We thank Ines Mittner (Institute of Animal Nutrition, University of Zurich)
and Katrin Kaempf (Musculoskeletal Research Unit, Center for Applied
Biotechnology and Molecular Medicine, University of Zurich) for assistance.
The use of the ZIRP Core Facility for Rodent Physiology is gratefully
acknowledged. We thank Nori Geary for critical revision of the manuscript.
GRANTS
This work was supported by the Swiss National Science Foundation, Swiss
National Centre of Competence in Research Kidney Control of Homeostasis
and the Forschungskredit of the University of Zurich.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
Author contributions: K.A., M.S., M.B., and T.A.L. conception and design
of research; K.A. and N.G. performed experiments; K.A., N.G., and C.A.W.
analyzed data; K.A., C.A.W., A.L., M.B., and T.A.L. interpreted results of
experiments; K.A. prepared figures; K.A. drafted manuscript; K.A., C.A.W.,
A.L., M.S., M.B., and T.A.L. edited and revised manuscript; K.A., N.G.,
C.A.W., A.L., M.S., M.B., and T.A.L. approved final version of manuscript.
REFERENCES
1. Aarts E, van Groningen L, Horst R, Telting D, van Sorge A, Janssen
I, de Boer H. Vitamin D absorption: consequences of gastric bypass
surgery. Eur J Endocrinol 164: 827–832, 2011.
2. Aasheim ET, Johnson LK, Hofso D, Bohmer T, Hjelmesaeth J.
Vitamin status after gastric bypass and lifestyle intervention: a compara-
tive prospective study. Surg Obes Relat Dis 8: 169–175, 2012.
3. Armbrecht HJ, Gross CJ, Zenser TV. Effect of dietary calcium and
phosphorus restriction on calcium and phosphorus balance in young and
old rats. Arch Biochem Biophys 210: 179–185, 1981.
4. Arnett TR. Acidosis, hypoxia and bone. Arch Biochem Biophys 503:
103–109, 2010.
5. Asarian L, Abegg K, Geary N, Schiesser M, Lutz TA, Bueter M.
Estradiol increases body weight loss and gut-peptide satiation after Roux-
en-Y gastric bypass in ovariectomized rats. Gastroenterology 143: 325–
327 322, 2012.
6. Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after
bariatric surgery. Nat Rev Endocrinol 8: 544–556, 2012.
7. Berthelot M. Violet d’aniline. Rep Chim App 1: 284, 1859.
7a.Bhardwaj A, Watanabe M, Shah JR. A 46-yr-old woman with ataxia
and blurred vision 3 months after bariatric surgery. Am J Gastroenterol
103: 1575–1577, 2008.
8. Bolt MJ, Liu W, Qiao G, Kong J, Zheng W, Krausz T, Cs-Szabo G,
Sitrin MD, Li YC. Critical role of vitamin D in sulfate homeostasis:
regulation of the sodium-sulfate cotransporter by 1,25-dihydroxyvitamin
D3. Am J Physiol Endocrinol Metab 287: E744–E749, 2004.
9. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits
bone formation by osteoblasts in vitro by preventing mineralization. Calcif
Tissue Int 77: 167–174, 2005.
10. Bueter M, Abegg K, Seyfried F, Lutz TA, and le Roux CW. Roux-en-Y
gastric bypass operation in rats. J Vis Exp: e3940, 2012.
11. Bueter M, Lowenstein C, Olbers T, Wang M, Cluny NL, Bloom SR,
Sharkey KA, Lutz TA, le Roux CW. Gastric bypass increases energy
expenditure in rats. Gastroenterology 138: 1845–1853, 2010.
12. Carlin AM, Rao DS, Yager KM, Parikh NJ, Kapke A. Treatment of
vitamin D depletion after Roux-en-Y gastric bypass: a randomized pro-
spective clinical trial. Surg Obes Relat Dis 5: 444–449, 2009.
13. Casagrande DS, Repetto G, Mottin CC, Shah J, Pietrobon R, Worni
M, Schaan BD. Changes in bone mineral density in women following
1-year gastric bypass surgery. Obes Surg 22: 1287–1292, 2012.
14. Clements RH, Yellumahanthi K, Wesley M, Ballem N, Bland KI.
Hyperparathyroidism and vitamin D deficiency after laparoscopic gastric
bypass. Am Surg 74: 469–474; discussion 474–465, 2008.
15. Doube M, Klosowski MM, Arganda-Carreras I, Cordelieres FP,
Dougherty RP, Jackson JS, Schmid B, Hutchinson JR, Shefelbine SJ.
BoneJ: Free and extensible bone image analysis in ImageJ. Bone 47:
1076–1079, 2010.
16. Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link
between obesity and low circulating 25-hydroxyvitamin D concentrations:
considerations and implications. Int J Obes (Lond) 36: 387–396, 2012.
17. Egan KP, Brennan TA, Pignolo RJ. Bone histomorphometry using free
and commonly available software. Histopathology 61: 1168–1173, 2012.
18. Erben RG, Glosmann M. Histomorphometry in rodents. Methods Mol
Biol 816: 279–303, 2012.
19. Fleischer J, Stein EM, Bessler M, Della Badia M, Restuccia N,
Olivero-Rivera L, McMahon DJ, Silverberg SJ. The decline in hip bone
density after gastric bypass surgery is associated with extent of weight
loss. J Clin Endocrinol Metab 93: 3735–3740, 2008.
20. Gassmann M, Grenacher B, Rohde B, Vogel J. Quantifying Western
blots: pitfalls of densitometry. Electrophoresis 30: 1845–1855, 2009.
21. Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A,
Considine RV, Peacock M. Serum leptin, parathyroid hormone, 1,25-
dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phospha-
tase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 97:
1655–1662, 2012.
22. Hock JM, Gunness-Hey M, Poser J, Olson H, Bell NH, Raisz LG.
Stimulation of undermineralized matrix formation by 1,25 dihydroxyvita-
min D3 in long bones of rats. Calcif Tissue Int 38: 79–86, 1986.
23. Idelevich A, Kerschnitzki M, Shahar R, Monsonego-Ornan E.
1,25(OH)2D3 alters growth plate maturation and bone architecture in
young rats with normal renal function. PLoS One 6: e20772, 2011.
24. Jehle S, Zanetti A, Muser J, Hulter HN, Krapf R. Partial neutralization
of the acidogenic Western diet with potassium citrate increases bone mass
in postmenopausal women with osteopenia. J Am Soc Nephrol 17: 3213–
3222, 2006.
25. Jin J, Robinson AV, Hallowell PT, Jasper JJ, Stellato TA, Wilhem
SM. Increases in parathyroid hormone (PTH) after gastric bypass surgery
appear to be of a secondary nature. Surgery 142: 914–920; discussion
914–920, 2007.
26. Johnson JM, Maher JW, Samuel I, Heitshusen D, Doherty C, Downs
RW. Effects of gastric bypass procedures on bone mineral density,
calcium, parathyroid hormone, and vitamin D. J Gastrointest Surg 9:
1106–1110; discussion 1110–1101, 2005.
27. Krapf R, Vetsch R, Vetsch W, Hulter HN. Chronic metabolic acidosis
increases the serum concentration of 1,25-dihydroxyvitamin D in humans
by stimulating its production rate. Critical role of acidosis-induced renal
hypophosphatemia. J Clin Invest 90: 2456–2463, 1992.
28. Lee GS, Jung EM, Choi KC, Oh GT, Jeung EB. Compensatory
induction of the TRPV6 channel in a calbindin-D9k knockout mouse: Its
regulation by 1,25-hydroxyvitamin D3. J Cell Biochem 108: 1175–1183,
2009.
29. Lieben L, Benn BS, Ajibade D, Stockmans I, Moermans K, Hediger
MA, Peng JB, Christakos S, Bouillon R, Carmeliet G. Trpv6 mediates
intestinal calcium absorption during calcium restriction and contributes to
bone homeostasis. Bone 47: 301–308, 2010.
30. Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J,
Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF,
Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is
maintained in mice under conditions of calcium malabsorption by vitamin
D-induced inhibition of bone mineralization. J Clin Invest 122: 1803–
1815, 2012.
31. Lucioni A, Womack C, Musch MW, Rocha FL, Bookstein C, Chang
EB. Metabolic acidosis in rats increases intestinal NHE2 and NHE3
expression and function. Am J Physiol Gastrointest Liver Physiol 283:
G51–G56, 2002.
32. Miao D, He B, Lanske B, Bai XY, Tong XK, Hendy GN, Goltzman D,
Karaplis AC. Skeletal abnormalities in Pth-null mice are influenced by
dietary calcium. Endocrinology 145: 2046–2053, 2004.
33. Nakamura KM, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ,
Melton LJ, 3rd, Kennel KA. Fracture risk following bariatric surgery: a
population-based study. Osteoporos Int In press.
34. Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJ. Acid-base
status determines the renal expression of Ca2! and Mg2! transport
proteins. J Am Soc Nephrol 17: 617–626, 2006.
35. Nowik M, Picard N, Stange G, Capuano P, Tenenhouse HS, Biber J,
Murer H, Wagner CA. Renal phosphaturia during metabolic acidosis
revisited: molecular mechanisms for decreased renal phosphate reabsorp-
tion. Pflügers Arch 457: 539–549, 2008.
36. Olbers T, Gronowitz E, Werling M, Marlid S, Flodmark CE, Peltonen
M, Gothberg G, Karlsson J, Ekbom K, Sjostrom LV, Dahlgren J,
Lonroth H, Friberg P, Marcus C. Two-year outcome of laparoscopic
R1008 GASTRIC BYPASS CAUSES BONE LOSS IN RATS
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00038.2013 • www.ajpregu.org
 	   35   
Roux-en-Y gastric bypass in adolescents with severe obesity: results from
a Swedish Nationwide Study (AMOS). Int J Obes (Lond) 36: 1388–1395,
2012.
37. Pan W, Borovac J, Spicer Z, Hoenderop JG, Bindels RJ, Shull GE,
Doschak MR, Cordat E, Alexander RT. The epithelial sodium/proton
exchanger, NHE3, is necessary for renal and intestinal calcium (re)absorp-
tion. Am J Physiol Renal Physiol 302: F943–F956, 2012.
38. Pansu D, Bellaton C, Roche C, Bronner F. Duodenal and ileal calcium
absorption in the rat and effects of vitamin D. Am J Physiol Gastrointest
Liver Physiol 244: G695–G700, 1983.
39. Pereira FA, de Castro JA, dos Santos JE, Foss MC, Paula FJ. Impact
of marked weight loss induced by bariatric surgery on bone mineral
density and remodeling. Braz J Med Biol Res 40: 509–517, 2007.
40. Petersen DC. Lactic acidosis. Nutr Clin Pract 20: 634–645, 2005.
41. Riedt CS, Brolin RE, Sherrell RM, Field MP, Shapses SA. True
fractional calcium absorption is decreased after Roux-en-Y gastric bypass
surgery. Obesity (Silver Spring) 14: 1940–1948, 2006.
42. Sernka TJ, Borle AB. Calcium in the intestinal contents of rats on
different calcium diets. Proc Soc Exp Biol Med 131: 1420–1423, 1969.
43. Shah M, Simha V, Garg A. Long-term impact of bariatric surgery on
body weight, comorbidities, and nutritional status. J Clin Endocrinol
Metab 91: 4223–4231, 2006.
44. Sinha N, Shieh A, Stein EM, Strain G, Schulman A, Pomp A, Gagner
M, Dakin G, Christos P, Bockman RS. Increased PTH and
1.25(OH)(2)D levels associated with increased markers of bone turnover
following bariatric surgery. Obesity (Silver Spring) 19: 2388–2393, 2011.
45. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH,
Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC.
Measurement of protein using bicinchoninic acid. Anal Biochem 150:
76–85, 1985.
46. Soleymani T, Tejavanija S, Morgan S. Obesity, bariatric surgery, and
bone. Curr Opin Rheumatol 23: 396–405, 2011.
47. Stemmer K, Bielohuby M, Grayson BE, Begg DP, Chambers AP, Neff
C, Woods SC, Erben RG, Tschop MH, Bidlingmaier M, Clemens TL,
Seeley RJ. Roux-en-Y gastric bypass surgery but not vertical sleeve
gastrectomy decreases bone mass in male rats. Endocrinology 154: 2015–
2024, 2013.
48. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van
Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R,
Carmeliet G. Duodenal calcium absorption in vitamin D receptor-knock-
out mice: functional and molecular aspects. Proc Natl Acad Sci USA 98:
13324–13329, 2001.
49. Viegas M, Vasconcelos RS, Neves AP, Diniz ET, Bandeira F. Bariatric
surgery and bone metabolism: a systematic review. Arq Bras Endocrinol
Metabol 54: 158–163, 2010.
50. Vilarrasa N, San Jose P, Garcia I, Gomez-Vaquero C, Miras PM, de
Gordejuela AG, Masdevall C, Pujol J, Soler J, Gomez JM. Evaluation
of bone mineral density loss in morbidly obese women after gastric
bypass: 3-year follow-up. Obes Surg 21: 465–472, 2011.
51. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch
Biochem Biophys 523: 123–133, 2012.
52. Woudenberg-Vrenken TE, Lameris AL, Weissgerber P, Olausson J,
Flockerzi V, Bindels RJ, Freichel M, Hoenderop JG. Functional
TRPV6 channels are crucial for transepithelial Ca2! absorption. Am J
Physiol Gastrointest Liver Physiol 303: G879–G885, 2012.
53. Xi Q, Wang S, Ye Z, Liu J, Yu X, Zhu Z, Su S, Bai J, Li C.
Adenovirus-delivered microRNA targeting the vitamin D receptor reduces
intracellular Ca2! concentrations by regulating the expression of Ca2!-
transport proteins in renal epithelial cells. BJU Int 107: 1314–1319, 2011.
54. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y,
Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-
Brown R. Human gut microbiota in obesity and after gastric bypass. Proc
Natl Acad Sci USA 106: 2365–2370, 2009.
R1009GASTRIC BYPASS CAUSES BONE LOSS IN RATS
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00038.2013 • www.ajpregu.org
 	   36 
6. Original Research Article: “Acute peripheral GLP-1 Receptor 
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Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy
expenditure in rats after Roux-en-Y gastric bypass☆
Kathrin Abegg a, Marc Schiesser b, Thomas A. Lutz a,c,⁎, Marco Bueter b,c
a Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
b University Hospital Zurich, Department of Surgery, Division of Visceral and Transplantation Surgery, Zurich, Switzerland
c Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
H I G H L I G H T S
• Compensatory fall in energy expenditure after weight loss is attenuated by RYGB.
• Acute injection of GLP-1 antagonist Exendin-9 increases eating only in RYGB rats.
• Enhanced release of GLP-1 may contribute to inhibitory effect of RYGB on eating.
• Acute administration of GLP-1 agonist Exendin-4 decreases eating more in RYGB rats.
• Acute modulation of GLP-1 signaling does not alter energy expenditure in RYGB rats.
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Compared to traditional weight loss strategies, the compensatory decrease in energy expenditure in response to
bodyweight loss ismarkedly attenuated after Roux-en-Y gastric bypass surgery (RYGB). Because basal and post-
prandial levels of glucagon-like peptide-1 (GLP-1) are increased after RYGB surgery, and because GLP-1 has been
shown to increase energy expenditure, we investigated if increasedGLP-1 levels are involved in the alterations in
energy expenditure after RYGB. Adult male Wistar rats were randomized for RYGB (n = 8) or sham surgery
(n = 17). Part of the sham-operated rats were food restricted and body weight-matched (n = 8) to the RYGB
animals. The effects of acute subcutaneous administration of the GLP-1 antagonist Exendin (9–39) (Ex-9,
30 μg/kg) or the GLP-1 agonist Exendin-4 (Ex-4, 5 μg/kg), respectively, on energy expenditure were tested
using indirect calorimetry. We found that Ex-9 increased food intake in RYGB, but not in sham-operated rats.
Energy expenditure was lower in RYGB and sham-operated body weight-matched rats compared to
sham-operated ad libitum fed rats, but signiﬁcantly higher in RYGB rats compared to sham-operated
body weight-matched rats. There was no effect of Ex-9 treatment on energy expenditure in either group
of animals. Similarly, Ex-4 decreased food intake more in RYGB than in sham-operated rats, but Ex-4 did
not modulate energy expenditure in any surgical group. We conclude that acute modulation of GLP-1 sig-
naling is not directly involved in altered energy expenditure after RYGB surgery in rats.
© 2013 Elsevier Inc. All rights reserved.
1. Introduction
Obesity with its resulting comorbidities has become a major topic in
global healthcare and disease prevention [1]. Currently, bariatric surgery
is the treatment of choice for obese patients because weight loss main-
tenance and improvement or even resolution of co-morbidities such as
type 2 diabetes mellitus is achieved in many cases [2–5]. The
Roux-en-Y Gastric Bypass (RYGB) is the most commonly performed
bariatric procedure and can be considered the gold standard in bariatric
surgery [6]. Several underlying physiological mechanisms have been
identiﬁed that potentially contribute to weight loss after RYGB; these
mechanisms include reduced hunger and increased satiation [7–9],
changes in meal patterns [10], a reduced preference for high fat diet
[11–13], alterations in sweet taste function [12–15], as well as absence
of a compensatory decrease in energy expenditure [16,17].
We and others previously reported that body weight loss in rats
after RYGB is not associated with the decrease in energy expenditure
that is observed with traditional weight loss strategies [16,17]. This
ﬁnding was interesting because maintenance of a lower body weight
by dietary caloric restriction fails in many obese patients due to
compensatory metabolic responses such as a decrease of energy
expenditure [18]. The reasons for the absence of decreased energy
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expenditure after RYGB surgery in rats are unknown, but it has been hy-
pothesized that the increased postprandial release of glucagon-like
peptide-1 from the distal small intestine after RYGB may be involved
[7,8,19]. From all gastrointestinal hormones affected by RYGB, GLP-1
has most consistently been reported to be elevated after RYGB in
humans and rats and is thought to be at least partly responsible for
the reduction in food intake and the early improvement of glucose tol-
erance after surgery [4,5,7,8,19,20].
GLP-1's effects on food intake have been characterized in numerous
studies (e.g., [21–25]), but its role in the control of energy expenditure
is less well investigated. However, there are some studies that suggest
an involvement of GLP-1 in energy expenditure. For example, Osaka et
al. showed a dose-dependent increase in oxygen consumption after in-
travenous GLP-1 administration [26]. Furthermore, mice lacking the
GLP-1 degrading enzyme dipeptidyl peptidase IV (DPP IV) are resistant
to high fat diet-induced obesity due to reduced food intake and in-
creased energy expenditure [27].
In this project, we therefore wanted to assess a possible role of the
endocrine system and in particular of the satiating gut hormone
GLP-1 in energy expenditure after RYGB in rats. We hypothesized
that acute peripheral modiﬁcation of GLP-1 signaling may inﬂuence
the changes of energy expenditure induced by RYGB.
2. Methods
2.1. Animals
Twenty-ﬁve adult maleWistar rats weighing 400–450 g preoper-
atively were allocated to either RYGB (n = 8) or sham-operation
(n = 17). After a recovery period of 10 days, sham-operated ani-
mals were randomly divided into two groups: sham-operated rats
with no dietarymanipulation (n = 9, ad libitum fed shamsweighing
441 ± 16 g 10 days after surgery) and food-restricted shams whose
postoperative weight was matched to the weight of RYGB rats (body
weight-matched shams (BWm) weighing 433 ± 20 g 10 days after
surgery). BWm shams received as much food daily as was necessary
to maintain a similar body weight as the RYGB rats. Based on experi-
ences from previous studies [16], rats were given approximately 14 g
of standard chow in the beginning of the food restriction period. This
amount of food was offered at dark onset and readjusted every third
day depending on the body weight development.
2.2. Housing
All animals were individually housed under an artiﬁcial 12 hour/
12 hour light–dark cycle (lights off at 1500) and at a room temperature
of 21 ± 2 °C unless otherwise stated. Water and standard chow were
available ad libitum. All experiments were approved by the Veterinary
Ofﬁce of the Canton Zurich, Switzerland.
2.3. Surgery
Anesthesia was induced in a chamber ﬁlled with 5% isoﬂurane in
oxygen (1 l/min). After an adequate depth of anesthesia was
achieved, rats were shaved from sternum to pelvis followed by disin-
fection with betadine scrub. Rats were then placed in supine position
on a heating pad and positioned in a nose cone to maintain anesthe-
sia (2–4% isoﬂurane in oxygen, 0.5 l/min) for the duration of surgery.
Operations were performed as previously described [28]. Brieﬂy, a
midline incision of approximately 4 cm starting just below the
xyphoid process was performed. For the RYGB procedure, the small
bowel was transected approximately 20 cm distal to the pylorus of
the stomach creating a proximal and distal end of small bowel. The
proximal end being still continuous with the remaining portion of the
stomach constituted the biliopancreatic limb and was anastomosed to
the ileum approximately 25–30 cm from the caecum creating the
common channel. For formation of the gastric pouch, the stomach was
transected approximately 5 mm below the gastro-esophageal junction
creating a gastric pouch of a size of nomore than 2–3% of original stom-
ach size. The Roux-en-Y reconstruction was completed by connecting
the distal end of the small bowel to the gastric pouch leading to forma-
tion of the alimentary limb. One single RYGB procedure lasted approx-
imately 70 min. For sham operations, an anterior gastrostomy and a
jejunostomy with subsequent closures were performed. One single
sham procedure lasted approximately 30 min. The abdominal wall
and the skin were closed in layers after both operations.
2.4. Indirect calorimetry
Measurements were conducted in an open circuit calorimetry
system (AccuScan Inc., USA) as previously described [29,30]. Brieﬂy,
rats were individually housed in Plexiglas airtight metabolic cages
(41 × 41 × 31 cm) on a layer of wood shavings under the same
light and temperature conditions as described above. Water and
standard powder chow (GLP3433, Provimi Kliba Ag, Switzerland)
were available ad libitum, unless otherwise stated. Food and water
intakes were measured continuously. Physical activity was moni-
tored by a 3-dimensional array of infrared light beams and sensors.
Thus, the activity data provided represent a relative measure of loco-
motor activity of the rats (movement/hour). The activity data do not
relate to an absolute measurement of distance moved or to a spatial
position.
Energy expenditure was calculated for each 30 second sample
according to Weir using the following equitation: total energy expen-
diture (kcal/h) = 3.9 × V(O2)L / h + 1.1 × V(CO2)L / h [29,30]. The
respiratory quotient was deﬁned as the quotient of CO2 production
and O2 consumption.
2.5. Experimental design
Measurements of energy expenditure in all groups were conducted
between postoperative weeks 5 and 11. Experiments were performed
in a randomized, saline-controlled, crossover manner. About one
week before treatment, all rats were placed for at least two days in
the metabolic chambers for adaptation.
First, the potency of endogenous GLP-1 to alter energy expendi-
ture after RYGB was tested with the GLP-1 receptor antagonist
Exendin (9–39) (Ex-9); we allowed two days of wash-out between
crossover days, i.e. between peptide and saline injections, respec-
tively. Tests were performed similar to Williams et al. [25]. As
shown in Fig. 1, rats were deprived of chow, but not water, 8 h
prior to dark onset (0700 h). At 1100 h, 30 μg/kg Ex-9 or the saline
vehicle (1 ml/kg) was injected subcutaneously and measurement of
energy expenditure was started. One hour later chow was provided
ad libitum again (1200 h, i.e. 3 h prior to dark onset).
Second, the potency of exogenous GLP-1 to alter energy expenditure
after RYGB was tested with the GLP-1 agonist Exendin-4 (Ex-4) with
three days of wash-out between peptide and saline. As demonstrated
in Fig. 2, rats were deprived of chow, but not water, 6 h prior to dark
onset (0900 h). At 1400 h, 5 μg/kg Ex-4 or the saline vehicle (1 ml/kg)
was injected subcutaneously and measurement of energy expenditure
was started. One hour later, i.e. at dark onset, chow was provided ad
libitum again (1500 h). The experiments using Ex-4 were performed
about 4 weeks after the experiments using Ex-9. Dose and time course
of Ex-4 administration were chosen based on an unpublished pilot ex-
periment that showed a signiﬁcant decrease in chow intake of intact
male Wistar rats (n = 12) up to 24 h after injection.
2.6. Statistical analysis
A one-way ANOVA was performed to analyze average daily food in-
take as well as differences in body weight between groups. Following a
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signiﬁcant F ratio, a Bonferroni post hoc test was used to determine dif-
ferences between groups. Differences in energy expenditure, food in-
take, physical activity and respiratory quotients after Ex-9 and Ex-4
treatments were analyzed with a two-way, repeated measures (RM)
group (between subjects) × treatment (within subjects) analysis of
variance (ANOVA) followed by Bonferroni post-hoc tests for each treat-
ment group when there was a signiﬁcant group × treatment interac-
tion. Signiﬁcance was established at p ≤ 0.05 for all statistical sets and
data are reported as mean ± SEM.
3. Results
3.1. Body weight
Fig. 3 shows the development of body weight for all three groups.
Body weight was signiﬁcantly lower in RYGB rats compared to the
sham-operated ad libitum fed group from postoperative day 6 (sham
ad lib: 441 ± 16 g vs. RYGB: 383 ± 16 g, p = 0.020). In postoperative
week 14, the difference in body weight was about 240 g (sham ad lib:
628 ± 34 g vs. RYGB: 389 ± 81 g, p = 0.012). After a short period of
post-surgical weight loss, shams ad libitum fed constantly gained
weight for the rest of the study. In contrast, RYGB animals lost 20% of
their preoperative weight by postoperative week 2 with a weight
nadir of 360 ± 45 g. Until postoperative week 5, RYGB rats then
regained a moderate amount of body weight followed by a plateau
around 380 and 390 g throughout the rest of the observation period.
Food restriction started ten days after surgery for sham-operated
BWm rats (n = 8). There was no signiﬁcant difference in body weight
between the RYGB group and the food restricted sham BWm rats at
postoperative week 4 (sham BWm: 405 ± 13 g vs. RYGB: 379 ± 43,
p = 0.56) and thereafter.
3.2. Average daily food intake
Fig. 4 shows the average daily food intake for all three groups
throughout the entire observation period from postoperative weeks
0–14. Daily food intake was consistently lower after RYGB (sham ad
lib: 29.6 ± 0.9 g vs. RYGB: 25.5 ± 0.8 g, p b 0.01). BWm shams
required signiﬁcantly less food than RYGB animals to maintain the
same level of body weight (sham BWm: 14.4 ± 0.04 g vs. RYGB:
25.5 ± 0.8 g, p b 0.001).
3.3. Effect of treatment with GLP-1 receptor antagonist Exendin (9–39)
3.3.1. Energy expenditure
Repeatedmeasures (RM) two-way ANOVA revealed a main effect of
surgical group formean 24 hour energy expenditure (p b 0.001); ener-
gy expenditure after RYGB was signiﬁcantly higher compared to
sham-operated BWm controls, but signiﬁcantly lower in comparison
to sham-operated ad libitum fed rats after both saline and Ex-9 treat-
ments (Fig. 5A). However, there was no difference in 24 hour energy
expenditure when comparing the corresponding surgery groups that
were treated with saline or Ex-9, respectively; RM two-way ANOVA
showed no main effect of treatment for saline or Ex-9 treatment, re-
spectively (p = 0.79). There was also no signiﬁcant group × treatment
interaction (p = 0.72).
During the ﬁrst hour after Ex-9 and saline injection with no food
available (1100–1200), RM two-way ANOVA revealed a main effect of
surgical group (p b 0.001). Energy expenditure tended to be higher
after RYGB in comparison to sham-operated BWm controls, but this
did not reach statistical signiﬁcance. However, energy expenditure
after RYGB was signiﬁcantly lower than after sham-operation and ad
libitum food; this was observed after both saline and Ex-9 treatments,
respectively (Fig. 5B). Similar to the 24 h values, Ex-9 had no effect on
energy expenditure during the ﬁrst hour after treatment in any surgery
group, i.e. there was no main effect of treatment for saline or Ex-9, re-
spectively (p = 0.88). There was also no signiﬁcant group × treatment
interaction (p = 0.58).
For the ﬁrst 2 h after food was made available ad libitum again
(1200–1400), RM two-way ANOVA showed no main effect of surgi-
cal group (p = 0.32) or treatment (p = 0.87) for energy expendi-
ture after Ex-9 and saline injections, respectively; there was also no
group × treatment interaction (p = 0.72) (Fig. 5C). Fig. 5D shows
the time course of the 24 hour energy expenditure after Ex-9 and saline
treatment for all three groups. The values of the RM two-way ANOVA
for energy expenditure after Ex-9 treatment are given in Table 1.
Fig. 1. Schematic illustration of the experimental protocol to analyze the treatment effect of GLP-1 receptor antagonist Exendin (9–39). Rats were deprived of food 8 h prior to dark
onset (0700 h). At 1100 h, 30 μg/kg Ex-9 or the saline vehicle (1 ml/kg) was injected subcutaneously. One hour later chow was provided ad libitum again (1200 h).
Fig. 2. Schematic illustration of the experimental protocol to analyze the treatment effect of GLP-1 receptor antagonist Exendin-4. Rats were deprived of food 6 h prior to dark onset
(0900 h). At 1400 h, 5 μg/kg Ex-4 or the saline vehicle (1 ml/kg) was injected subcutaneously. One hour later, chow was provided ad libitum again (1500 h).
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3.3.2. Food intake, physical activity and respiratory quotient (RQ)
Food intake was analyzed for the ﬁrst 2 h once food was made
available ad libitum again (1200–1400). Here, RM two-way ANOVA
showed a main effect of surgical group for mean food intake
after Ex-9 and saline injections, respectively (p b 0.001) (Fig. 6A).
While there was no main effect of treatment for mean food
intake (p = 0.13), RM two-way ANOVA revealed a signiﬁcant
group × treatment interaction for mean food intake after Ex-9 or
saline injection (p = 0.004), respectively, indicating that the Ex-9
effect differed signiﬁcantly between the surgical groups. RYGB rats,
but not sham-operated rats ate signiﬁcantly more after Ex-9 than
after saline (RYGB: saline 3.5 ± 0.4 g vs. Ex-9 4.9 ± 0.6 g,
p b 0.01); in fact, sham-operated rats ate about 25% less after Ex-9
compared to saline, and RYGB rats ate about 65% more after Ex-9
during the ﬁrst 2 h of food access (Fig. 6B; sham: 73.7 ± 13.2% vs.
RYGB: 165.1 ± 25.3%, p b 0.05). Further, sham-operated BWm rats
showed the highest food intake in this two hour period, which is
clearly the result of being conditioned to a feeding regime with
long periods of fasting before a limited amount of food was offered
at dark onset. Thus, it was not surprising that we did not observe
an effect of Ex-9 treatment in this group of rats.
Repeated measures (RM) two-way ANOVA further revealed a
main effect of surgical group for the physical activity during the ﬁrst
2 h after food return (p b 0.001), with sham-operated BWm controls
showing more movements per hour than sham-operated ad libitum
fed or RYGB operated rats (Fig. 6C). However, there was no main
effect for treatment (p = 0.87) and no signiﬁcant group × treatment
interaction (p = 0.72). Finally, RM two-way ANOVA showed a sig-
niﬁcant main effect of surgical group for the respiratory quotient
during the ﬁrst 2 h after food return (p b 0.05), but there was no
main effect for treatment and no group × treatment interaction
(Fig. 6D). Sham-operated BWm controls had signiﬁcantly higher re-
spiratory quotients than sham-operated ad libitum fed and RYGB op-
erated rats, irrespective of Ex-9 or saline injection. The p values of the
RM two-way ANOVA for food intake, physical activity and respirato-
ry quotient after Ex-9 treatment are given in Table 1.
3.4. Effect of GLP-1 receptor agonist Exendin-4
3.4.1. Energy expenditure
Repeated measures (RM) two-way ANOVA revealed a main effect
of surgical group for mean 24 hour energy expenditure (p b 0.001)
with energy expenditure after RYGB being signiﬁcantly higher com-
pared to sham-operated BWm controls, but signiﬁcantly lower in
comparison to sham-operated ad libitum fed rats after both saline
and Ex-4 treatments (Fig. 7A). However, there was no Ex-4 effect in
any surgical group; RM two-way ANOVA showed no main effect of
treatment for saline or Ex-4, respectively (p = 0.69) and no signiﬁ-
cant group × treatment interaction (p = 0.83).
Similar to the 24 h values, RM two-way ANOVA revealed a main
effect of surgical group on energy expenditure during the ﬁrst hour
after Ex-4 and saline when no food was available (1400–1500)
(p b 0.001). Energy expenditure tended to be higher after RYGB
compared to sham-operated BWm controls after saline or Ex-4, re-
spectively (p > 0.05), but lower than after sham-operation and ad
libitum food (Fig. 7B).
Overall, we found a main effect of treatment during the ﬁrst hour
after Ex-4 and saline, respectively, when rats were fasted (p b 0.001);
Ex-4 reduced energy expenditure in all surgical groups of rats, but dif-
ferences were only signiﬁcant in sham-operated BWm rats (sham: sa-
line: 2.5 ± 0.2 kcal/h vs. Ex-4: 2.4 ± 0.1 kcal/h, p > 0.05; sham
BWm: saline: 1.9 ± 0.2 kcal/h vs. Ex-4: 1.5 ± 0.03 kcal/h, p b 0.01;
RYGB: saline: 2.1 ± 0.1 kcal/h vs. 1.9 ± 0.1 kcal/h, p > 0.05). There
was no signiﬁcant group × treatment interaction (p = 0.17).
Repeated measures (RM) two-way ANOVA further showed a main
effect of surgical group (p b 0.001), but not treatment (p = 0.16), on
energy expenditure during the dark phase after Ex-4 and saline injec-
tions (Fig. 7C), respectively, but there was also no group × treatment
interaction (p = 0.48). Similar to the complete 24 h period, energy
expenditure was higher after RYGB than in sham-operated BWm con-
trols during the dark phase, but signiﬁcantly lower in comparison to
sham-operated ad libitum fed rats after both saline and Ex-4 treat-
ments. Fig. 7D shows the time course of the 24 hour energy expendi-
ture after Ex-4 and saline treatment for all three surgical groups. The
values of the two-way ANOVA for energy expenditure after Ex-4
treatment are given in Table 2.
3.4.2. Food intake, physical activity and respiratory quotient (RQ)
Repeated measures (RM) two-way ANOVA showed a main effect of
the surgical group formean food intake during the dark phase following
Ex-4 or saline injection, respectively (p b 0.001) (Fig. 8A). There was
also a main effect of treatment for mean food intake (p b 0.001) and a
signiﬁcant group × treatment interaction (p b 0.001). Sham-operated
and RYGB rats reduced their food intake after Ex-4 administration
(sham: saline: 25.3 ± 0.5 g vs. Ex-4: 20.8 ± 0.8 g, p b 0.001; RYGB:
saline: 18.9 ± 2.2 g vs. Ex-4: 11.6 ± 1.2 g, p = 0.004). The Ex-4
induced reduction in dark phase eating was signiﬁcantly stronger in
RYGB than in sham-operated rats (Fig. 8B [saline control = 100%];
sham: 82.3 ± 2.3% vs. RYGB: 64.4 ± 5.9%, p = 0.008).
Fig. 3. Body weight change for the sham-operated rats ad libitum fed (white circles,
n = 9), sham-operated BWm rats (gray circles, n = 8) and for RYGB rats (black cir-
cles, n = 8). E Body weight was signiﬁcantly lower in RYGB rats compared to the
sham-operated ad libitum fed group from postoperative day 6 as indicated
(p b 0.001). Energy expenditure measurements were performed between postopera-
tive week 5 and 11as indicated. Data are shown as mean values ± SEM.
Fig. 4. Average daily food intake over 14 weeks for sham-operated ad libitum fed rats
(n = 9, white column), for sham-operated BWm rats (n = 8, gray column) and for
RYGB rats (n = 8, black column). Data are shown as mean values ± SEM.
4 K. Abegg et al. / Physiology & Behavior xxx (2013) xxx–xxx
Please cite this article as: Abegg K, et al, Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after
Roux-en-Y gastric bypass, Physiol Behav (2013), http://dx.doi.org/10.1016/j.physbeh.2013.03.027
 	   41 
Repeated measures (RM) two-way ANOVA further revealed no
signiﬁcant differences in physical activity and respiratory quotient
between the three groups during the dark phase after Ex-4 and
saline injections, respectively (Fig. 8C and D). However, there
was a main effect of treatment during the ﬁrst hour after Ex-4
and saline, respectively, when rats were fasted (p b 0.01); Ex-4
reduced activity in all surgical groups of rats, but differences
were only signiﬁcant in sham-operated BWm rats (sham: saline:
86.78 ± 18.6 movements/h vs. Ex-4: 54.0 ± 6.0 movements/h,
p > 0.05; sham BWm: saline: 171.8 ± 34.5 movements/h vs. Ex-4:
64.4 ± 10.4 movements/h, p b 0.05; RYGB: saline: 125.5 ± 32.4 move-
ments/h vs. 61.1 ± 11.4 movements/h, p > 0.05). The values of the RM
two-way ANOVA for food intake, physical activity and respiratory
quotient after Ex-4 treatment are given in Table 2.
4. Discussion
We demonstrated that acute subcutaneous administration of a low
dose of the GLP-1 antagonist Exendin (9–39) (Ex-9, 30 μg/kg) or the
GLP-1 agonist Exendin-4 (Ex-4, 5 μg/kg) did not alter energy expendi-
ture in RYGB or sham-operated rats. Overall energy expenditure was
lower in RYGB compared to sham-operated ad libitum fed rats, but
energy expenditure was signiﬁcantly higher in RYGB rats compared to
their body weight matched counterparts. Against our hypothesis, we
Fig. 5. A. Mean 24 h energy expenditure. B. Average energy expenditure during the ﬁrst hour after Exendin (9–39) (30 μg/kg) and saline s.c. administration without food available.
C. Average energy expenditure during the ﬁrst 2 h after food return after Exendin (9–39) (30 μg/kg) and saline s.c. administration. D. Time course of 24 h energy expenditure after
Exendin (9–39) (30 μg/kg) and saline s.c. administration. In A, B and C sham-operated rats ad libitum fed are shown by white columns, sham-operated BWm rats by gray columns
and RYGB rats by black columns. In D a similar color code is used with squares representing Exendin (9–39) and circles representing saline treated rats. When two-way ANOVA
revealed a signiﬁcant F ratio, a Bonferroni post hoc test was used to determine differences between groups (*** = p b 0.001, ** = p b 0.01, * = p b 0.05). Data are shown as
mean values ± SEM.
Table 1
RM two-way ANOVA values for energy expenditure, food intake, physical activity and respiratory quotient during 24 h or the ﬁrst 3 h and after Ex-9 or saline treatment, respec-
tively, as a function of surgical group treatment.
Surgical group Treatment group Interaction
24 h energy expenditure F(2,22) = 32.8, p b 0.001 F(1,22) = 0.7, p = 0.79 F(2,22) = 0.34, p = 0.72
1 h energy expenditure (1100–1200, no food) F(2,22) = 11.74, p b 0.001 F(1,22) = 0.02, p = 0.88 F(2,22) = 0.34, p = 0.58
2 h energy expenditure (1200–1400, with food) F(2,22) = 1.21, p = 0.32 F(1,22) = 0.03, p = 0.87 F(2,22) = 0.34, p = 0.72
2 h food intake (1200–1400) F(2,21) = 457.3, p b 0.001 F(1,21) = 2.47, p = 0.13 F(2,21) = 7.46, p = 0.004
2 h physical activity (1200–1400, with food) F(2,21) = 36.8, p b 0.001 F(1,21) = 0.03, p = 0.87 F(2,21) = 0.34, p = 0.72
2 h respiratory quotient (1200–1400, with food) F(2,21) = 5.3, p = 0.013 F(1,21) = 0.15, p = 0.71 F(2,21) = 1.35, p = 0.28
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found that the administration of Ex-9 or Ex-4, respectively, at doses that
affected eating had no measurable effect on energy expenditure in ei-
ther group of animals.
Consistent with this study, we and others had previously reported
that bodyweight loss in rats after RYGBwas not associatedwith the de-
crease in energy expenditure that is usually observed with traditional
weight loss strategies [16,17,31,32]. Such compensatory metabolic re-
sponses with a decrease in the resting metabolic rate are believed to
be the main reason why maintenance of a lower body weight only by
caloric restriction fails in the majority of obese patients [18]. The lack
of this compensatory decrease in energy expenditure is therefore an im-
portant and promising ﬁnding that requires further investigation in
order to detect the underlying mechanisms.
We and others had reported that the RYGB procedure leads to an in-
creased postprandial release of GLP-1 in humans and rats. GLP-1's
effects on food intake have been characterized in numerous studies
(e.g., [21,23–25,33]), and elevated GLP-1 is thought to be at least partly
responsible for the reduction in food intake after RYGB surgery. Several
studies point to an additional role of GLP-1 in the regulation of energy
balance by directly inﬂuencing energy expenditure. For example,
Osaka et al. [26] showed a dose-dependent increase in oxygen con-
sumption after intravenous GLP-1 administration; this effect was
thought to be mediated by the lower brainstem and to require the in-
tegrity of the sympathoadrenal system. In addition, Lockie et al. [34]
reported an increase in brown adipose tissue (BAT) thermogenesis
after acute central injection of GLP-1, which was associated with in-
creased activity of sympathetic ﬁbers that innervate BAT. Further-
more, mice lacking the GLP-1 degrading enzyme dipeptidyl
peptidase IV (DPP IV) are resistant to high fat diet-induced obesity
because of reduced food intake and increased energy expenditure
[27]. However, the latter results have to be interpreted with caution
because DPP IV not only degrades GLP-1, but is also involved in the
metabolism of many other peptides including PYY (which is activat-
ed to PYY3–36), oxyntomodulin (OXM) and glucagon-like peptide-2
(GLP-2). Like GLP-1, postprandial levels of these hormones are in-
creased after RYGB surgery [8,19,35–37], and several studies show
an involvement of PYY [38] and OXM [39,40] in the control of energy
expenditure.
In the present study, we found no evidence that acute modulation
of GLP-1 signaling affects the changes in energy expenditure seen
after RYGB, even though we saw the expected effects of Ex-9 (in-
crease) and Ex-4 (decrease) on eating. In fact, we provide evidence
that at least under our experimental conditions enhanced GLP-1 sig-
naling contributes to the eating inhibitory effect of RYGB, because
Ex-9 increased eating only in RYGB but not in sham-operated rats.
We also showed that Ex-4 decreased eating more in RYGB than in
sham-operated rats. Hence, despite higher baseline and postprandial
GLP-1 levels [19,41,42], RYGB rats exhibit no desensitization to the
effect of exogenous GLP-1 or its agonists, respectively, which is in
consistent with previous reports [43].
Considering our ﬁndings that do not support a role of GLP-1, we
have to presume that other mechanisms need to be considered in
order to explain the absence of a compensatory decrease in energy
expenditure after RYGB surgery in rats. One possible mechanism
consists of a higher energy requirement due to the signiﬁcant hyper-
trophic changes of the small intestine after RYGB surgery [16,37]. In
fact, increased GLP-2 levels after RYGB may be responsible for muco-
sal hypertrophy, and this may help to limit malabsorptive conse-
quences of the RYGB surgery [37]. GLP-2 has well-characterized,
positive effects on epithelial proliferation particularly in the small
Fig. 6. A. Average spontaneous food intake during the ﬁrst 2 h when food was available. B. Percentage change in 2 h food intake after Ex-9 treatment compared to saline treatment.
C. Average physical activity during the ﬁrst 2 h after food return D Average Respiratory Quotient during the ﬁrst 2 h after food return for sham-operated rats ad libitum fed (white
columns), sham-operated BWm rats (gray columns) and RYGB rats (black columns). As two-way ANOVA revealed a signiﬁcant F ratio, a Bonferroni post hoc test was used to
determine differences between groups (*** = p b 0.001, ** = p b 0.01, * = p b 0.05). Data are shown as mean values ± SEM.
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intestine [44] leading to an increased resorptive surface by enhanced
crypt cell proliferation and reduced apoptosis of enterocytes [45,46].
Because the gastrointestinal tract is a metabolically very active organ
[47], its hypertrophy is likely to contribute to the increase in energy
expenditure after RYGB especially in response to a meal.
Differences in energy expenditure between RYGB and control rats
might also be related to alterations in postprandial (or diet-induced)
thermogenesis [16], even though they seem to be GLP-1 independent.
Diet-induced thermogenesis is mediated in part by BAT [48,49], and it
has recently been found that BAT in adult humans correlated nega-
tively with BMI, fasting glucose levels [50] and non-alcoholic fatty
liver disease [51]. However, using 18F-FDG PET/CT imaging for mea-
surement of the metabolic activity of brown adipose tissue in RYGB
and sham-operated rats, Hankir et al. were unable to demonstrate
an increase in BAT activity, suggesting that other mechanisms are in-
volved to explain the increased energy expenditure after RYGB [52].
Furthermore, there was no difference in the UCP-1 mRNA content of
BAT between the two groups [52].
Our study has several limitations. First, we decided to study acute
effects of GLP-1 receptor modulation on energy expenditure after
RYGB surgery without investigating chronic effects. This experimen-
tal approach was based on previous results demonstrating that our
indirect calorimetry system allowed us to speciﬁcally detect
short-term changes in energy expenditure [29,30]. However, there
is some evidence that the acute administration of GLP-1 agonists de-
creases energy expenditure, potentially as a direct consequence of
the reduction in food intake [53]. Consistently, Ex-4 treatment led
to a decrease in fasting energy expenditure in our study, which was
Fig. 7. A. Mean 24 h energy expenditure. B. Average energy expenditure during the ﬁrst hour after Ex-4 and saline injections, respectively (1400–1500). C. Average energy expen-
diture during the dark phase. D. Time course of 24 h energy expenditure after Exendin-4 (5 μg/kg) and saline s.c. administration. In A, B and C sham-operated rats ad libitum fed are
shown by white columns, sham-operated BWm rats by gray columns and RYGB rats by black columns. In D a similar color code is used with squares representing Exendin-4
and circles representing saline treated rats. As two-way ANOVA revealed a signiﬁcant F ratio, a Bonferroni post hoc test was used to determine differences between groups
(*** = p b 0.001, ** = p b 0.01, * = p b 0.05). Data are shown as mean values ± SEM.
Table 2
RM two-way ANOVA values for 24 hour energy expenditure as well as for energy expenditure, food intake, physical activity and respiratory quotient during the dark phase after
Ex-4 and saline treatment, respectively, as a function of surgical group treatment.
Surgical group Treatment group Interaction
24 h energy expenditure F(2,22) = 17.8, p b 0.001 F(1,21) = 0.15, p = 0.69 F(2,22) = 0.19, p = 0.82
1 h energy expenditure (1400–1500, no food) F(2,22) = 9.8, p b 0.001 F(1,22) = 15.6, p b 0.001 F(2,22) = 1.93, p = 0.17
Energy expenditure (dark phase, with food) F(2,22) = 22.02, p b 0.001 F(1,22) = 2.1, p = 0.16 F(2,22) = 0.75, p = 0.48
Food intake (dark phase) F(2,21) = 29.70, p b 0.001 F(1,21) = 52.73, p b 0.001 F(2,21) = 16.92, p b 0.001
Physical activity (dark phase, with food) F(2,22) = 1.24, p = 0.31 F(1,22) = 7.66, p = 0.011 F(2,22) = 1.16, p = 0.33
1 h physical activity (1400–1500, no food) F(2,22) = 2.84, p = 0.08 F(1,22) = 12.80, p b 0.01 F(2,22) = 1.31, p = 0.29
Respiratory quotient (dark phase, with food) F(2,22) = 0.37, p = 0.695 F(1,22) = 4.88, p = 0.038 F(2,22) = 1.05, p = 0.37
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associated with reduced physical activity probably due to reduced
food-seeking behavior. Because the acute effects of a single-dose in-
jection may be very different from the effects of chronic alterations
in hormone signaling as observed after RYGB surgery, it would be
important to see whether chronic GLP-1 receptor agonism or antag-
onism does have an effect on energy expenditure after RYGB or not,
e.g. by using subcutaneous mini-pump systems. It would also be in-
teresting to compare the effects of peripheral and central GLP-1 re-
ceptor modulation after RYGB surgery. Second, we only performed
single dose studies. Since the mechanisms underlying the control of
energy expenditure and food intake, respectively, by GLP-1 may
not be identical, the absence of an acute effect of the respective com-
pounds on energy expenditure could still be due to an ineffective
dose, even though we observed the expected effects on food intake.
However, the decrease in fasting energy expenditure after Ex-4 in-
jection suggests that the acute administration of a higher dose is un-
likely to yield results that would support our hypothesis, i.e. an effect
consistent with the idea that elevated GLP-1 post RYGB contributes
to the increase in energy expenditure. Third, endogenous GLP-1
levels were not routinely measured in our RYGB rat model. However,
we have previously demonstrated increased postprandial GLP-1
levels in this model on several occasions [14,43].
In summary, our data suggest that acutemodulation of GLP-1 signal-
ing is not directly involved in the altered energy expenditure after RYGB
surgery in rats. The underlying mechanisms leading to the changes in
energy expenditure in RYGB rats therefore remain unclear. It seems
likely that altered energy expenditure is caused by the combined effects
of several different factors rather than by just one speciﬁc gut hormone.
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7. Unpublished results 
As previously mentioned (see 3.1.2), there are currently two major issues that need to be 
considered when analyzing EE data. One is the influence of potential differences in body weight 
and body composition on EE. The other is the importance of performing experiments at 
thermoneutrality, because performing them at lower temperatures can either cause thermogenesis-
induced artifacts that are interpreted as “real” effects, or it can mask small differences in EE 
between groups due to an overall thermogenesis-induced increase in EE. Since these questions 
repeatedly came up when presenting our findings of altered EE in RYGB rats, we wanted to 
address both of them. 
7.1. Changes in whole body composition after RYGB surgery 
7.1.1. Background 
When alterations in EE in our RYGB rat model were first reported, measurement of body 
composition using a rodent computerized tomography (CT) scanner was included in the study.124 
Based on previous careful validation of scanner and software,248 the region between lumbar 
vertebrae L1 and L5 was scanned to estimate whole body composition since a strong correlation 
between L1-L5 and whole body measurement had previously been shown. This analysis revealed 
a higher lean mass in RYGB compared to sham operated body weight-matched (BWM) rats (80.9 
± 2.4 g in RYGB vs 71.0 ± 1.1 g in BWM); however, the measured L1-L5 adipose tissue mass was 
also higher (11.6 ± 1.3 g in RYGB vs 5.3 ± 0.9 g in BWM). All factors combined this caused a 
difference of over 15 g in total measured L1-L5 tissue mass between RYGB and BWM rats even 
though there was no difference in body weight (408.7 ± 9.4 g in RYGB vs 412.2 ± 3.0 g in 
BWM).124 This suggests that, although verified for unoperated rats, L1-L5 analysis may not be 
representative of whole body composition in RYGB rats. We therefore wanted to evaluate whole 
body composition, i.e. lean mass, subcutaneous fat mass and visceral fat mass, in RYGB, BWM 
and sham operated ad libitum fed (AL) rats. We further wanted to assess the correlation of the 
obtained whole body results with results obtained by only analyzing the lumbar region in the same 
scans for each group. 
 
7.1.2. Design 
The same whole body CT images that were used for bone density analysis 14 weeks after surgery 
(see 5) were analyzed for lean mass, subcutaneous fat mass and visceral fat mass with the 
validated Aloka software.248 Body weight was stable in all groups at this time point and was 
significantly higher in AL than in RYGB and BWM rats (p < .001, Figure 2) 
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Before calculating lean and fat mass, manual image-by-
image correction of software miscategorization was 
performed. This included (1) correct definiton of 
subcutaneous fat that had been miscategorized as visceral 
fat and vice versa, (2) exclusion of lung tissue from the 
analysis since this was often miscatecorized as visceral fat 
and (3) exclusion of intestinal content containing air pockets 
that were often miscategorized as visceral fat (Figure 3). 
Calculations of whole body lean and fat mass and L1-L6 
lean and fat mass were then performed on the same set of 
corrected images for each animal (Figure 4). We decided to 
use L1-L6 since this had been shown to have a slightly 
higher accuracy of whole body estimation than L1-L5 in 
normal rats.248 
Data were analyzed by one-way ANOVA followed by Bonferroni post-hoc testing to find differences 
between surgery groups. Furthermore, one-way ANOVA followed by Bonferroni post-hoc testing 
was used to analyze the effect of ambient temperature within the individual surgery groups. Linear 
regression analyses were performed to determine the correlation between whole body and L1-L6 
measurents for each surgery group separately. Data are represented as mean ± SEM and 
statistical significance was established at p < .05. 
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Figure 2 Body weight of sham 
operated ad libitum fed (AL, n = 9), 
sham operated body weight-matched 
(BWM, n = 8) and gastric bypass 
operated (RYGB, n = 12) rats 14 weeks 
after surgery. ***p < .001 vs AL. Data 
represent mean ± SEM. 
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Figure 3 Representative images of AL (I), BWM (II) and RYGB (III) rats in gray scale (A), after automated lean and fat 
mass categorization (B) and after manual correction of lean and fat mass categorization (C). Blue = lean mass; magenta 
= visceral fat mass; yellow = subcutaneous fat mass. 
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Figure 4 Representative scout images of AL (A), BWM (B) and RYGB (C) rats. Red frame represents region used for 
calculation of whole body composition, blue frame represents region used for calculation of L1-L6 body composition. 
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7.1.3. Results 
7.1.3.1. Body composition 
Body composition as calculated by whole body and L1-L6 analysis is illustrated in Figure 5. Lean 
mass, visceral fat mass and subcutaneous fat mass were all significantly decreased in RYGB and 
BWM compared to AL rats, but there was no difference between RYGB and BWM rats (Figure 6). 
 
Figure 5 Estimated whole body (A) and L1-L6 (B) lean mass, visceral fat mass and subcutaneous fat mass in sham 
operated ad libitum fed (AL, n = 9), sham operated body weight-matched (BWM, n = 8) and gastric bypass operated 
(RYGB, n = 12) rats 14 weeks after surgery. Data represent mean ± SEM. 
 
 
 
Figure 6 Estimated whole body (A) and L1-L6 (B) lean mass, visceral fat mass and subcutaneous fat mass in sham 
operated ad libitum fed (AL, n = 9), sham operated body weight-matched (BWM, n = 8) and gastric bypass operated 
(RYGB, n = 12) rats 14 weeks after surgery. *p < .05, **p < .01, ***p < .001 vs AL. Data represent mean ± SEM. 
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7.1.3.2. Correlation between whole body and L1-L6 measurements 
For all surgery groups, slopes of the linear regression analyses of whole body compared to L1-L6 
lean mass, visceral fat mass and subcutaneous fat mass differed significantly from zero, 
suggesting a strong relationship between the two measurements (Figure 7 and Table 1). However, 
there was a significant difference between AL and RYGB rats in the slope of visceral fat mass 
correlation and between all groups in the y-intercept of lean mass correlation. Furthermore, while 
the high R2 values of visceral fat mass correlation suggest a very well fitted regression line for all 
surgery groups, the R2 values of lean mass and subcutaneous fat mass correlations were much 
lower in RYGB rats (Table 1). 
 
Table 1 Linear regression analysis of calculated tissue mass based on either whole body or L1-L6 measurement. S.E.E. 
standard error of estimate. *p < .05, **p< .01, ***p < .001 vs AL; §p < .05 vs BWM; ++p < 0.01, +++p < .001 vs zero 
slope. Data represent mean ± SEM. 
 AL BWM RYGB 
Lean mass 
Whole body 368.1 ± 15.0  297.5 ± 8.0*** 295.5 ± 8.6*** 
L1-L6 100.90 ± 4.47 84.79 ± 2.54** 89.93 ± 2.18* 
Slope 3.191 ± 0.391+++ 3.113 ± 0.227+++ 2.984 ± 0.816++ 
Y-intercept 46.09 ± 39.73 33.59 ± 19.28* 27.22 ± 73.59***§ 
R2 0.9050 0.9692 0.5723 
S.E.E. 14.81 4.313 20.41 
Visceral fat 
Whole body 59.05 ± 5.07 31.93 ± 2.48*** 31.48 ± 2.72*** 
L1-L6 39.65 ± 3.73 20.13 ± 1.80*** 19.40 ± 1.70*** 
Slope 1.357 ± 0.040+++ 1.370 ± 0.066+++ 1.585 ± 0.075*+++ 
Y-intercept 5.236 ± 1.635 4.353 ± 1.367 0.744 ± 1.512 
R2 0.9940 0.9862 0.9782 
S.E.E. 1.259 0.8907 1.458 
Subcutaneous fat 
Whole body 53.49 ± 5.15 34.53 ± 2.80** 31.49 ± 2.93*** 
L1-L6 9.774 ± 1.128 6.823 ± 0.557* 5.791 ± 0.467** 
Slope 4.228 ± 0.646+++ 4.355 ± 1.026++ 4.439 ± 1.397++ 
Y-intercept 12.17 ± 0.65 4.815 ± 7.16 5.792 ± 8.38 
R2 0.8594 0.7501 0.5023 
S.E.E. 6.188 4.279 7.499 
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Figure 7 Relationships of lean mass (A), visceral fat mass (B) and subcutaneous fat mass (C) calculated based on either 
whole body or L1-L6 measurement in sham operated ad libitum fed (AL, n = 9), sham operated body weight-matched 
(BWM, n = 8) and gastric bypass operated (RYGB, n = 12) rats 14 weeks after surgery. 
7.1.4. Conclusions 
Our data show that 3 months after surgery, when body weight was stable (Figure 2), there was no 
difference in body composition or in total lean mass between RYGB and BWM rats. This suggests 
that the increase in EE observed after RYGB-induced weight loss compared to weight loss 
achieved by food restriction124,249 is not due to smaller loss of lean tissue. However, since lean 
mass is very heterogenous and consists of various tissues with very different metabolic 
requirements (see 3.1.2), we cannot completely exclude that differences in lean mass composition 
account for the observed alterations. In fact, it has been shown that RYGB rats display an almost 
two-fold increase in gut weight compared to sham operated rats,124,250 which, if associated with a 
decrease in a metabolically less active lean tissue, could cause a relative increase in total lean 
mass EE.  
We also confirmed that generally there is a very good correlation between body composition 
measured in abdominal L1-L6 or whole body CT scans. However, linear regression analysis 
revealed that this correlation is not as accurate in RYGB rats as it is in AL and BWM rats. First, the 
slope of the regression line for visceral fat was significantly higher in RYGB than in AL rats, which 
means that in case of high levels of visceral adiposity, L1-L6 analysis may underestimate whole 
body visceral fat in RYGB rats, while in case of very low visceral adiposity, L1-L6 analysis may 
overestimate whole body adiposity in RYGB compared to AL rats. Second, the y-intercept of the 
regression line for lean mass was significantly lower in BWM compared to AL rats and in RYGB 
compared to AL and BWM rats. This means that L1-L6 analysis may generally overestimate whole 
body lean mass in BWM and even more in RYGB rats. Third, while the data fitted the regression 
line very well in AL and BWM rats, this was not the case for lean mass and subcutaneous fat in 
RYGB rats, suggesting that L1-L6 analysis is not as accurate for estimation of whole body lean 
mass and subcutaneous fat in RYGB as in sham rats. Together, these results show that within the 
examined body weight range, L1-L6 analysis did not significantly change the outcome of body 
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composition estimation compared to whole body analysis. However, the linear regression analyses 
suggest that whenever possible, whole body CT scans should be performed since it results in a 
more accurate estimation of body composition in RYGB rats. The two main limitations of this study 
were (1) the small group sizes and relatively small body weight range of the animals within groups 
and (2) the lack of EE data of the animals used for CT evaluation. Ideally, effects of RYGB surgery 
on body composition should be evaluated in a large group of animals including diet-induced obese 
rats and correlated with EE recordings in the same animals.  
7.2. Determination of the thermoneutral zone of RYGB and sham rats 
7.2.1. Background 
We and others have repeatedly shown that the decrease in EE that occurs as a compensatory 
response to weight loss (e.g. induced by food restriction) is attenuated by RYGB surgery.124,125,249 
However, as previously discussed, the ambient temperature at which EE is recorded can have a 
strong influence on the outcome of such measurements;70,71 and the aforementioned studies were 
performed at room temperature, i.e. at around 22°C. Since there is some evidence of an influence 
of hormonal signaling on the TNZ,251 we hypothesized that changes in hormone levels and 
neuroendocrine signaling and the lower fat mass after RYGB surgery could lead to a shift in the 
TNZ of rats to higher ambient temperatures, which would mean that the observed increase in EE 
was at least partly caused by higher adaptive thermogenesis. The aim of this experiment was to 
identify the TNZ, i.e. the LCT and the UCT, of sham operated ad libitum fed (AL), sham operated 
body weight-matched (BWM) and gastric bypass operated (RYGB) rats to determine whether the 
reported alterations in EE are partly an artifact due to differences in adaptive thermogenesis. 
7.2.2. Design 
16 male Wistar rats (400 - 450 g) were maintained on a normal chow diet (Provimi Kliba, 
Kaiseraugst, Switzerland) for 2 weeks  before randomization for sham (n = 11) or RYGB surgery (n 
= 5) as previously described. Directly after the RYGB or sham procedure, telemetry sensors (F40-
TT; Data Sciences International, St. Paul, USA) were implanted intraperitoneally for the 
measurement of body core temperature and physical activity. After surgery, the sham rats were 
further divided into an ad libitum fed (AL, n = 6) and a body weight-matched (BWM, n = 5) group. 
The BWM rats were food restricted to the extent that was necessary for them to maintain the same 
body weight as RYGB rats. Four weeks after surgery when body weight in RYGB rats had 
stabilized, rats were placed in an open circuit indirect calorimetry system (TSE Systems, Bad 
Homburg, Germany) allowing simultaneous recording of VO2, VCO2, and food and water intake 
located in an environmental chamber that allowed precise manipulation of ambient temperatures. 
EE, intraperitoneal temperature, physical activity, and food and water intake were recorded 
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throughout the measurement period. After 3 days of adaptation to the cages at 24°C, ambient 
temperature was increased to 32°C and maintained for a day. Temperature was then stepwise 
decreased by 2°C per day until a temperature of 22°C was reached. EE was calculated from VO2 
and VCO2 according to the Weir formula.252 
Data were analyzed by two-way ANOVA to detect main effects of surgery group or ambient 
temperature, followed by Bonferroni post-hoc testing to find differences between groups at the 
individual ambient temperatures. Furthermore, one-way ANOVA followed by Bonferroni post-hoc 
testing was used to analyze the effect of ambient temperature within the individual surgery groups. 
Pearson correlation coefficient was used to measure the linear correlation between body core 
temperature and ambient temperature. Data are represented as mean ± SEM and statistical 
significance was established at p < .05. 
 
7.2.3. Results 
7.2.3.1. Body weight 
Body weight in RYGB rats decreased rapidly after surgery and was significantly lower compared to 
AL rats from postsurgical week 1 (p < .01). Weight loss in BWM rats occurred very slowly and 
required severe food restriction (see Figure 16); however, at the time of indirect calorimetry 
recordings for the determination of thermoneutrality, there was no significant difference in body 
weight between RYGB and BWM rats, while BW of AL rats was significantly higher (p < .001, 
Figure 8 and Figure 9). When comparing presurgical body weight with body weight at the time of 
indirect calorimetry recordings, two-way ANOVA revealed a significant main effect of surgery group 
(F2,13 = 13.14; p < .001) and time (F1,13 = 39.24; p < .001) and a significant interaction of surgery 
group x time (F2,13 = 52.89; p < .001), representing significant weight gain in AL rats and significant 
weight loss in RYGB and BWM rats (Figure 9). 
 
Figure 8 Body weight (BW) development 2 weeks before and 7 weeks after surgery in sham operated ad libitum fed (AL, 
n = 6), sham operated body weight-matched (BWM, n = 5) and gastric bypass operated (RYGB, n = 5) rats. **p < .01, 
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***p < .001 AL vs RYGB; +++ p < .001 AL vs BWM; §p < .05, §§p < .01 BWM vs RYGB. Data represent mean ± SEM. 
Red bar indicates the time of indirect calorimetry recordings for the determination of thermoneutrality. 
 
 
Figure 9 Body weight (BW) before surgery 
(Pre SX) and during indirect calorimetry 
recordings for the determination of 
thermoneutrality (Exp) in sham operated ad 
libitum fed (AL, n = 6), sham operated body 
weight-matched (BWM, n = 5) and gastric 
bypass operated (RYGB, n = 5) rats. ***p < 
.001 vs AL; ++p < .01, +++p < .001 Exp vs 
Pre SX. Data represent mean ± SEM.  
	  
7.2.3.2. Energy expenditure 
At all measured ambient temperatures between 22 and 32°C, 24-hour EE was significantly higher 
in AL and RYGB compared to BWM rats (p < .001). EE was significantly higher in AL than in 
RYGB animals at 22 (p < .001), 24 and 32°C (p < .01), but not at ambient temperatures between 
26 and 30°C (Figure 10). In AL rats, lowest EE was measured at 30°C. EE was significantly higher 
at 22 (p < .01), 24 (p < .05) and 32°C (p < .01, Figure 11A and Table 2). In BWM rats, lowest EE 
was measured at 26°C; however, the absolute values of EE were very similar between 26 and 
32°C (range 6.039-6.152 kJ / h), while EE at 22°C was significantly increased (p < .001, Figure 
11B and Table 2). In RYGB rats, lowest EE was measured at 28°C; however, there was no 
significant increase in EE compared to that value at any other ambient temperature (Figure 11C 
and Table 2). 
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Figure 10 24-hour energy expenditure (EE) of sham operated ad libitum fed (AL, n = 6), sham operated body weight-
matched (BWM, n = 5) and gastric bypass operated (RYGB, n = 5) rats at different ambient temperatures. **p < .01, ***p 
< .001 AL vs RYGB; +++p < .001 AL vs BWM; §§§p < .001 BWM vs RYGB. Data represent mean ± SEM. 
 
Figure 11 24-hour energy expenditure (EE) of AL (A), BWM (B) and RYGB (C) rats at different ambient temperatures. *p 
< .05, **p < .01, ***p < .001 vs  lowest measured EE, i.e. vs EE at thermoneutrality. Data represent mean ± SEM. 
Table 2 Mean values ± SEM for 24-hour energy expenditure  of AL, BWM and RYGB rats at different ambient 
temperatures. See Figure 10 and Figure 11 for significances. 
 22°C 24°C 26°C 28°C 30°C 32°C 
AL 13.10 ± 0.26 12.57 ± 0.31 11.69 ± 0.32 11.36 ± 0.19 11.08 ± 0.31 13.11 ± 0.65 
BWM 6.69 ± 0.22 6.18 ± 0.26 6.04 ± 0.26 6.15 ± 0.16 6.15 ± 0.18 6.04 ± 0.13 
RYGB 10.87 ± 0.49 10.56 ± 0.46 10.44 ± 0.44 10.13 ± 0.47 10.16 ± 0.51 10.68 ± 0.73 
 
7.2.3.3. Body core temperature 
At all measured ambient temperatures between 22 and 32°C, body core temperature (TC) was 
significantly higher in AL compared to BWM rats (p < .01). At 22 (p < .01), 24 (p < .05), 26 (p < .01) 
and 32°C (p < .001), TC was also significantly higher in RYGB compared to BWM rats. There was 
no significant difference in TC between AL and RYGB rats at any ambient temperature (Figure 12).  
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In both AL and RYGB rats, there was a significant increase in TC at 32°C (p < .001 and p < .05, 
respectively, Figure 13A,C and Table 3), while there was no significant difference in TC of BWM 
rats between different ambient temperatures (Figure 13B and Table 3). 
 
Figure 12 Body core temperature of sham operated ad libitum fed (AL, n = 6), sham operated body weight-matched 
(BWM, n = 5) and gastric bypass operated (RYGB, n = 5) rats at different ambient temperatures. ++p < .01 AL vs BWM; 
§p < .05, §§p < .01, §§§p < .001 BWM vs RYGB. Data represent mean ± SEM. 
 
 
Figure 13 Body core temperature of AL (A), BWM (B) and RYGB (C) rats at different ambient temperatures. *p < .05, 
***p < .001 vs all other ambient temperatures. Data represent mean ± SEM. 
Table 3 Mean values ± SEM for body core temperature of AL, BWM and RYGB rats at different ambient temperatures. 
See Figure 12 and Figure 13 for significances. 
 22°C 24°C 26°C 28°C 30°C 32°C 
AL 37.48 ± 0.04 37.48 ± 0.05 37.47 ± 0.04 37.55 ± 0.05 37.73 ± 0.05 38.23 ± 0.14 
BWM 36.14 ± 0.17 36.28 ± 0.19 36.36 ± 0.23 36.54 ± 0.21 36.84 ± 0.18 36.86 ± 0.20 
RYGB 37.04 ± 0.13 37.09 ± 0.14 37.16 ± 0.13 37.17 ± 0.12 37.36 ± 0.14 38.10 ± 0.35 
 
7.2.3.4. Physical activity 
There was no significant difference in physical activity between groups at any measured ambient 
temperature between 22 and 32°C (Figure 14), although two-way ANOVA revealed a significant 
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main effect of surgery group (F2,76 = 4.625; p < .05). However, physical activity seemed to be 
increased at 32°C in all surgery groups, although this increase only reached statistical significance 
in BWM rats (Figure 15 and Table 4). 
 
Figure 14 Physical activity of sham operated ad libitum fed (AL, n = 6), sham operated body weight-matched (BWM, n = 
5) and gastric bypass operated (RYGB, n = 5) rats at different ambient temperatures. Data represent mean ± SEM. 
 
Figure 15 Physical activity of AL (A), BWM (B) and RYGB (C) rats at different ambient temperatures. *p < .05 vs all other 
ambient temperatures. Data represent mean ± SEM. 
Table 4 Mean values ± SEM for physical activity of AL, BWM and RYGB rats at different ambient temperatures. See 
Figure 14 and Figure 15 for significances. 
 22°C 24°C 26°C 28°C 30°C 32°C 
AL 2002 ± 345 1924 ± 369 1777 ± 355 1696 ± 269 1716 ± 232 2232 ± 295 
BWM 1240 ± 146 1148 ± 158 1067 ± 173 1244 ± 278 1181 ± 147 1791 ± 325 
RYGB 1751 ± 700 1490 ± 463 1614 ± 573 1431 ± 286 1879 ± 433 2596 ± 585 
 
7.2.3.5. Food and water intake 
The amount of food required for BWM rats to maintain the same body weight as RYGB rats was 
significantly lower than 24-hour food intake of both AL and RYGB rats at ambient temperatures 
between 22 and 30°C (p < .001). Food intake of RYGB rats was only significantly decreased 
compared to AL rats at 24°C (p < .05, Figure 16). The difference in food intake between BWM and 
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the other two groups disappeared at 32°C due to a marked reduction in FI of AL and RYGB rats (p 
< .01,Figure 16, Figure 17 and Table 5). 
Water intake was significantly lower in BWM compared to AL rats at ambient temperatures 
between 22 and 30°C (p < .05), but this difference disappeared at 32°C due to a reduction in water 
intake of AL rats. WI of RYGB rats did not significantly differ from the other two groups (Figure 18). 
There was no significant effect of ambient temperature on water intake within the different surgery 
groups (Figure 19 and Table 6). 
 
Figure 16 24-hour food intake (FI) of sham operated ad libitum fed (AL, n = 6), sham operated body weight-matched 
(BWM, n = 5) and gastric bypass operated (RYGB, n = 5) rats at different ambient temperatures. *p < .05 AL vs RYGB; 
+++p < .001 AL vs BWM; §§§p < .001 BWM vs RYGB. Data represent mean ± SEM. 
  
Figure 17 24-hour food intake (FI) of AL (A), BWM (B) and RYGB (C) rats at different ambient temperatures. **p < .01 vs 
all other ambient temperatures. Data represent mean ± SEM. 
Table 5  Mean values ± SEM for food intake of AL, BWM and RYGB rats at different ambient temperatures. See Figure 
16 and Figure 17 for significances. 
 22°C 24°C 26°C 28°C 30°C 32°C 
AL 25.44 ± 1.23 26.58 ± 1.13 24.98 ± 2.05 25.81 ± 0.72 20.75 ± 1.70 8.58 ± 2.21 
BWM 6.96 ± 0.15 6.98 ± 0.13 6.67 ± 0.11 6.93 ± 0.10 7.04 ± 0.09 7.12 ± 0.11 
RYGB 22.70 ± 2.39 19.08 ± 2.07 22.21 ± 1.65 22.29 ± 2.03 21.15 ±2.30 12.03 ±1.10 
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Figure 18 24-hour water intake (WI) of sham operated ad libitum fed (AL, n = 6), sham operated body weight-matched 
(BWM, n = 5) and gastric bypass operated (RYGB, n = 5) rats at different ambient temperatures. +p < .05 AL vs BWM. 
Data represent mean ± SEM. 
  
Figure 19 24-hour water intake (WI) of AL (A), BWM (B) and RYGB (C) rats at different ambient temperatures. Data 
represent mean ± SEM. 
Table 6 Mean values ± SEM for water intake of AL, BWM and RYGB rats at different ambient temperatures. See Figure 
18 and Figure 19 for significances. 
 22°C 24°C 26°C 28°C 30°C 32°C 
AL 29.53 ± 4.35 30.17 ± 2.98 30.40 ± 3.39 36.45 ± 2.72 32.39 ± 5.04 21.96 ± 5.90 
BWM 10.66 ± 0.43 11.24 ± 1.32 12.10 ± 0.84 14.78 ± 1.34 14.99 ± 0.85 10.73 ± 1.28 
RYGB 19.71 ± 3.38 15.51 ± 2.51 17.97 ± 2.19 21.57 ± 3.95 24.33 ± 7.56 25.69 ± 8.54 
 
7.2.4. Conclusions 
The main goal of this study was to determine and compare the individual TNZ of AL, BWM and 
RYGB rats. Thermoneutrality is classically defined as the temperature range where the metabolic 
rate is minimal due the absence of thermoregulatory processes;43 its identification should therefore 
in theory be relatively easy. However, our data were not as clear as expected, which complicated 
the analysis and interpretation. Nevertheless, there are several important and interesting 
conclusions that can be drawn from the present experiment. 
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First, the EE data of AL rats were very consistent with the literature on thermoneutrality in freely 
feeding rats.75,76 EE was lowest and relatively stable at ambient temperatures between 26 and 
30°C, suggesting that this range represents the TNZ of AL rats. EE slowly increased when ambient 
temperature was lowered to 24°C and was further elevated at 22°C, pointing to a progressive 
activation of adaptive thermogenesis. In line with this, TC, food and water intake and physical 
activity were stable within the 22-30°C range, suggesting that a small increase in adaptive 
thermogenesis was sufficient to maintain normal metabolic functions at temperature slightly below 
the TNZ. At an ambient temperature of 32°C, however, EE and TC increased markedly despite a 
reduction in food intake. This strongly suggests that a temperature of 32°C was above the UCT; 
the increase in physical activity, although not significant, further supports the initiation of 
thermoregulatory behavior.43 Water intake could be expected to increase when the UCT is reached 
due to increased evaporative water loss. We do not know why this was not the case in our AL rats, 
but it has to be mentioned that we did not control for humidity in the current study. It is therefore 
possible that the increased evaporative water loss led to a higher humidity in the cages, which 
could have caused the reduction in food and water intake, as well as increased physical activity 
due to escape behavior. However, although this may be a limitation of this study that needs to be 
considered for future experiments, it does not contradict the main conclusion that an ambient 
temperature of 32°C lies above the TNZ of AL rats. 
Second, BWM rats seem to have a higher TNZ than AL rats, which is also consistent with the 
literature showing a fasting-induced shift of about 1°C in the TNZ of rats.253 This conclusion can be 
made based on two observations. (1) BWM rats did not show any increase in EE at 32°C 
compared to lower temperatures and (2) their TC was almost identical at 30 and 32°C, while there 
was a progressive increase at lower temperatures up to 30°C. Since the amount of food that the 
BWM rats received daily was kept constant at all temperatures, their only option to maintain a 
stable energy balance at lower temperatures was to reduce the TC. When analyzing TC at ambient 
temperatures between 22 and 30°C, there was indeed a very strong correlation between ambient 
temperature and TC (R2 = 0.96, p<0.001), which was not the case in AL rats (R2 = 0.68, p=0.09). 
This suggests that only at 30°C, BWM reached an ambient temperature at which there was no 
necessity for a decreased TC to compensate for the higher energetic requirement of adaptive 
thermogenesis. 
Third, the RYGB rats are the most difficult to interpret. Even though they showed a similar increase 
in TC and decrease in FI as AL rats at 32°C, there was no considerable change in EE at this 
temperature that would point to an exceeding of the UCT. Based on this it could be speculated that 
RYGB rats have a very slight shift in their TNZ compared to AL rats, although they also had lowest 
EE values around 28-30°C. Surprisingly, they did not show an increase in EE at lower 
temperatures as did the AL rats. One potential interpretation is that the metabolic requirement at 
temperatures below the LCT, i.e. the requirement of adaptive thermogenesis, is reduced in RYGB 
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rats. The metabolic requirement at lower temperatures 
strongly depends on thermal conductance, since higher 
thermal conductance leads to higher heat loss when ambient 
temperature decreases. Two major determinants of thermal 
conductance are body weight and skin blood flow.43 In rats 
and mice, the tail is a crucial thermoregulatory organ; the 
blood flow to the tail is therefore a major determinant of 
thermal conductance. Thermal conductance has a positive 
correlation with skin or tail blood flow, but is generally 
negatively associated with body weight. However, there is 
also a strong influence of body composition, i.e. the 
proportion of fat mass. In particular, the thickness of the 
subcutaneous fat layer has an important influence on body 
insulation and thereby thermal conductance. The strong 
impact of body weight on thermal conductance can partly 
explain why BWM rats may have a higher TNZ than AL rats. 
However, it does not explain why the metabolic requirement 
at temperatures below LCT should be smaller in RYGB than 
in AL rats; on the contrary, the opposite would be expected based on the large differences in body 
weight. What remains as a potential explanation is therefore that RYGB may have reduced skin 
blood flow, which would decrease their thermal conductance and thereby their requirement of 
adaptive thermogenesis. It has indeed been shown in humans that RYGB surgery significantly 
reduces skin blood flow.254 Furthermore, measurement of UCP-1 content in BAT of rats kept at 
room temperature (22°C) revealed lower UCP-1 levels in RYGB than in AL rats (Figure 19, 
unpublished data), which is also consistent with a lower requirement of adaptive thermogenesis. 
Finally, with regard to the main question if differences in TNZ led to a false reporting of RYGB- 
induced alterations in EE, we could clearly show that the differences in EE between BWM and 
RYGB rats did not disappear at thermoneutrality (Figure 10). On the contrary, in the current study, 
the difference between RYGB and AL rats that was reported in an earlier study249 was only 
statistically significant at temperatures outside the TNZ. This finding should be further investigated 
by recording EE in RYGB and sham rats at thermoneutrality, ideally directly after surgery before 
significant weight loss occurs. In addition, it would be of high interest to measure skin blood flow in 
RYGB and sham rats at different ambient temperatures, or, alternatively, use a heat camera to 
detect differences in thermal conductance.  
  
Figure 20 Representative images (A) and 
quantification (B) of uncoupling protein-1 
(UCP-1) content relative to β-tubulin in 
brown adipose tissue of sham operated 
ad libitum fed (AL, n=9) and gastric 
bypass operated (RYGB, n=7) rats fasted 
for 8 hours at 22°C. ***p < 0.001 vs AL. 
Data represent mean ± SEM  
A 
B 
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8. Further Publications 
8.1. Original research article: “Bone-mineral density and expression of 
vitamin-D receptor dependent calcium uptake mechanisms in the 
proximal small intestine after Roux-en-Y gastric bypass surgery.” 
 
 
This section contains an original research article that was submitted for publication to the British 
Journal of Surgery in October 2013. 
 
My contribution to this manuscript includes data analysis, data interpretation and revising the 
manuscript.  
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ABSTRACT 
Context: Bypass of the proximal small intestine after Roux-en-Y Gastric Bypass (RYGBP) surgery 
may lead to decreased calcium uptake and possibly osteopenia. 
Objectives: To examine the operation-specific effects of RYGBP on bone mineral density (BMD) 
and to explore potential mechanisms for decreased calcium uptake after RYGBP. 
Methods: Patients randomized to either RYGBP or vertical banded gastroplasty (VBG) were 
compared. Dual-energy X-ray absorptiometry (DXA) data were analyzed for operation-specific 
changes in total BMD and non-weight bearing (skull) BMD up to six years after surgery. These 
patients were not routinely supplemented with calcium or vitamin-D. Bone resorption markers in 
serum and calcium uptake mechanisms in the jejunal mucosa after RYGBP surgery were 
compared at baseline and post-operatively. 
Results: Postoperative weight loss was similar in RYGBP and VBG patients during the first year. 
Skull BMD was decreased in the RYGBP patients (P<0.001), but not after VBG. During the weight 
stable phase, from one to six years postoperatively, the RYGBP patients, but not VBG patients, 
continued to decrease in skull BMD as well as total BMD. In line with the BMD decrease, serum C-
terminal telopeptide (CTX) levels increased at 18 months postoperatively in RYGBP patients. 
Proteomic analysis of the jejunal Roux-limb mucosa in RYGBP patients revealed a decrease in the 
levels of Heat shock protein (Hsp) 90β, a co-activator of the vitamin-D receptor (VDR). Despite 
increased VDR levels, the levels of the VDR-regulated calcium transporter protein TRPV6 were 
also decreased.  
Conclusion: RYGBP is associated with a decrease in BMD at one to six years after surgery, in 
contrast to VBG. This could be attributed to impaired active calcium absorption caused by a 
combination of the duodenal bypass and decreased activation of components of the vitamin-D 
dependent calcium absorption mechanisms including Hsp90β and TRPV6.  
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INTRODUCTION 
Bariatric surgery is currently the most effective treatment of obesity. Roux-en-Y Gastric Bypass 
(RYGBP) has been shown to reduce mortality and obesity-related metabolic complications 
compared to non-surgical obesity treatment (1).  
Although calorie malabsorption is not believed to be the primary mechanism explaining the weight 
loss after RYGBP, there is some concern regarding the risk of a decreased uptake of specific 
vitamins and minerals due to the rerouting of the proximal gastrointestinal tract. RYGBP results in 
exclusion of the major part of the stomach and the entire duodenum as well as diversion of bile and 
pancreatic juices from the alimentary-limb, i.e. the proximal jejunum. Uptake of certain nutrients 
that are primarily absorbed in the proximal small intestine could therefore be affected.  
Intestinal calcium uptake is dependent on the amount of calcium ingested and the efficiency of 
intestinal calcium uptake (3). Intestinal calcium uptake is partly an active transcellular process, 
which is saturable, and partly a passive paracellular process that is non-saturable (3). The active 
calcium absorption is an energy dependant process that is localised to the proximal small intestine, 
i.e. duodenum and proximal jejunum (3). The efficiency of active calcium transportation is 
regulated by activated vitamin-D via the vitamin-D receptor (VDR) (3). The exact mechanism by 
which VDR regulates calcium uptake is unclear but several studies have shown that VDR activated 
by vitamin-D, transcriptionally regulates several proteins believed to participate in active calcium 
absorption, such as the calcium transporter protein TRPV6 (4, 5).  
We hypothesized that the exclusion of the duodenum and the diversion of bile and pancreatic 
juices from the proximal jejunum could affect intestinal calcium absorption and possibly result in a 
decreased bone mineral density (BMD). As RYGBP induces weight loss that by itself may affect 
whole body BMD we also studied non weight-bearing skull BMD. Further, we measured pre- and 
18 month postoperative levels of bone resorption marker C-terminal telopeptide (CTX), parathyroid 
hormone (PTH), 25 (OH) vitamin D, 1,25 (OH)2 vitamin D and vitamin D binding protein in RYGBP 
patients. 
We performed a proteomics analysis of the alimentary-limb jejunal mucosa before and after 
RYGBP to identify changed protein expression levels that could potentially affect VDR activity. We 
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also examined expression levels of proteins regulated by VDR to find and evaluate possible 
changes in VDR activity after RYGBP.  
 
MATERIALS AND METHODS 
Study outline 
As described previously (6-8), 82 patients were randomized in a clinical trial comparing gastric 
bypass (n=37) and VBG (n=45). Both procedures were performed laparoscopically according to 
previously described surgical techniques. Blood samples for bone resorption markers from RYGBP 
operated patients were retrieved at baseline and 18 months after the operation in another study 
setting where 63 patients (43 females and 20 men) were recruited for standard meal tests before 
and 18 months after surgery. Only preoperative and 18 month fasting baseline samples were used 
for the analysis of bone resorption markers in the present study. The local ethics committee of the 
University of Gothenburg approved the study protocols (reference numbers 380-06 and 583-07) 
and the studies were conducted according to the principles of the Helsinki declaration. All patients 
gave written informed consent. All randomized patients were invited to a clinical follow up at 12, 18 
months and six years after surgery, which included measurement of body weight, body 
composition, blood sampling and eating habits. In a small number of the patients gastroscopy was 
performed at 6-8 months postoperatively for sampling of jejunal mucosa for proteomic analysis.  
 
Weight, height, BMI and body composition 
Weight and height were measured with the patient in light underwear after an overnight fast. Height 
was measured to the closest 0.5 cm using a wall mounted standard stadiometer with the patient in 
a standing position. Weight was measured to the nearest 0.1 kilogram on an electronic scale, 
which was calibrated at regular intervals. Body mass index (BMI kg/m2) was calculated as 
kilogram body weight divided by height square meters. Weight outcome at two years 
postoperatively has been previously reported from this study (6). 
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Body composition was assessed in patients with primary gastric bypass (n=28, 0-1 year 
postoperatively and n=17, 1-6 years postoperatively) and VBG (n=35, 0-1 year postoperatively and 
n=14, 1-6 years postoperatively) using a LUNAR DPX-IQ DXA scanner (Lunar Co., Madison WI). 
Software version 4.7, 4.7c or 4.7e was used at baseline and version 4.7e at the 6 year follow up. 
An extended analysis program for total body analysis (LUNAR Radiation, Madison, WI) was used. 
Body fat, lean tissue mass, bone mineral content, bone mineral density and body weight were 
assessed as previously described (9) 
 
Dietary intake 
All patients were prescribed a multi-vitamin and mineral supplementation after primary surgery and 
patients in the gastric bypass group were additionally prescribed a supplementation of vitamin B12. 
When the study commenced calcium and vitamin-D supplementation was not prescribed routinely. 
Therefore, patients in the randomized controlled clinical trial used for analysis of BMD did not 
systematically receive calcium and vitamin-D supplementation. However, the patients in the 
second study recruited for standard meal tests were prescribed calcium/vitamin-D supplementation 
(500 mg/400 IE, twice daily). 
Patients were asked to fill in a recall questionnaire in which they were instructed to describe their 
food intake over the previous three months. The questionnaire has been validated for assessment 
in obese and lean subjects. Total energy intake, intake of macronutrients (fat, carbohydrates and 
protein) and different food groups (e.g. fruit and vegetable, desserts, candy or prepared food) were 
analyzed from the questionnaire (10) . 
 
Measurement of bone resorption markers in serum 
25 (OH) vitamin-D was measured by Liaison® (DiaSorin.Inc, USA). The reference range for 25 
(OH) vitamin-D was 25-100 nmol/L. 1,25-dihydroxy vitamin-D (1,25(OH)2D) was measured using a 
commercially available radioimmunoassay kit (AA-54F, Immunodiagnostic Systems Ltd., Baldon, 
UK). The intra- and inter-assay CVs were 8.7% (n=20) and 12.6% (n=20), respectively. The 95% 
CI for normal adults for the 1,25 assay was 43-168 pmol/L. Intact PTH (iPTH) was measured by 
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ADVIA Centaur® (SIEMENS Healthcare Diagnostic Ltd, UK). Interassay CV for PTH was 3.4-5.2% 
and intraassay CV was 4.3-9.1%. The reference range for PTH was 10-70 ng/ml. Serum 
CrossLaps® ELISA kit (IDS Ltd, UK) was used for the measurement of CTX, with an interassay CV 
of <6% and an intraassay CV of <10 %. The reference range for CTX was: pre-menopausal 
women = 0.122-0.738 ng/ml (95% CI; mean value 0.287); post-menopausal women = 0.142-1.351 
ng/ml (mean 0.439). Quantakine® ELISA kit (R&D Systems, USA) was used to measure vitamin-D 
binding protein. 
 
Protein expression in the alimentary-limb mucosa after RYGBP 
For the proteomics analysis, tissue samples were collected as previously described (11). In short, 
samples were collected from eight patients that went through a first time laparoscopic RYGBP or a 
conversion from VBG to RYGBP. The operative technique included an antecolic-antegastric Roux-
en-Y construction with a 10 to 20 ml gastric pouch. The gastro-entero- anastomosis was 
constructed with a straight 45 mm stapler and complementary hand-suturing. A tissue sample was 
removed from the jejunum between the gastro-entero and the entero- entero anastomosis as the 
75 cm loop was divided to create the Roux-en-Y construction. After excision the 
mucosa/submucosa was separated from the musculature by means of sharp dissection. Between 
six to eight months after surgery the patients underwent an endoscopic examination of the 
alimentary-limb. Mucosal biopsies were collected approximately 8 cm distal to the stoma. Mucosal 
tissue specimens were snap-frozen in liquid nitrogen and kept frozen (-70°C) for later analysis of 
protein expression. Global protein expression analysis of proximal jejunal mucosal epithelium was 
performed by 2-D gel electrophoresis and mass spectrometry by nanoflow LC-MS/MS as 
described elsewhere (manuscript in preparation). Only proteins that were regulated in the same 
direction in all patients (N=8), and at least 50% from baseline were selected for further analysis.  
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Western blot 
Total protein samples were diluted in SDS buffer and heated at 70˚C for 10 min. before they were 
loaded on a NuPage 10 % Bis-Tris gel, and electrophoresis run using a MOPS buffer (Invitrogen 
AB, Lidingo, Sweden). One lane of each gel was loaded with a prestained molecular weight 
standard (SeeBlue, Invitrogen AB, Lidingo, Sweden). A positive control was loaded when available. 
After the electrophoresis the proteins were transferred to a polyvinyldifluoride transfer membrane, 
Hybond, 0.45µm, RPN303F, (Amersham, Buckinghamshire, UK) using an iBlot (Invitrogen AB, 
Lidingö, Sweden). Membranes were then incubated with polyclonal specific primary antibodies 
against Hsp90β, VDR or TRPV6. A secondary alkaline phosphatase conjugated goat anti-rabbit 
IgG antibody was used with CDP-Star (Tropix, Bedford, MA, USA) as a substrate, to identify 
immunoreactive proteins by chemiluminescense. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, IMG-5143A, Imgenex, BioSite, San Diego, CA, USA) was used as control for equal 
loading and for each tested sample the optical density of primary antibody/GAPDH represents the 
result. The membrane was stripped for reprobing with other primary antibodies using a stripping 
buffer (Re-Blot Plus Mild Solution (10X), Millipore, Temecula, CA, USA). Images were captured by 
a Chemidox XRS cooled CCD camera, and semi-quantification was performed using Quantity One 
software (Bio-Rad Laboratories, Hercules, USA).  
 
Statistical analyses  
Statistical analyses of DXA data and Western blot data were performed using SPSS v.16 and non-
parametric tests, i e Wilcoxon sign rank test and Mann–Whitney U. A multiple linear regression 
model was used to evaluate impact of operation type and weight loss with regards to changes in 
skull BMD from baseline to year one. Paired-samples t-test was used for analysis of intra-individual 
changes in hormone levels of CTX, 25 (OH) vitamin D, 1,25 (OH)2 vitamin D, PTH and vitamin D-
binding protein, as well as for the analysis of changes of the protein levels in the proteomics 
analysis of the spot intensities on the 2D-gel electrophoreses.  
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RESULTS 
 
Baseline data 
Baseline statistics have previously been presented in earlier publications (6, 7). In short, there 
were no statistical differences between preoperative BMI, age, total BMD, sex ratio and smoking. 
 
Weight loss phase, zero to one year postoperatively 
 
Weight baseline to one year postoperatively 
At one year postoperatively, body weight was significantly lower in the RYGBP vs. the VBG 
operated patients (Table 1). The weight loss (preop weight-postop weight) was however not 
significantly different between the groups but both groups decreased significantly in weight (Table 
1). 
 
Total BMD baseline to one year postoperatively 
There were no significant differences in total BMD prior to surgery (Table 1). At one year 
postoperatively, there was no significant difference between the groups in total BMD or in the 
change of total BMD (Table 1). VBG operated patients had a small but significant increase in total 
BMD (Table 1). 
 
Skull BMD baseline to one year postoperatively 
There was no significant difference in skull BMD at baseline or at one year postoperatively 
between the RYGBP and the VBG patients (Table 1). In the RYGB operated patients, but not in the 
VBG patients, skull BMD was however significantly reduced at one year compared to baseline 
(Table 1). Delta skull BMD (skull BMD pre-op – skull BMD post-op) in the RYGBP operated 
patients after one year was also significantly different compared to the VBG patients (Table 1). 
 
Multiple linear regression analysis 
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In a multiple linear regression model analyzing factors predicting changes in skull BMD during the 
first year postoperatively, operation type (VBG or RYGBP) had significant influence on the changes 
in skull BMD (P=0,002), whereas the weight loss (delta weight 0 to1 years postoperatively) did not 
have a significant influence (P= 0,21).  
 
Weight stable phase, one to six years postoperatively  
  
Weight one to six years postoperatively 
RYGBP patients did not change significantly in weight during the period from one to six years 
(Table 2). The VBG patients had significantly higher body weight at six years compared to the 
RYGBP patients (Table 2). Although VBG operated patients had a greater weight at six years 
postoperatively, there was neither a statistically significant increase in weight within the VBG group 
nor between the groups (Table 2). 
 
BMD one to six years postoperatively 
Postoperatively, in the weight-stable phase from years one to six, total body BMD decreased 
significantly in the RYGBP group (Table 2). Patients operated with VBG also decreased slightly in 
total BMD from year one to six but still had significantly higher BMD compared to the RYGBP 
patients at six years postoperatively (Table 2). The RYGBP operated patients had a larger 
decrease of BMD years one to six compared to the VBG operated patients (Table 2).  
 
Skull BMD one to six years postoperatively 
During years one to six, the RYGBP operated patients continued to decrease in skull BMD (Table 
2). Skull BMD was significantly lower at six years compared to one year postoperatively, and delta 
skull BMD was significantly decreased in the RYGBP patients (Table 2). There was no statistically 
significant change in skull BMD in the VBG operated patients from year one to six (Table 2). 
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Calcium intake at baseline, one and six years after surgery 
Dietary questionnaires were sent out to all patients that were randomized to VBG or RYGBP and 
deemed eligible for inclusion, (n= 50, 50) preoperatively and one year post-operatively. After six 
years dietary questionnaires were sent out to patients that were included in the study and 
remained in their original group.  
Pre-operatively, patients in the RYGBP group reported a mean daily calcium intake of 1,5 ± 0,8 g 
(mean ± SD; n=43), patients in the VBG group reported a mean daily calcium intake of 1,9 ± 0,9 g 
(n=48) One year postoperatively patients in the RYGBP group reported a mean daily calcium 
intake of 1,0 ± 0,5 g (n=46), patients in the VBG group reported a mean daily calcium intake of 1,3 
± 0,7 g (n=44).  
After six years patients in the RYGBP group reported a mean daily calcium intake of 1,1 ± 0,4 g 
(n=9), patients in the VBG group reported a mean daily calcium intake of 2,0 ± 0,8 g (n=7).  
 
Bone resorption markers at baseline and 18 months after RYGBP surgery 
CTX levels were significantly increased from baseline to 18 months post-operatively (table 3). Both 
25 (OH) vitamin-D and 1,25 (OH)2 vitamin-D also increased from baseline to post-operatively 
(table 3). The ratio between 25 (OH) vitamin-D and 1,25 (OH)2 vitamin-D was however, not 
changed (table 3). 
There was also a small but significant decrease in PTH from baseline to post-operatively (table 3). 
Vitamin-D binding protein was not changed (table 3). 
 
Changed protein expression in the Roux-limb 
Proteomic analysis. 
In order to explore the mechanisms for the potentially decreased active calcium uptake in the 
proximal jejunum, global protein expression analysis of jejunal biopsies preoperatively and six to 
eight months postoperatively after RYGBP surgery was performed. This showed, among several 
other protein regulations, a significant decrease in signal intensity in a spot that mass spectroscopy 
identified as containing Hsp90β (average ratio -1,64, P<0,01, N=8). After searching relevant 
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literature, this was the only protein change identified that was found to be related to active 
intestinal calcium absorption. 
 
VDR and VDR-associated proteins assessed by Western blots. 
 
Hsp90β 
Western blot analysis of paired intra-individual jejunal mucosal samples before and after RYGBP 
from 10 additional patients analyzed in a similar setting confirmed a significant decrease in Hsp 
90β levels after RYGBP (Figure 1)  
 
TRPV6. 
Protein expression levels of the calcium transporter protein TRPV6 in the jejunum decreased after 
RYGBP (Figure 2). Changes were analyzed intra-individually within the same patient before and 
after surgery. The change in TRPV6 levels was significantly correlated with the change in Hsp 90β 
levels (R=0.78, P<0.01, N=10; Figure 3).  
 
VDR 
Jejunal VDR protein levels increased significantly after RYGBP (Figure 4).  
 
 
DISCUSSION 
Several previous studies have indicated reduced intestinal calcium absorption after RYGBP 
surgery (12, 13). Insufficient calcium uptake could eventually lead to demineralization of the 
skeleton, subsequent osteoporosis and increased fracture risk (14, 15). In the present article, we 
aimed to characterize changes in BMD after two mechanistically different bariatric procedures, 
RYGBP and VBG. After RYGBP, the foregut is excluded from passage of ingested food, and bile is 
diverted from the majority of the jejunum. We therefore hypothesized that calcium uptake through 
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the vitamin-D dependent active transport mechanisms in the proximal small intestine might be 
affected by RYGBP, but not by VBG.  
We describe the effects of RYGBP and VBG on BMD in both the weight-loss phase (0 to one years 
post-operatively) and the long-term weight-stable phase (one to six years postoperatively). As 
weight loss induced by RYGBP may influence BMD we compared patients that were randomized 
to RYGBP or to VBG operations. We also analyzed skull BMD as a non weight-bearing bone that 
should not be affected by weight loss per se. 
We show that RYGBP specifically induces a reduction in non-weight-bearing skull BMD during the 
first year after surgery and that RYGBP seems to have a long-term impact also on total body BMD 
at six years after the operation. This was not seen in patients that underwent VBG surgery, but had 
a similar weight change during the first six years postoperatively. The bone resorption marker CTX 
was prominently increased after RYGBP surgery. Further, we describe a changed expression 
pattern of key proteins involved in the active calcium uptake in the proximal small intestine after 
RYGBP surgery. 
The strengths of this article are that the patient data on RYGBP vs. VBG originates from a 
randomized controlled clinical trial and that the patients did not receive oral calcium 
supplementation, which was not routine at our center in 1999 when the study was initiated. 
Calcium and vitamin-D is now routinely prescribed postoperatively to all bariatric patients. 
Weaknesses include the lack of blood samples from the randomized controlled clinical trial and 
relatively short follow up time of only six years post-operatively. A large number of patients 
originally assigned to VBG had been converted to RYGBP at the six-year follow-up. Only patients 
that remained in their original group per protocol were analyzed at six years, hence the lesser 
number of subjects at this time point. Therefore, intention to treat group analysis of osteoporotic 
fracture risk was not meaningful. Further, a weakness is that we were not able to measure 
intestinal calcium uptake per se, and we are not aware of a method for this that is useful in the 
clinical setting of this study. 
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Within one year postoperatively, weight loss induced by the two procedures did not significantly 
differ, yet BMD data showed two distinct patterns. The group that underwent VBG did not decrease 
their skull BMD and somewhat surprisingly even increased slightly in total BMD, possibly reflecting 
increased physical activity after the rapid weight loss during the first post-operative year. On the 
other hand, the RYGBP operated patients did not show an increase in total BMD, but showed a 
significant decrease in skull BMD, as early as one year post-operatively (Table 1).  
As previously mentioned, we analyzed skull BMD as a non-weight bearing bone that would not be 
affected by weight loss, and this was supported using a multiple linear regression model that 
indicated that the type of operation rather than weight loss predicted the changes in skull BMD. 
During the weight-stable period one to six years post-operatively, RYGBP operated patients where 
weight stable, however they continued to decrease their skull BMD and also decreased their total 
BMD (Table 2). 
Data from dietary questioners were used to calculate calcium intake. These data indicate that 
calcium intake at all times was well above the recommended daily intake of calcium for both 
groups (Livsmedelsverket, Uppsala, Sweden). 
Since we did not have blood samples left from the first series of RYGBP and VBG patients, we 
analyzed bone resorption markers in blood samples from another series of RYGBP patients 
operated at our center. The difference between these studies was that in this latter series all 
patients were prescribed calcium and vitamin-D supplements (500 mg/400 IE, twice daily).  
We found that most profoundly CTX levels in serum doubled at 18 months postoperatively. This 
should reflect increased bone turnover and may well be in line with increased bone resorption and 
the decreased BMD levels in the first series of patients. Alternatively, it could merely be a response 
to the decreased bodyweight leading to increased bone turnover, although the lack of BMD 
decrease in the VBG patients, with similar weight loss during the first year postoperatively is not 
consistent with increased bone turnover as a response primarily to the weight loss per se. Skull 
BMD as a non-weight bearing part of the skeleton should also not decrease due to decreased body 
weight. Further, in the first series of RYGBP, but not VBG patients we saw a continued decrease of 
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BMD six years post-operatively. At that time, body weight had stabilized and was not further 
decreased compared to one year post-operatively.  
25 (OH) and 1,25 (OH)2 vitamin-D levels increased postoperatively compared to baseline, and 
were high compared to the reference range, probably reflecting the vitamin-D substitution therapy 
given to these patients. The ratio between 25 (OH) and 1,25 (OH)2 vitamin-D levels were however 
not changed, suggesting an unchanged 1α-hydroxylase activity.  
We also found a small but significant decrease of PTH at 18 months postoperatively. The 
decreased PTH levels could be a response to the increased vitamin-D levels. This may reflect a 
non-functional regulation since vitamin-D signaling in the proximal small intestine seemed to be 
decreased based on the down-regulations of Hsp90β and TRPV6, despite increased VDR levels. 
Other explanations are also possible, as it has been reported that obese patients in general tend to 
have low vitamin-D levels, and these seem to be normalized postoperatively (16, 17). The 
decreased PTH levels could be a secondary response to that.  
Our data suggests that calcium absorption could be affected by RYGBP and based on previous 
research hypothesized that it is a consequence of impaired active intestinal calcium absorption in 
the proximal small intestine. 
As previously mentioned, active intestinal calcium absorption is located in the proximal intestine (3) 
and the exclusion of the duodenum will negate calcium uptake there. There is also a possibility that 
the diversion of bile from the proximal jejunum i.e. the alimentary-limb might inhibit normal calcium 
absorption (18).  
Therefore, we also performed a proteomic analysis of jejunal mucosa before and after RYGBP to 
determine changes in protein expression levels that might influence active intestinal calcium 
absorption. Among the regulated proteins was Hsp90β that has been reported to influence VDR 
activity (19). Western blot analysis confirmed decreased levels of Hsp90β in alimentary-limb 
mucosa after RYGBP (Figure 1). We then chose to measure protein levels of TRPV6 as a marker 
for VDR activity. TRPV6 has previously been shown to be transcriptionally regulated by VDR in the 
human proximal intestine (4). As TRPV6 was significantly decreased (Figure 2) we suggest that 
this reflects a decrease in VDR activity after RYGBP caused by the reduced Hsp90β levels. There 
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was also a significant correlation between the decrease in Hsp90β and TRPV6 (Figure 3). The 
increase in VDR expression levels may reflect a compensatory response that could result from 
insufficient calcium absorption (Figure 4). A hypothetical figure for the changes of active vitamin-D 
receptor mediated calcium uptake mechanisms after RYGBP is provided in Figure 5. 
A large proportion of patients undergoing RYGB receive oral calcium supplementation as well as 
vitamin-D substitution. However, if intestinal vitamin-D induced uptake of calcium is impaired, oral 
supplementation could be insufficient. There are recent data indicating that calcium uptake may be 
decreased after RYGBP, even with calcium and vitamin-D supplementation, and lead to increased 
PTH activity (12). A recent publication showed that RYGBP patients are at increased risk for 
recalcitrant symptomatic hypocalcemia after thyroidectomy (20). This is well in line with our present 
findings. 
Taken together, we have demonstrated a decrease in BMD (weight bearing and non-weight 
bearing) over time in non-supplemented RYGBP patients. We suggest a hypothesis of a decrease 
in proximal small intestinal active calcium uptake after RYGBP. This calls for long-term studies on 
risk of osteoporosis after RYGBP surgery also exploring whether calcium and vitamin-D 
supplementation can abolish this decline. 
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Figure legends  
 
Figure 1. Western blot of Hsp90β (A) and GAPDH (B) protein expression levels in jejunal mucosa 
before and after RYGBP. All samples were paired, i e from same individual before and after 
surgery. The paired samples are divided by the dotted lines. Grey boxes/bars show baseline 
samples and white boxes/bars show 6-8 month postoperative samples. * P<0.05 between 
preoperative and postoperative samples. 
 
Figure 2. Western blot of calcium channel protein TRPV6 (A) and GAPDH (B) protein expression 
levels in jejunal mucosa before and after RYGBP. All samples were paired, i e from same 
individual before and after surgery. The paired samples are divided by the dotted lines. Grey 
boxes/bars show baseline samples and white boxes/bars show 6-8 month postoperative samples. 
** P<0.01 between preoperative and postoperative samples. 
 
Figure 3. Correlation analysis between Δ TRPV6 vs. Δ Hsp 90β protein expression levels 
measured by Western blot.  
 
Figure 4. Western blot of vitamin-D receptor (VDR; A) and GAPDH (B) protein expression levels in 
jejunal mucosa before and after RYGBP. All samples were paired, i e from same individual before 
and after surgery. The paired samples are divided by the dotted lines. Grey boxes/bars show 
baseline samples and white boxes/bars show 6-8 month postoperative samples. ** P<0.01 
between preoperative and postoperative samples. 
 
Figure 5. Schematic presentation of the hypothetic regulation of the active vitamin D-induced 
calcium absorption mechanisms in the proximal jejunum postoperatively after Roux-en-Y gastric 
bypass surgery: Hsp90β that acts as a co-activator of VDR is decreased. VDR transcriptionally 
regulates several proteins believed to participate in active calcium absorption, such as the calcium 
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transporter protein TRPV6. Despite increased VDR expression, TRPV6 expression is decreased, 
and may ultimately lead to decreased calcium uptake and decreased BMD. 
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8.2. Brief Report: “Estradiol increases body-weight loss and gut-
peptide satiation after Roux-en-Y gastric bypass in 
ovariectomized rats” 
 
 
This section contains a brief report that was submitted for publication to Gastroenterology in 
February 2012 and accepted for publication in revised form in May 2012. 
 
My contribution to this manuscript includes data acquisition, data interpretation and revising the 
manuscript. 
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Estradiol Increases Body Weight Loss and Gut-Peptide Satiation After
Roux-en-Y Gastric Bypass in Ovariectomized Rats
LORI ASARIAN,*,! KATHRIN ABEGG,* NORI GEARY,‡ MARC SCHIESSER,§ THOMAS A. LUTZ,*,! and MARCO BUETER§,!
*Institute of Veterinary Physiology, Vetsuisse Faculty and !Zurich Center for Integrative Human Physiology, University of Zurich, Zurich; ‡Zielackerstrasse 10,
Schwerzenbach; and §Department of Surgery, Division of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Despite the fact that !85% of bariatric operations are
performed in women, the effects of the reproductive
axis function on outcome of bariatric surgery remain
to be determined. Here we developed the first pub-
lished model of Roux-en-Y gastric bypass (RYGB) in
female rats. We show in ovariectomized rats receiving
estradiol or control treatment that (1) RYGB-induced
body weight loss and (2) the satiating efficacy of en-
dogenous glucagon-like peptide-1 and cholecysto-
kinin satiation were significantly increased in estradi-
ol-treated rats. These data are relevant to the care of
obese women, in particular perimenopausal women,
undergoing bariatric surgery.
Keywords: Bariatric Surgery; Obesity; CCK; GLP-1.
Bariatric surgery is currently the most effective treat-ment for morbid obesity. Morbid obesity (body mass
index "40 kg/m2) is more prevalent in women than in
men,1,2 and the adverse effects of obesity on psychological
well-being are more pronounced in women.3 Correspond-
ingly, more than 85% of patients undergoing bariatric
surgery are female.4 Despite the well-known effects of
normal reproductive axis function on eating and body
weight,5 the impact of reproductive axis function on the
outcome of bariatric surgery remains to be determined.
Here we investigated the effects of Roux-en-Y gastric by-
pass (RYGB) surgery on body weight and glucagon-like
peptide 1 (GLP-1)– and cholecystokinin (CCK)-induced
satiation in a rat model of menopause.
Adult Long–Evans female rats were fattened for 3 weeks
by offering only a high-energy diet (phase 1) before ovariec-
tomy, the standard rodent menopause model, and RYGB or
sham surgery (Supplementary Materials and Methods). Rats
were then fed high-energy and regular chow ad libitum for
28 days (phase 2). A near-physiological regimen of estradiol
treatment (2 !g estradiol benzoate once each 4th day sub-
cutaneously) or oil-vehicle treatment (100!L sesame oil) was
begun on day 12, resulting in 4 groups: SHAM-E2, SHAM-
OIL, RYGB-E2, and RYGB-OIL. Beginning on day 29, rats
were fed Ensure Plus (Abbott AG, Baar, Switzerland) liquid
diet and chow for 21 days (phase 3). Finally, the acute effects
of exendin (9–39) and devazepide on Ensure intake were
tested (phase 4).
At arrival, rats weighed 165 # 6 g. During phase 1, rats
gained!80 g, reaching an overall mean preoperative body
weight of 247 # 3 g (Figure 1A). The continued rapid
weight gain of SHAM-OIL rats during phases 2 and 3 was
significantly attenuated in RYGB-OIL rats (19 vs 42 g and
30 vs 67 g in phases 2 and 3, respectively; standard errors
of the difference, 8 and 7 g, respectively; Figure 1A). The
weight-lowering effect of RYGB was significantly greater
in estradiol-treated rats than oil-treated rats by 31 and
49 g in phases 2 and 3, respectively. Overall, SHAM-OIL
rats gained 109 g during phases 2 and 3 versus 49 g in
RYGB-OIL rats and $1 g in RYGB-E2 rats.
RYGB and estradiol treatment had similar effects on en-
ergy intake as on body weight both during phase 2, when
rats were fed a solid, high-energy diet, and during phase 3,
when the rats were fed Ensure, which increased energy intake
in all groups (Figure 1B). RYGB-OIL rats ate less than
SHAM-OIL rats in both phases, RYGB-E2 rats ate less than
RYGB-OIL in phase 2 and tended to eat less in phase 3 (P%
.06), and SHAM-E2 rats ate less than SHAM-OIL rats in both
phases. RYGB also reduced the rats’ selection of both test
diets versus chow (Table 1).
We tested the effects of exendin (9–39) and devazepide,
which are potent and selective receptor antagonists of
GLP-1 and CCK, respectively, during 60-minute Ensure
tests (phase 4). In both sham-operated and RYGB rats, the
eating-stimulatory effects of the antagonists were signifi-
cantly greater in estradiol-treated than oil-treated rats
(Figure 2). In neither case, however, was the antagonist
effect greater in RYGB-E2 rats than in SHAM-E2 rats.
We consider three aspects of our data important. First,
to our knowledge, this is the first study investigating the
influence of reproductive axis function on the outcome of
bariatric surgery. These data are critical because the great
majority of gastric bypass operations are performed in
women and because the reproductive axis, in particular
estrogens, potently influence the physiology of eating and
body weight control. Second, we showed that estradiol
significantly increased the potency of RYGB to reduce
weight gain and to inhibit eating. Similar effects were
obtained when RYGB rats were fed a high-energy solid
diet (phase 2) and Ensure, a 57% energy liquid diet (phase
3), suggesting that they do not depend on particular
dietary forms or components. Our data suggest that
RYGB may be more effective in healthy premenopausal
Abbreviations used in this paper: GLP-1, glucagon-like peptide 1;
RYGB, Roux-en-Y gastric bypass.
© 2012 by the AGA Institute
0016-5085/$36.00
http://dx.doi.org/10.1053/j.gastro.2012.05.008
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women than in postmenopausal women who do not re-
ceive hormone replacement therapy or in women with
reduced estrogen levels, such as patients with polycystic
ovary syndrome.6 We are not aware of any clinical studies
assessing this question, although we found recently that
bariatric surgery was more effective in postmenopausal-
age women than premenopausal-age women (Ochner,
Geary, and Asarian, unpublished data, September 2007).
Whether estrogens enhance the eating and body weight–
lowering effects of RYGB via the same mechanisms by
which they contribute to the normal control of eating and
body weight also deserves further research. Furthermore,
it is unclear whether estrogens affect the outcome of other
types of bariatric surgery procedures, such as gastric band-
ing or gastric sleeve resection. Third, we provide novel
evidence that estrogens increase endogenous GLP-1 and
Figure 1. (A) Body weight and (B) food intake following RYGB or sham
operation in ovariectomized rats that were treated with estradiol (E2) or
the oil vehicle (OIL). #SHAM-OIL vs RYGB-OIL; *RYGB-OIL vs RYGB-E2;
!SHAM-OIL vs SHAM-E2; P" .01 for body weight gains and P" .05 for
food intake.
Table 1. Percent of Each Diet Consumed Out of the Overall
Intake
Group
Phase 2 Phase 3
HFD CHOW ENSURE CHOW
SHAM-OIL 71 # 7 29 # 7 99 # 0.3 1 # 0.3
SHAM-E2 74 # 4 26 # 4 98 # 0.3 2 # 0.3*
RYGB-OIL 52 # 11 48 # 10 92 # 3 8# 4!
RYGB-E2 52 # 11 48 # 10 77 # 5! 23 # 4*!
*vs OIL within diet and surgical group.
!vs SHAM within diet and hormone group.
Figure 2. Effects of RYGB on the de-satiating actions of (A) GLP-1
antagonism with exendin (9–39) and (B) CCK antagonism with devaz-
epide in ovariectomized rats treated with estradiol (E2) or the oil vehicle
(OIL). !Estradiol decreased Ensure intake after control injections in the
same surgery group; *antagonist increased Ensure intake in the same
surgery group; P " .05.
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CCK satiation in RYGB rats. In previous reports, estradiol
increased CCK satiation in rats with intact intestines.7–9
This is the first report that estradiol also increases GLP-1
satiation in intestine-intact rats and that estradiol in-
creases the satiating effect of CCK and GLP-1 in RYGB
rats. We did not, however, detect any difference in the
potency of either GLP-1 or CCK antagonism in estra-
diol-treated RYGB versus estradiol-treated, sham-oper-
ated rats, suggesting that increases in the satiating
potencies of these peptides alone are not sufficient to
account for the decreased total food intake and de-
creased weight gain in our model of RYGB. Possibly
larger doses of the antagonists, chronic antagonist
treatment, or modifications of the RYGB method (eg,
longer intestinal bypass) would reveal a surgical effect.
Finally, other estrogenic effects, such as metabolic ef-
fects, may also have contributed.
Supplementary Materials
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at http://
dx.doi:10.1053/j.gastro.2012.05.008.
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Supplementary Materials and Methods
Subjects and Housing
Adult, female Long–Evans rats (Centre d’Elevage
R. Janvier, Le Genest-Saint-Isle, France) weighing !165 g
at arrival were used. Rats were initially housed 4 per cage
in Makrolon cages (56 " 38 " 22 cm) with wood chip
bedding (Abbed Espen, Indulab AG, Holland). Postsur-
gery rats were single housed in stainless-steel-wire-mesh
cages (48 " 25 " 18 cm). Rats were housed in a colony
room with an average temperature of 23 # 2°C and a
12-hour light/dark cycle (lights off at 1300). The Can-
tonal Zurich Veterinary Office approved all procedures.
Materials
17!-estradiol-3-benzoate (catalog no. E8515; Sigma,
Schnelldorf, Germany), sesame oil (catalog no. S3547;
Sigma), exendin (9–39) (catalog no. H8740; Bachem,
Bubendorf, Switzerland), devazepide (catalog no. 2304; Toc-
ris Biosciences, Bristol, England), purified condensed-milk
high-energy diet (D12266B, 4.41 kcal/g, 25% energy from
sugar, 32% from fat; Research Diets, New Brunswick, NJ),
Ensure Plus Chocolate (catalog no. S256, 1.5 kcal/mL,
57% energy from sugar, 28% from fat; Abbott AG, Baar,
Switzerland), laboratory chow (catalog no. 3430, 3.15
kcal/g, 41% energy from carbohydrates, 4.5% from fat;
Provimi Kliba, Kaiseraugst, Switzerland).
Methods
Surgeries. Forty-eight rats were allocated to ei-
ther RYGB (n $ 24, body weight, mean # SD, 237 #
10 g) or sham-operated (sham, n $ 24, 237 # 15 g)
surgery groups. Anesthesia was induced in a chamber
filled with 5% isoflurane in oxygen (1 L/min). After an
adequate depth of anesthesia was achieved, each rat was
shaved from sternum to pelvis followed by disinfection
with Betadine scrub (Mundi Pharma, Basel, Switzerland).
The rat was then placed in a supine position on a heating
pad and positioned in a nose cone to maintain anesthesia
(2%–4% isoflurane in oxygen, 0.5 L/min) for the duration
of the surgery. All surgeries were conducted as previously
described.1 Briefly, a midline incision of approximately 4
cm starting just below the xiphoid process was per-
formed. For the RYGB procedure, the small bowel was
transected approximately 20 cm distal to the pylorus of
the stomach, creating a proximal and distal end of small
bowel. The proximal end, being still continuous with the
remaining portion of the stomach, constituted the bilio-
pancreatic limb and was anastomosed to the ileum ap-
proximately 25–30 cm from the cecum, creating the com-
mon channel. For formation of the gastric pouch, the
stomach was transected approximately 5 mm below the
gastroesophageal junction, creating a gastric pouch of a
size of no more than 2%–3% of original stomach size. The
Roux-en-Y reconstruction was completed by connecting
the distal end of the small bowel to the gastric pouch,
leading to formation of the alimentary limb. One single
RYGB procedure lasted approximately 70 minutes. For
sham operations, an anterior gastrostomy and a jejunos-
tomy with subsequent closures were performed. One sin-
gle sham procedure lasted approximately 30 minutes.
The abdominal wall and the skin were closed in layers
after both operations.
Bilateral ovariectomy was performed subsequent to
RYGB or sham surgery. A suture was placed between the
ovary and the tip of the uterus, and the ovary was cut
free. The ovary was then separated from the retroperito-
neal fat with a cautery and removed. Postoperatively,
enrofloxacin (0.15 mg/kg; Baytril, Bayer, Provet AG, Lys-
sach, Switzerland), flunixin meglumine (5 mg/kg; Bio-
kema SA, Lausanne, Switzerland), and meloxicam (5 mg/
kg; Boehringer Ingelheim, Basel, Switzerland) were
administered for infection and pain prophylaxis, respec-
tively. Two RYGB rats died during surgery. Immediately
following surgery, each rat received 5 mL of warm saline
subcutaneously to compensate for fluid loss. Rats were
then placed under indirect red light in a polycarbonate
cage until they fully recovered from anesthesia, at which
time they were returned to their home cages. Baytril was
also administered on the first postoperative day. Rats
were allowed at least 10 days to recover before further
testing. During recovery, rats were offered chow, high-
energy diet, water, and, for RYGB rats, 5% sucrose solu-
tion during the first week. Recovery was uneventful for
most rats, but 7 RYGB rats became acutely ill 3–7 days
postoperatively and either died or were killed with a
pentobarbital overdose; necropsy indicated that each of
these rats had severe peritonitis secondary to failed in-
testinal anastomoses.
Hormone replacement treatment. Cyclic estradiol
treatment was begun after 12 days of postoperative
recovery. RYGB rats were divided into 2 groups of
approximately equal body weight and received, every
fourth day, single interscapular subcutaneous injec-
tions of 2 "g estradiol in 100 "L sesame oil or oil alone
(RYGB-E2, n$ 7; RYGB-OIL, n $ 8). Sham rats were
culled to similar group sizes and similarly allocated
(SHAM-E2, n $ 8; SHAM-OIL, n $ 9). Injections were
performed between 0900 and 0930 h. This regimen
produces increases in plasma estradiol levels similar in
magnitude and duration to those during 4-day ovarian
cycles in intact rats.2,3
Test procedure. The experiment consisted of 4
phases. Surgery was performed on day 0. In phase 1 (days
%21 to %1), beginning 5 days after the rats arrived, rats
were fed the high-energy diet to induce overweight and to
mimic human idiopathic “dietary” obesity.
In phase 2 (days 0 to 28), estradiol or oil treatment
was begun on day 12. Rats were offered high-energy
diet and regular chow ad libitum throughout. Food
intake and body weight were measured daily between
0900 and 0930.
327.e1 ASARIAN ET AL GASTROENTEROLOGY Vol. 143, No. 2
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During phase 3 (days 29 to 50) rats were offered En-
sure and chow ad libitum; the method was otherwise
unchanged.
During phase 4 (days 51 to 69), the satiating potencies
of endogenous GLP-1 and CCK were tested in within-
subject crossover tests, performed during the second noc-
turnal period after estradiol or oil injections, when, sim-
ilar to estrus in intact, cycling rats, the effect of estradiol
on eating is greatest.2
The satiating potency of endogenous GLP-1 was tested
with the GLP-1 receptor antagonist exendin (9–39) using
a method similar to that of Williams et al.4 Rats were
deprived of both chow and Ensure, but not water, 4
hours before dark onset (0900). At dark onset (1300),
Ensure was returned. At 1400, intake of Ensure was
measured and 100 !g/kg exendin (9–39) or the saline
vehicle (1 mL/kg) was injected intraperitoneally. Intake of
Ensure was measured 1 hour later (1500). Finally, Ensure
and chow were provided ad libitum until the next day at
0900.
The satiating potency of endogenous CCK was tested
with the CCK-1 receptor antagonist devazepide using a
method similar to that used previously.5 Rats were de-
prived of food at 0900, 4 hours before dark onset. At
1200, 1 mg/kg devazepide or vehicle (1:10 dimethyl sul-
foxide/saline, 1 mL/kg) was intraperitoneally injected.
Ensure was returned at 1300 (dark onset), and intake was
measured 1 hour later (1400). Ensure and chow were then
provided ad libitum until the next day at 0900.
Statistical Analyses
The difference in body weight between RYGB and
sham rats after phase 1 was!20 g. This occurred because
the RYGB rats that died during and after surgery (n " 9)
were a bit heavier than those that did not. Figure 1 shows
data for the surviving rats. This difference prompted us
to analyze changes in body weight rather than absolute
weights during phases 2 and 3. Changes in body weight
were analyzed using planned comparisons, with standard
errors of the difference (SED) computed from analysis of
variance–generated residual errors and Bonferroni–
Hochberg corrected t tests. Comparisons were (1)
whether RYGB decreased weight gain in oil-treated rats
(ie, SHAM-OIL vs RYGB-OIL), (2) whether estradiol in-
creased this effect (ie, RYGB-OIL vs RYGB-E2), and (3)
whether estradiol decreased weight gain in sham-oper-
ated rats (ie, SHAM-OIL vs SHAM-E2) as a positive con-
trol for the effect of estradiol in these novel diet condi-
tions; SEDs were 8.3 g in phase 2 and 6.6 g in phase 3.
Mean daily intakes of high-energy diet, Ensure, and chow
were converted to kilocalories, and intake of total kilo-
calories per day during the last weeks of phases 2 and 3
were analyzed as previously described; SEDs were 4.1
kcal/day in phase 2 and 6.2 kcal/day in phase 3. The
comparisons used to test the effects of exendin (9–39)
and devazepide on 1-hour Ensure intakes in phase 4 were
(1 and 2) whether estradiol reduced food intake after
control injections in sham-operated rats (ie, SHAM-OIL/
control vs SHAM-E2/control) or in RYGB rats (ie, RYGB-
OIL/control vs RYGB-E2/control), (3 and 4) whether the
antagonist increased Ensure intake in estradiol-treated
rats (ie, SHAM-E2/control vs SHAM-E2/antagonist and
RYGB-E2/control vs RYGB-E2/antagonist), and (5)
whether the effects of the antagonist differed between
sham-operated and RYGB rats (ie, 3 vs 4). To increase
statistical power, the effects of the antagonists were
tested using one-tailed tests. SEDs were 0.9 mL for the
exendin (9–39) tests and 0.5 mL for the devazepide tests.
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8.3. Brief communication: “Roux-en-Y gastric bypass surgery in rats 
alters gut microbiota profile along the intestine” 
 
 
This section contains a brief communication that was submitted for publication to Physiology & 
Behavior in November 2012 and accepted for publication in revised form in June 2013. 
 
My contribution to this manuscript includes data acquisition and revising the manuscript.
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Roux-en-Y gastric bypass (RYGB) surgery might modify the gut microbiota composition differently in the
three distinct anatomical sections of the small intestine compared to sham surgery. We showed that RYGB
induced changes in the microbiota of the alimentary limb and the common channel resembling those seen
after prebiotic treatment or weight loss by dieting. These changes may be associated with altered production
of intestinal hormones known to control energy balance. Postsurgical modulation of gut microbiota may sig-
niﬁcantly contribute to the beneﬁcial metabolic effects of RYGB surgery.
© 2013 Elsevier Inc. All rights reserved.
1. Introduction
Recent studies examined the association between changes in intesti-
nal microbial diversity in obese rodents and humans; some bacterial
groups were associated with changes in the nutritional status. Obesity
was associated with higher Firmicutes and lower Biﬁdobacterium spp.,
Bacteroides-related bacteria and Lactobacillus spp. in comparison with
the lean counterparts [1–4]. Interestingly, weight loss achieved by dieting
was able to reverse those changes [5]. Furthermore, nutrients with prebi-
otic properties induced qualitative changes in the composition of the
gastrointestinal microbiota and peptide release (e.g., glucagon-like
peptide-1 (GLP-1)) similar to those seen after dieting. In diet-induced
obese and type 2 diabetic (T2DM) mice the release of gut peptides in-
duced by treatment with prebiotics improved glucose and lipid metabo-
lism as well as systemic inﬂammation [6].
Roux-en-Y gastric bypass (RYGB) is currently, themost effective strat-
egy for long term weight loss maintenance. RYGB signiﬁcantly reduces
bodyweight, improves T2DMand changes the postprandial enteric endo-
crine responses.
Gut microbiota analysis of fecal samples from humans and rats after
RYGB suggested that the reduction of Firmicutes and Bacteroidetes may
partly explain the weight loss and beneﬁcial effects on metabolism and
inﬂammation associated with the RYGB surgery [7–9]. Liou [10] con-
ﬁrmed these ﬁndings and also showed that cecal transplants from
mice after RYGB to unoperated germ free mice decreased the body
weight and adiposity compared to recipients of microbiota from
sham-operated mice.
There are currently no data on the impact of gut microbiota on the
hormonal and metabolic changes associated with RYGB. In most of
the human and rodent studies investigating the ecology and activity
of intestinal microbiota, fecal or cecal samples have been used. How-
ever, these may not be representative of the microbiome in RYGB
where the intestine is surgically manipulated into three discrete sec-
tions which may each contribute to distinct metabolic signals com-
pared to feces that represents a amalgamate of the microbiome
from the intestine as a whole. Therefore, we assessed the bacterial
composition in the different anatomically corresponding intestinal
segments after RYGB or sham surgery.
2. Materials and methods
2.1. Subjects and housing
Sixteen maleWistar rats (Harlan Laboratories Inc., Blackthorn, UK;
Elevage Janvier, Le-Genest-St. Isle, France) were individually housed
under a 12 h/12 h light–dark cycle at a room temperature of 21 ±
2 °C. Water and standard chow were available ad libitum. All experi-
ments were approved by the Veterinary Ofﬁce of the Canton Zurich,
Switzerland. All rats were given one week of acclimatization before
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being randomized to RYGB (n = 8) or sham-operation (n = 8). After
surgery, rats received Ensure (chocolate Ensure Plus, Abbott Nutri-
tion, Baar, Switzerland) for 3 days before access to normal chow
was reinstalled. Body weight was measured weekly. A food restricted
sham-operated group of rats (n = 7), whose postoperative weight
matched the weight of bypass-treated animals, was also studied
(data not shown; see also ref [11]); data were comparable to the
sham-operated ad libitum fed controls except for one parameter
(see below).
2.2. Surgery
Rats were allocated to either RYGB (n = 8, body weight, mean ±
SEM, 445 ± 5 g) or sham-operated (sham, n = 8; 435 ± 5 g) surgery
groups. Anesthesia was induced in a chamber ﬁlled with 5% isoﬂurane
in oxygen (1 L/min). After an adequate depth of anesthesia was
achieved, rats were shaved from sternum to pelvis followed by disin-
fection with Betadine scrub (Mundi Pharma, Basel, Switzerland).
Rats were then placed in a supine position on a heating pad and po-
sitioned in a nose cone to maintain anesthesia (2%–4% isoﬂurane in
oxygen, 0.5 L/min) for the duration of the surgery. All surgeries
were conducted as previously described [11–13] and the small intes-
tinal segments after RYGB (biliopancreatic limb; alimentary limb;
common channel) are depicted in Fig. 1. Brieﬂy, a midline incision of
approximately 4 cm starting just below the xiphoid process was
performed. For the RYGB procedure, the small bowelwas transected ap-
proximately 20 cmdistal to the pylorus of the stomach, creating a prox-
imal and distal end of the small bowel. The proximal end, being still
continuous with the remaining portion of the stomach, constituted
the biliopancreatic limb and was anastomosed to the ileum approxi-
mately 25–30 cm from the cecum, creating the common channel. For
formation of the gastric pouch, the stomach was transected approxi-
mately 5 mm below the gastroesophageal junction, creating a gastric
pouch of a size of no more than 2%–3% of original stomach size. The
Roux-en-Y reconstruction was completed by connecting the distal end
of the small bowel to the gastric pouch, leading to formation of the
alimentary limb. One single RYGB procedure lasted approximately
70 min. For shamoperations, an anterior gastrostomy and a jejunostomy
with subsequent closures were performed. One single sham procedure
lasted approximately 30 min. The abdominal wall and the skin were
closed in layers after both operations.
2.3. DNA isolation
The content of intestinal tracts (n = 6–8 per group) collected
immediately after euthanasia was stored at −80 °C (biliopancreatic
limb, alimentary limb, common channel, cecum and colon after RYGB
and in the anatomically corresponding segments after sham surgery).
Metagenomic DNAwas extracted from the intestinal content using a
QIAamp-DNA stool minikit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions.
2.4. qPCR: primers and conditions
The primers and probes used to detect total bacteria, Biﬁdobacterium
spp., Lactobacillus spp. and Bacteroides–Prevotella spp. were based on
16S rRNA gene sequences and as described by Vincent et al. [14,15]. De-
tection was achieved with a STEP one PLUS instrument and software
(Applied Biosystems, Foster City, CA) using a MESA FAST quantitative
PCR MasterMix Plus for SYBR Assay (Eurogentec, Verviers, Belgium).
Each assay was performed in duplicate in the same run. The cycle
threshold of each sample was then compared to a standard curve
(performed in triplicate) made by diluting genomic DNA (ﬁve-fold seri-
al dilution) (BCCM/LMG, Ghent, Belgium). The statistical analysis was
done on logarithmic values.
2.5. DDP IV activity
Snap frozen intestinal tissue samples (200 mg) were homogenized
in 1 mL cold homogenization buffer (10 mM Tris–HCl, pH 8.2), and
analyzed immediately for enzyme activity. The serum from blood
samples was separated by centrifugation and stored at −20 °C
until analysis of enzyme activity.
Determination of intestinal and serum dipeptidyl peptidase-IV
(DPP IV) activities, which degrades gut peptides like GLP-1, was
performed as described by Kreisel et al. [16]. DPP IV activities were
determined by measuring the release of 4-nitroaniline from an
assay mixture containing 0.1 mol Tris–HCl (pH 8.0), 2 mmol Gly-Pro
Fig. 1. Schematic illustration of the surgical diagramof our animalmodel of RYGB. A: Normal gut anatomy. B: Gut anatomy after RYGB surgery: 1: biliopancreatic limb/duodenum. 2: alimentary
limb/proximal jejunum. 3: common channel/distal jejunum. 4: cecum.
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p-nitroanilide (Sigma-Aldrich, Saint Louis MO, USA) as the substrate and
enzyme in a total volume of 0.20 mL. After 30 min of incubation at 37 °C,
the reactionwas stopped by the addition of 0.4 mL of 2 M sodiumacetate
buffer (pH 4.5). Human recombinant DPP IV (Sigma-Aldrich, Saint Louis
MO, USA) was used as standard. The absorbance at 405 nm was mea-
sured by the use of a Lab Systems Multiskan RC 96-well plate reader
(Thermo Fisher Scientiﬁc, Waltham MA, USA). All reactions were
performed in duplicate.
Protein concentrations in homogenates were determined according
to the method of Pierce [17]. Enzyme activities in homogenates were
expressed as international units per gramof protein, and in serum as in-
ternational units per liter of serum. One unit corresponds to the hydro-
lysis of 1 mmol of substrate per minute under the assay conditions.
2.6. Statistical analyses
Results are presented as mean ± S.E.M. Statistical signiﬁcance of dif-
ference between groupswas assessed byMann–Whitney nonparametric
t-test (Graph-Pad Prism Software, San Diego, CA, USA; www.graphpad.
com).
3. Results and discussion
Average presurgical body weight of rats was 430 ± 4 g. Seven
days after surgery, sham-operated controls weighed signiﬁcantly
more compared with gastric bypass rats (sham: 370 ± 9 g vs. bypass:
450 ± 6 g, p b 0.001). Body weight changes for both groups are
shown in Fig. 2.
Total bacterial content was signiﬁcantly increased in the alimentary
limb and common channel after RYGB compared to sham rats. In the
cecum after RYGB the changes in the microbial ecology were similar to
that seen after prebiotic treatment [4], with Biﬁdobacterium spp. and
Lactobacillus spp. and were signiﬁcantly lower. RYGB also increased
Biﬁdobacterium spp. and Bacteroides–Prevotella spp. in the common
channel, the alimentary limb and in the colon (Fig. 3). After RYGB
surgery, DPP IV activity was decreased by 27% in the alimentary limb
(p = 0.01) and by 32% in serum (p = 0.002) (Fig. 4).
Most changes in microbial composition seen in the RYGB rats
were body weight-independent. In fact, sham-operated body weight-
matched rats did not show signiﬁcant modiﬁcation of gut microbiota
compared to ad libitum fed sham-operated controls, with the exception
for the increase in Bacteroides Prevotella spp. in the alimentary limb and
the common channel of the body-weightmatched rats (data not shown).
Although changes in gut microbiota seen after RYGB resembled those
obtained after weight loss in obese rodents [5], our data indicate that
RYGB may have speciﬁc effects on intestinal microbiota.
The major ﬁnding of the study is that the most substantial shifts in
the composition of the microbiota were observed in the alimentary
limb and the common channel. Interestingly, we recently found that
the total gene expression of the gut hormones preproglucagon,
peptide YY and cholecystokinin was increased in the alimentary
limb and common channel of RYGB rats but not in sham-operated
rats that were body weight-matched to the RYGB rats [18].
Our ﬁndings suggest that the bypass of the proximal intestine may
contribute to the changes of the gut microbiota observed after RYGB.
The exclusion of the proximal intestine from contact with ingested
nutrients has been demonstrated to play a major role in the beneﬁcial
effects of RYGB surgery [19]. Although a putative mechanism promot-
ing such beneﬁcial effects of the surgery remains to be elucidated, our
data suggest a possible role for changes in the microbial composition
of the proximal small bowel.
Fig. 2. Body weight change for the gastric bypass (-●-) (n = 8) and sham-operated
rats ad libitum fed (-○-) (n = 8). Data are expressed as mean ± SD.
Fig. 3. RYGB-associated changes in gut microbiota. Results are given as the Log10 of
bacterial/intestinal content (g). Data are expressed as mean ± S.E.M *p b 0.05;
**p b 0.01; ***p b 0.001 compared to sham-operated rats.
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In the present study, a decreased activity of intestinal and serumDDP
IV activity was detected. A direct link between the decreased DPP IV ac-
tivity and changes in gut microbiota composition was not investigated;
however, we have previously shown that prebiotic-induced changes in
gut microbiota and increased GLP-1 levels were associated with reduced
DPP IV activity [20]. The gut microbiota changes that we observed in this
study resemble in part those seen after treatment with prebiotics, thus
we think that similar mechanisms may have prevailed under the condi-
tions of our study.
The modest decrease in serum DPP IV activity in response to RYGB
compared to pharmacological approaches is consistent with other
studies in humans [21]. It could be secondary to the experimental
conditions; it is e.g. known that the diabetic status may inﬂuence
the level of DPP4 activity [22]. In our RYGB model, however, the dif-
ference of glucose tolerance between sham-operated and RYGB is
not supposed to differ as much as in some models of obesity and
type 2 diabetes frequently used to test pharmacological approaches.
Hence, we expected the difference of DPP-4 activity in our study to
be smaller.
Further, because DPP-4 is mainly a tissue enzyme, changes in serum
DPP-4 activity may not completely reﬂect the total decrease in activity
of the enzyme and the consequent decreased inactivation of incretins.
In the present study, DPP-4 activity in the alimentary limb was also de-
creased and might explain the robust increase in circulating incretin
levels usually detected in our RYGB rat model [1]. In other words, re-
duced intestinal and serumDDP IV activitymay contribute to enhanced
bioavailability of endogenous GLP-1 and be consistent with the modu-
lation of jejunal microbiota altering the production or breakdown of
gastrointestinal hormones known to control energy balance.
4. Conclusions
In conclusion, these data are critical because they accurately repre-
sent howRYGB surgerymay affectmicrobial communities in different in-
testinal segments after surgery. Because most changes in gut microbiota
were independent fromweight loss,we conclude that othermechanisms
than weight loss per se seem to be responsible for the alteration of the
intestinal microbial population after RYGB surgery.
Postsurgical modulations of the gastrointestinal microbial commu-
nity, e.g. the bypass of the intestinal foregut, may inﬂuence gut peptide
synthesis, release and breakdown; hence, these changes may signiﬁ-
cantly contribute to the beneﬁcial metabolic effects of RYGB surgery
independent of the RYGB-induced body weight loss. The transplant ex-
periment with cecal contents of RYGB mice clearly is consistent with
this idea [10].
The impact of RYGBon themicrobiota of the different intestinal tracts
remains to be conﬁrmed in other experimental models, e.g. in a high fat
diet or a genetic model of obesity, and in large-scale studies including
bodyweight-matched controls and using pyrosequencing,metagenomic
analysis and metabolic proﬁling. These tools will enable further insight
into the composition of the intestinal microbiota and its functional evo-
lution after bariatric surgery. Elucidating the mechanisms by which gut
microbiota interact with the host will provide a new basis for putative
pharmacological or dietary intervention for obesity and its related
comorbidities.
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9. Discussion 
Since the individual studies are discussed in detail in the respective articles or sections, I will now 
only briefly summarize the results and focus on potential links between the studies and try to draw 
general conclusions from the entire set of experiments. 
We showed that RYGB surgery caused weight loss-independent changes in bone metabolism that 
led to a decrease in BMD, bone volume and trabecular thickness. Bone loss occurred early after 
surgery and coincided with intestinal calcium malabsorption. However, in contrast to previous 
reports,237-242 this seemed to be independent of vitamin D malabsorption, since increased vitamin D 
activation compensated for lower total vitamin D levels, and PTH levels were not elevated in RYGB 
rats. Although intestinal calcium absorption normalized between two and seven weeks after surgery, 
there was no restoration of bone mass. We identified chronic metabolic acidosis, which was 
associated with increased lactate levels, as a potential mechanism underlying inhibited bone mass 
restoration. A decrease in BMD was also shown in human patients after RYGB, but not after vertical 
banded gastroplasty. Increased markers of bone resorption were found, but there was no evidence 
of secondary hyperparathyroidism or vitamin D deficiency.  
We were also able to reproduce the alterations in EE of RYGB rats that we previously reported,124 
and showed that these changes were not an artifact caused by changes in body composition or a 
shift in the TNZ. However, we could not confirm our hypothesis that increased GLP-1 levels in 
RYGB rats are directly involved in altering EE, since there was no effect of acute GLP-1 agonism or 
antagonism on EE. 
Finally, we found that weight loss and the satiating effect of CCK and GLP-1 were increased by 
estrogen replacement in ovariectomized rats, suggesting that RYGB may be more effective in pre- 
versus postmenopausal women; and provided further evidence supporting recent findings of altered 
gut microbiota in rats and humans after RYGB.255-258  
 
9.1. Effects of RYGB on bone metabolism 
9.1.1.  Transferability to human RYGB patients 
The main findings of our study investigating RYGB-induced changes in bone metabolism in rats 
were that (1) bone loss occurred independent of body weight loss, (2) calcium malabsorption was 
only transient, (3) vitamin D activation was increased, thereby compensating for lower total vitamin 
D levels that were probably caused by intestinal vitamin D malabsorption, and (4) metabolic acidosis 
associated with increased lactate levels interfered with the regulation of renal calcium homeostasis 
and potentially inhibited bone mass restoration (see 5). 
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These results were partly supported by a prospective randomized trial in human patients undergoing 
either RYGB or vertical banded gastroplasty (see 8.1). The study showed that, although similar 
weight loss was achieved in both groups, only RYGB led to a marked decrease in both total body 
and skull BMD. The simultaneous assessment of total body and skull BMD is one strength of the 
study, because the skull is not a weight-bearing bone. Hence, the decrease in skull BMD after 
RYGB further supports that bone loss does not occur due to a reduction in mechanical loading of the 
skeleton. That bone loss is specific to the RYGB procedure and not a general side effect of bariatric 
surgery is also confirmed in a recent study by Stemmer et al.,259 which showed similar bone loss in 
RYGB rats as observed in our study, while there were no significant changes in bone mass in a rat 
model of vertical sleeve gastrectomy. 
Unfortunately, the role of calcium malabsorption could not be determined in the human study since 
fecal calcium loss was not measured and calcium intake was only evaluated based on a 
questionnaire. We could, however, confirm the finding of increased active vitamin D levels in human 
RYGB patients 18 months post surgery, even though they were associated with increased levels of 
total vitamin D due to postoperative supplementation and therefore with an unaltered active to total 
vitamin D ratio. Since active vitamin D levels were markedly above the reference range, one may 
still speculate that the negative feedback of active vitamin D on the vitamin D activating 1α-
hydroxylase is attenuated either by a higher requirement for active vitamin D or by other factors 
directly influencing the feedback mechanism.  
Because metabolic acidosis after RYGB has never been reported before, this was not considered in 
the human study, which commenced long before we performed our experiments. In order to include 
this factor in future human studies, it is important to further elucidate the origin of increased lactate 
levels and the contribution of chronic metabolic acidosis to bone loss observed in our rat model. 
Interestingly, Stemmer et al. reported a decreased pH in the jejunum of RYGB rats,259 which could 
be indicative of increased intestinal lactate production. We did not determine the cause of increased 
lactate levels in our study; however, there are two main hypotheses that could explain an intestinal 
origin. First, Saeidi et al.250 recently showed that the gut hypertrophy in RYGB rats was associated 
with a reprogramming of intestinal glucose metabolism, which led to increased lactate production. 
Second, the alterations in the intestinal bacterial flora that have repeatedly been described in 
humans and rats after RYGB surgery255-258 and that we also demonstrated in our rat model (see 0) 
could lead to an increase in lactate producing bacteria. It has furthermore been speculated that the 
gut microbiota can directly regulate bone mass, potentially by interactions with the immune 
system.260 Germ-free mice exhibited increased bone mass, which could be normalized by 
colonalization with normal gut microbiota. The general increase in intestinal bacteria number after 
RYGB could therefore have a negative impact on bone mass via similar mechanisms. Of note, while 
the changes in gut microbiota seem to be very similar in rats and humans, however, it has not been 
 	   101 
investigated yet if RYGB in humans also leads to gut hypertrophy and altered intestinal glucose 
metabolism. 
9.1.2. Relevance to female patients 
We have shown that the effects of RYGB on food intake and body weight loss in ovariectomized 
female rats are enhanced by an estrogen replacement regimen.261 This suggests an interaction 
between estrogen and the factors leading to RYGB-induced weight loss, such as increased gut 
hormone levels or the action of these hormones, respectively. Since the major influence of 
menopausal state on bone metabolism is well known,262,263 it will be of high interest to determine 
whether there is a similar interaction between estrogen and RYGB-induced bone loss. There are 
very limited studies on changes in bone metabolism after RYGB surgery that take into account 
whether the included women were pre- or postmenopausal, and only few studies specifically 
analyzed differences based on menopausal state.264,265 However, the scarce literature suggests that 
postmenopausal women may be more affected by postsurgical changes in bone 
metabolism.235,236,264,265 Whether this is caused by a direct interaction between the factors leading to 
bone loss after RYGB and the effects of decreased estrogen levels or whether it only represents the 
higher osteoporosis incidence in postmenopausal women in general is unclear. Estrogen exerts its 
protective effect on bone mass by a complex interaction of several factors. Its most dominant 
influence is the decrease of bone resorption through suppression of osteoclast formation and 
activation.266,267 By inhibiting osteoblast apoptosis,268,269 it also has direct effects on bone formation. 
Further, there are several mechanisms by which estrogen affects bone metabolism indirectly, such 
as an increased activation of vitamin D that leads to higher intestinal calcium absorption.270 This is of 
particular interest in the context of our data suggesting a dysregulation of vitamin D metabolism 
potentially associated with tissue specific alterations in vitamin D signaling in rats.  
9.1.3. Future perspectives 
Although we were able to show that RYGB-induced bone loss is not simply caused by vitamin D 
deficiency but is associated with metabolic acidosis and changes in vitamin D metabolism, we were 
not able to identify the exact mechanisms that led to the decrease in bone mass. One important next 
step would be to determine whether and how correction of the chronic acidosis may influence the 
effects of RYGB on bone metabolism in rats, and whether lactic acidosis also occurs in human 
patients after RYGB.  
However, one major challenge when evaluating bone metabolism after RYGB is that the surgery 
causes changes in various factors interfering with bone homeostasis, and it is extremely difficult to 
identify the contribution of each factor individually to the observed alterations. The anatomical 
rearrangement of the gastrointestinal tract has direct effects on calcium and vitamin D absorption, 
but it may also have indirect effects due to changed neuronal signaling from the intestine. The 
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adiposity signals insulin and leptin can both affect bone mass negatively by increasing SNS 
activity,55,56 since activation of β2-adrenergic receptors on osteoblasts seems to inhibit bone 
formation and indirectly increase bone resorption.271 Postprandial insulin secretion is increased after 
RYGB115,145 and this potentially coincides with increased postprandial SNS activity.272 Leptin levels 
decrease in response to RYGB-induced weight loss, but increased leptin sensitivity could in theory 
lead to a higher impact of leptin on bone mass after RYGB.273 Finally, many of the gut hormones 
that are changed in RYGB patients have recently been shown to be involved in bone mass 
regulation. Most of them seem to have beneficial effects on bone mass, such as amylin,274-276 GLP-
1,277 and glucose-dependent insulinotropic hormone,278 which argues against a role of these 
hormones in RYGB-induced bone loss. In contrast, PYY may negatively influence bone mass by 
decreasing osteoblast activity.279 These findings are however relatively new and there are often 
contradictory results when comparing in vitro and in vivo studies280 or central versus peripheral 
action of such hormones. The concept of the skeleton as an endocrine organ that interacts with the 
homeostatic control of EE currently receives a lot of attention and is constantly being adapted due to 
new findings. The RYGB model provides an interesting opportunity to further investigate the 
connection between bone and energy homeostasis. 
9.2. Effects of RYGB on energy expenditure 
One main goal of this thesis was to investigate the mechanisms that underlie alterations in EE after 
RYGB surgery.124,125 Importantly, we were able to show that these changes were not caused by 
differences in body composition, i.e. increased lean mass compared to BWM rats, or by a shift in the 
TNZ leading to increased thermogenesis in RYGB rats at lower temperatures. On the contrary, while 
the difference in EE between RYGB and BWM rats remained constant at thermoneutrality, the 
difference between RYGB and AL rats was diminished. This suggests that RYGB rats in fact require 
less adaptive thermogenesis than AL rats below thermonetrality.  
Various factors that have been shown to influence EE are altered by RYGB surgery, including gut 
hormone levels,113-115 bile acids,281-285 meal patterns118,286 and gut microbiota255-258,287, and the 
potential interactions between these factors are therefore manifold. We hypothesized that the 
marked increase in postprandial GLP-1 secretion after RYGB increases EE via the SNS,57 but failed 
to provide evidence to support this idea (see 0). However, since we generally did not find any effect 
of acute GLP-1 agonism or antagonism on EE in our study although there is evidence for an 
influence of GLP-1 signaling on EE,288,289 the negative outcome could potentially be due to the study 
design. Williams et al.7 have shown that the effects of GLP-1 antagonism on food intake strongly 
depend on the study design, i.e. the feeding state of rats and the time point of the light cycle. They 
further showed that peripheral and central GLP-1 effects may be mediated independently of each 
other, and it has been suggested that in contrast to peripheral GLP-1 acting as a short-term satiation 
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signal, central GLP-1 signaling may be involved in long-term control of energy balance.290 Central 
GLP-1 infusion has indeed been shown to increase EE compared to pair-fed control mice.291 Central 
administration of a GLP-1-antagonist could therefore possibly reveal a role for GLP-1 in EE changes 
after RYGB. However, in contrast to peripheral GLP-1, alterations in central GLP-1 signaling have 
not been investigated after RYGB. It is further possible that the subcutaneous injections in our did 
not lead to the expected results due to a lack of GLP-1 receptor activation on vagal nerve endings, 
which could have been achieved by intraperitoneal injections. The anorectic dose of intraperitoneally 
administered GLP-1 agonists is markedly increased in rats after complete subdiaphragmatic vagal 
deafferentation, suggesting that the effects of peripheral GLP-1 on food intake strongly depend on 
vagal signaling292. If this were also the case for potential effects of peripheral GLP-1 on EE, we 
could perhaps have detected such effects by intraperitoneal injections. It has to be mentioned 
though that we did find an effect of both GLP-1 agonism and antagonism on food intake in our rats, 
and this effect was stronger in RYGB compared to AL rats. This proves that the negative outcome 
regarding an effect on EE was not caused by a general inefficacy of the drugs or the used doses, 
but rather suggests that the contribution of GLP-1 or the mediating pathways are different for EE 
and food intake.  
However, in addition to GLP-1, there is also evidence of an involvement of other gut hormones in EE 
control, and the observed changes in global EE may represent a combined effect of increased levels 
of all these peptides. This would explain why the antagonism of one single hormone did not lead to 
detectable changes. Recently, the increase in both fasting and postprandial levels of bile acids after 
RYGB281-285 received a lot of attention since bile acids are thought to contribute to improved glucose 
homeostasis after bariatric surgery.282-284 They have further been shown to increase EE by BAT 
stimulation293-295 and could therefore also play a role in EE control after RYGB. 
It has to be mentioned in this context that, even though very similar changes in postprandial gut 
hormone release and in bile acid levels occur after vertical sleeve gastrectomy, no effect of this 
procedure on EE has been found,106,296,297 which suggests that other mechanisms may be 
responsible for the findings in RYGB rats and human patients. 
One such potential mechanism is the gut hypertrophy that we and others observed after RYGB in 
rats.124,134,250 Even though we could show that there was no difference in body composition when 
analyzing body fat content and total lean mass of RYGB rats and rats that were body weight-
matched by food restriction, the increased mass of the gastrointestinal tract could contribute to 
higher EE. Saeidi et al.250 have recently shown that the hypertrophy of the alimentary limb is 
associated with increased cellular proliferation, a process with very high metabolic requirements. We 
speculate that these adaptations to the rearrangement of the gastrointestinal tract in the RYGB 
procedure do not only lead to an increase in resting EE, but also explain the reported increase in 
DIT,124,272,298,299 since differences in energetic requirements of the gut are more pronounced after 
ingestion of a meal. Importantly, gut hypertrophy seems to be specific to the RYGB surgery and has 
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not been reported after other bariatric procedures including sleeve gastrectomy, which supports an 
involvement in EE changes that have also only been observed after RYGB. 
Another possibility are the changes in gut microbiota that we and others reported after RYGB.255-
258,287 These changes could lead to an increase in short-chain fatty acids, including butyrate, which 
are formed by microbial fermentation of complex carbohydrates. Butyrate has been shown to 
chronically increase EE when administered to mice by dietary supplementation300. Like gut 
hypertrophy, alterations in the bacterial flora of the gastrointestinal tract have so far only been 
reported in response to the RYGB procedure. Furthermore, such alterations could also explain 
increased DIT, since butyrate production can be expected to be highest directly after carbohydrate 
ingestion.  
In order to further investigate the underlying causes of altered EE in RYGB rats, it could be of 
interest to measure EE in female ovariectomized rats with and without estrogen replacement. If 
increased gut hormone levels were involved in EE changes, we could potentially expect an 
interaction with estrogen replacement similar to the one observed for food intake (see 0). Estrogen 
replacement seems to increase the satiating potential of gut hormones and may have the same 
effect on their effects on EE. However, if the changes in EE were due to gut hypertrophy, we would 
not expect an interaction with estrogen replacement, unless there were a significant additional 
increase in the mass due to the estrogen treatment. Not enough is known about the mechanisms by 
which butyrate increases EE to speculate if there could be an interaction with estrogen, but we 
would not expect the bacterial flora and therefore butyrate production itself to be altered by 
estrogen. 
In conclusion, the RYGB model provides a very interesting opportunity to further investigate the 
homeostatic systems controlling food intake, energy expenditure and bone metabolism. It could also 
serve to expand the emerging concept of interactions between bone remodeling, energy metabolism 
and adipogenesis.197,301-307 However, the simultaneous alteration of different interacting homeostatic 
systems makes it very challenging to determine the potential effects or influences of one single 
factor.  
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10. Abbreviations 
αMSH  α-melanocyte stimulating hormone 
AEE  activity related energy expenditure 
AgRP/NPY agouti-related protein / neuropeptide Y  
AL  sham operated, ad libitum fed  
ARC  arcuate nucleus of the hypothalamus  
BAT  brown adipose tissue 
BMD  bone mineral density 
BMI  body mass index 
BMR  basal metabolic rate 
BWM  sham operated, body weight-matched 
CCK  cholecystokinin  
CNS  central nervous system 
DIT  diet-induced thermogenesis 
DPP IV  dipeptidyl-peptidase 4  
EE  energy expenditure 
GLP-1  glucagon-like peptide-1 
IL-6  interleukin-6 
LCT  lower critical temperature 
NTS  nucleus of the solitary tract 
OXM  oxyntomodulin 
POMC  pro-opiomelanocortin  
PPARγ  peroxisome proliferator-activated gamma  
PTH  parathyroid hormone 
PYY  peptide YY 
RQ  respiratory quotient 
RYGB  Roux-en-Y gastric bypass 
SNS  sympathetic nervous system 
TC  body core temperature 
TEE  total daily energy expenditure 
TNF-α  tumor necrosis factor-alpha  
TNZ  thermoneutral zone 
UCT  upper critical temperature 
UCP-1  uncoupling protein-1 
VCO2  carbon dioxide production 
VO2  oxygen consumption 
WAT  white adipose tissue 
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